<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://schizophreniabulletin.oxfordjournals.org">
<title>Schizophrenia Bulletin - Advance Access</title>
<link>http://schizophreniabulletin.oxfordjournals.org</link>
<description>Schizophrenia Bulletin - RSS feed of articles</description>
<prism:eIssn>1745-1701</prism:eIssn>
<prism:publicationName>Schizophrenia Bulletin</prism:publicationName>
<prism:issn>0586-7614</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp139v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp131v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp126v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp133v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp132v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp129v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp127v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp123v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp119v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp124v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp122v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp128v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp118v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp117v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp088v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp107v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp098v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp112v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp103v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp101v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp108v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp105v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp095v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp094v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp093v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp099v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp097v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp096v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn181v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp087v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp092v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp086v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp089v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp062v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp084v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp083v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp085v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp081v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp074v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp066v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp073v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp067v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp059v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn118v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp018v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp061v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp060v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp063v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp058v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp057v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp037v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn191v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp056v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp044v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp010v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn165v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp053v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp055v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp052v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp048v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp039v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp022v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn190v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp034v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp035v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp033v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp032v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp029v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp028v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp031v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp030v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp009v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp011v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp012v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp026v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp024v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp015v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn192v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp007v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp003v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp002v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp005v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp001v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn170v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn178v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn174v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn180v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn193v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn172v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn167v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn161v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn141v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn160v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn148v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn138v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn146v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn145v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn144v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn137v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn136v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn132v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn130v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn120v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn131v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn119v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn128v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn129v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn115v2?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn127v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn107v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn077v3?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn112v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn110v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn106v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn102v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn104v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn100v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn098v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn095v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn091v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn094v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn075v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn088v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn069v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn074v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn072v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn066v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn065v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn064v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn063v1?rss=1" />
  <rdf:li rdf:resource="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn061v1?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp139v1?rss=1">
<title><![CDATA[Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp139v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Barch, D. M., Keefe, R. S.E.]]></dc:creator>
<dc:date>Wed, 18 Nov 2009 06:13:33 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp139</dc:identifier>
<dc:title><![CDATA[Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-18</prism:publicationDate>
<prism:section>Commentary</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp131v1?rss=1">
<title><![CDATA[Altered Functional and Anatomical Connectivity in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp131v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: Schizophrenia is characterized by a lack of integration between thought, emotion, and behavior. A disruption in the connectivity between brain processes may underlie this schism. Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) were used to evaluate functional and anatomical brain connectivity in schizophrenia. <I>Methods</I>: In all, 29 chronic schizophrenia patients (11 females, age: mean = 41.3, SD = 9.28) and 29 controls (11 females, age: mean = 41.1, SD = 10.6) were recruited. Schizophrenia patients were assessed for severity of negative and positive symptoms and general cognitive abilities of attention/concentration and memory. Participants underwent a resting-fMRI scan and a DTI scan. For fMRI data, a hybrid independent components analysis was used to extract the group default mode network (DMN) and accompanying time-courses. Voxel-wise whole-brain multiple regressions with corresponding DMN time-courses was conducted for each subject. A t-test was conducted on resulting DMN correlation maps to look between-group differences. For DTI data, voxel-wise statistical analysis of the fractional anisotropy data was carried out to look for between-group differences. Voxel-wise correlations were conducted to investigate the relationship between brain connectivity and behavioral measures. <I>Results</I>: Results revealed altered functional and anatomical connectivity in medial frontal and anterior cingulate gyri of schizophrenia patients. In addition, frontal connectivity in schizophrenia patients was positively associated with symptoms as well as with general cognitive ability measures. <I>Discussion</I>: The present study shows convergent fMRI and DTI findings that are consistent with the disconnection hypothesis in schizophrenia, particularly in medial frontal regions, while adding some insight of the relationship between brain disconnectivity and behavior.</p>
]]></description>
<dc:creator><![CDATA[Camchong, J., MacDonald, A. W., Bell, C., Mueller, B. A., Lim, K. O.]]></dc:creator>
<dc:date>Tue, 17 Nov 2009 06:00:07 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp131</dc:identifier>
<dc:title><![CDATA[Altered Functional and Anatomical Connectivity in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp126v1?rss=1">
<title><![CDATA[Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp126v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> To examine the influence of cannabis use on long-term outcome in patients with a first psychotic episode, comparing patients who have never used cannabis with (<I>a</I>) those who used cannabis before the first episode but stopped using it during follow-up and (<I>b</I>) those who used cannabis both before the first episode and during follow-up. <I>Methods:</I> Patients were studied following their first admission for psychosis. They were interviewed at years 1, 3, and 5. At follow-up after 8 years, functional outcome and alcohol and drug abuse were recorded. Patients were classified according to cannabis use: 25 had cannabis use before their first psychotic episode and continuous use during follow-up (CU), 27 had cannabis use before their first episode but stopped its use during follow-up (CUS), and 40 never used cannabis (NU). <I>Results:</I> The 3 groups did not differ significantly in symptoms or functional outcome at baseline or during short-term follow-up. The CUS group exhibited better long-term functional outcome compared with the other 2 groups and had fewer negative symptoms than the CU group, after adjusting for potential confounders. For the CUS group, the effect size was 1.26 (95% confidence interval [CI] = 0.65 to 1.86) for functional outcome and &ndash;0.72 (95% CI = &ndash;1.27 to &ndash;0.14) for negative symptoms. All patients experienced improvements in positive symptoms during long-term follow-up. <I>Conclusion:</I> Cannabis has a deleterious effect, but stopping use after the first psychotic episode contributes to a clear improvement in outcome. The positive effects of stopping cannabis use can be seen more clearly in the long term.</p>
]]></description>
<dc:creator><![CDATA[Gonzalez-Pinto, A., Alberich, S., Barbeito, S., Gutierrez, M., Vega, P., Ibanez, B., Haidar, M. K., Vieta, E., Arango, C.]]></dc:creator>
<dc:date>Fri, 13 Nov 2009 12:08:26 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp126</dc:identifier>
<dc:title><![CDATA[Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-13</prism:publicationDate>
<prism:section>Regular Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp133v1?rss=1">
<title><![CDATA[Review of Pathological Hallmarks of Schizophrenia: Comparison of Genetic Models With Patients and Nongenetic Models]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp133v1?rss=1</link>
<description><![CDATA[
<p>Schizophrenia is a condition that impairs higher brain functions, some of which are specific to humans. After identification of susceptibility genes for schizophrenia, many efforts have been made to generate genetics-based models for the disease. It is under debate whether behavioral deficits observed in rodents are sufficient to characterize these models. Alternatively, anatomical and neuropathological changes identified in brains of patients with schizophrenia may be utilized as translatable characteristics between humans and rodents, which are important for validation of the models. Here, we overview such anatomical and neuropathological changes in humans: enlarged ventricles, dendritic changes in the pyramidal neurons, and alteration of specific subtypes of interneurons. In this review, we will overview such morphological changes in brains from patients with schizophrenia. Then, we will describe that some of these alterations are already recapitulated even in classic nongenetic models for schizophrenia. Finally, in comparison with the changes in patients and nongenetic models, we will discuss the anatomical and neuropathological manifestation in genetic models for schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V., Sawa, A.]]></dc:creator>
<dc:date>Tue, 10 Nov 2009 06:28:24 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp133</dc:identifier>
<dc:title><![CDATA[Review of Pathological Hallmarks of Schizophrenia: Comparison of Genetic Models With Patients and Nongenetic Models]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-10</prism:publicationDate>
<prism:section>Mutant mouse models, John Waddington</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp132v1?rss=1">
<title><![CDATA[Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp132v1?rss=1</link>
<description><![CDATA[
<p>In recent years, there have been huge advances in the use of genetically modified mice to study pathophysiological mechanisms involved in schizophrenia. This has allowed rapid progress in our understanding of the role of several proposed gene mechanisms in schizophrenia, and yet this research has also revealed how much still remains unresolved. Behavioral studies in genetically modified mice are reviewed with special emphasis on modeling psychotic-like behavior. I will particularly focus on observations on locomotor hyperactivity and disruptions of prepulse inhibition (PPI). Recommendations are included to address pharmacological and methodological aspects in future studies. Mouse models of dopaminergic and glutamatergic dysfunction are then discussed, reflecting the most important and widely studied neurotransmitter systems in schizophrenia. Subsequently, psychosis-like behavior in mice with modifications in the most widely studied schizophrenia susceptibility genes is reviewed. Taken together, the available studies reveal a wealth of available data which have already provided crucial new insight and mechanistic clues which could lead to new treatments or even prevention strategies for schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[van den Buuse, M.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 05:27:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp132</dc:identifier>
<dc:title><![CDATA[Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-09</prism:publicationDate>
<prism:section>Mutant mouse models: phenotypic relationship to domains of psychopathology in schizophrenia - Prof John Waddington</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp129v1?rss=1">
<title><![CDATA[Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp129v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> The majority of first-episode psychosis (FEP) patients reach clinical remission; however, rates of relapse are high. This study sought to undertake a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the effectiveness of pharmacological and non-pharmacological interventions to prevent relapse in FEP patients. <I>Methods:</I> Systematic review and meta-analysis of RCTs. <I>Results:</I> Of 66 studies retrieved, 18 were eligible for inclusion. Nine studies investigated psychosocial interventions and 9 pharmacological treatments. The analysis of 3 RCTs of psychosocial interventions comparing specialist FEP programs vs treatment as usual involving 679 patients demonstrated the former to be more effective in preventing relapse (odds ratio [OR] = 1.80, 95% confidence interval [CI] = 1.31&ndash;2.48; <I>P</I> &lt; .001; number needed to treat [NNT] = 10). While the analysis of 3 different cognitive-behavioral studies not specifically intended at preventing relapse showed no further benefits compared with specialist FEP programs (OR = 1.95, 95% CI = 0.76&ndash;5.00; <I>P</I> = .17), the combination of specific individual and family intervention targeted at relapse prevention may further improve upon these outcomes (OR = 4.88, 95% CI = 0.97&ndash;24.60; <I>P</I> = .06). Only 3 small studies compared first-generation antipsychotics (FGAs) with placebo with no significant differences regarding relapse prevention although all individual estimates favored FGAs (OR = 2.82, 95% CI = 0.54&ndash;14.75; <I>P</I> = .22). Exploratory analysis involving 1055 FEP patients revealed that relapse rates were significantly lower with second-generation antipsychotics (SGAs) compared with FGAs (OR = 1.47, 95% CI = 1.07&ndash;2.01; <I>P</I> &lt; .02; NNT = 10). <I>Conclusions:</I> Specialist FEP programs are effective in preventing relapse. Cognitive-based individual and family interventions may need to specifically target relapse to obtain relapse prevention benefits that extend beyond those provided by specialist FEP programs. Overall, the available data suggest that FGAs and SGAs have the potential to reduce relapse rates. Future trials should examine the effectiveness of placebo vs antipsychotics in combination with intensive psychosocial interventions in preventing relapse in the early course of psychosis. Further studies should identify those patients who may not need antipsychotic medication to be able to recover from psychosis.</p>
]]></description>
<dc:creator><![CDATA[Alvarez-Jimenez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., Gleeson, J. F.]]></dc:creator>
<dc:date>Mon, 09 Nov 2009 05:27:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp129</dc:identifier>
<dc:title><![CDATA[Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp127v1?rss=1">
<title><![CDATA[Updated Schizophrenia PORT Treatment Recommendations: A Commentary]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp127v1?rss=1</link>
<description><![CDATA[
<p>This commentary on the updated Patient Outcomes Research Team recommendation from a policy perspective notes that the quality of research recommendations is improved but that there has been only limited impact and utility for providers.</p>
]]></description>
<dc:creator><![CDATA[Hogan, M.]]></dc:creator>
<dc:date>Thu, 05 Nov 2009 07:05:14 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp127</dc:identifier>
<dc:title><![CDATA[Updated Schizophrenia PORT Treatment Recommendations: A Commentary]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp123v1?rss=1">
<title><![CDATA[Anxiety Interacts With Expressed Emotion Criticism in the Prediction of Psychotic Symptom Exacerbation]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp123v1?rss=1</link>
<description><![CDATA[
<p>Psychotic symptoms are exacerbated by social stressors in schizophrenia and schizoaffective disorder patients as a group. More specifically, critical attitudes toward patients on the part of family members and others have been associated with a higher risk of relapse in the patients. Some patients appear to be especially vulnerable in this regard. One variable that could affect the degree of sensitivity to a social stressor such as criticism is the individual&rsquo;s level of anxiety. The present longitudinal study assessed 27 relatively stable outpatients with schizophrenia or schizoaffective disorder and the single "most influential other" (MIO) person for each patient. As hypothesized, (1) patients with high critical MIOs showed increases in psychotic symptoms over time, compared with patients with low critical MIOs; (2) patients high in anxiety at the baseline assessment showed increases in psychotic symptoms at follow-up, compared with patients low in anxiety, and (3) patients with high levels of anxiety at baseline and high critical MIOs showed the greatest exacerbation of psychotic symptoms over time. Objectively measured levels of criticism were more predictive than patient-rated levels of criticism.</p>
]]></description>
<dc:creator><![CDATA[Docherty, N. M., St-Hilaire, A., Aakre, J. M., Seghers, J. P., McCleery, A., Divilbiss, M.]]></dc:creator>
<dc:date>Thu, 05 Nov 2009 07:05:13 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp123</dc:identifier>
<dc:title><![CDATA[Anxiety Interacts With Expressed Emotion Criticism in the Prediction of Psychotic Symptom Exacerbation]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp119v1?rss=1">
<title><![CDATA[Political Abuse of Psychiatry--An Historical Overview]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp119v1?rss=1</link>
<description><![CDATA[
<p>The use of psychiatry for political purposes has been a major subject of debate within the world psychiatric community during the second half of the 20th century. The issue became prominent in the 1970s and 1980s due to the systematic political abuse of psychiatry in the Soviet Union, where approximately one-third of the political prisoners were locked up in psychiatric hospitals. The issue caused a major rift within the World Psychiatric Association, from which the Soviets were forced to withdraw in 1983. They returned conditionally in 1989. Political abuse of psychiatry took also place in other socialist countries and on a systematic scale in Romania, and during the first decade of the 21st century, it became clear that systematic political abuse of psychiatry is also happening in the People's Republic of China. The article discusses the historical background to these abuses and concludes that the issue had a major impact on the development of concepts regarding medical ethics and the professional responsibility of physicians.</p>
]]></description>
<dc:creator><![CDATA[van Voren, R.]]></dc:creator>
<dc:date>Thu, 05 Nov 2009 07:05:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp119</dc:identifier>
<dc:title><![CDATA[Political Abuse of Psychiatry--An Historical Overview]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp124v1?rss=1">
<title><![CDATA[Should the PANSS Be Rescaled?]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp124v1?rss=1</link>
<description><![CDATA[
<p>The design of the Positive and Negative Syndrome Scale (PANSS) with item levels ranging from 1 to 7 leads to the trivial result that the 30-item scale&rsquo;s zero level (no symptoms) is 30. This causes serious problems when ratios are calculated which always implicitly depend on a natural zero point (equals 0). Recent publications concerning efficacy of antipsychotics correctly suggest a subtraction of 30 points to every PANSS before calculating percent change (PC). Nevertheless, the traditional approach using uncorrected scores is still in common practice. This analysis aims to clarify which approach is the most appropriate from a statistical perspective.For analysis, data from a naturalistic study on 400 patients with a schizophrenic spectrum disorder and simulated data sets were used. While calculations concerning absolute score values and their differences are not affected, considerable problems arise in calculations of PC and related response criteria. Even significance levels of estimated treatment effects change, depending on the structure of the data (eg, baseline symptom severity). Using a PANSS version with items ranging from 0 to 6 would avoid such often neglected pitfalls.</p>
]]></description>
<dc:creator><![CDATA[Obermeier, M., Mayr, A., Schennach-Wolff, R., Seemuller, F., Moller, H.-J., Riedel, M.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 09:39:11 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp124</dc:identifier>
<dc:title><![CDATA[Should the PANSS Be Rescaled?]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp122v1?rss=1">
<title><![CDATA[Posttraumatic Stress Disorder and Negative Symptoms of Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp122v1?rss=1</link>
<description><![CDATA[
<p>Posttraumatic stress disorder (PTSD) is highly comorbid with schizophrenia and may be associated with higher levels or lower levels of negative symptoms. In the current study, we attempted to clarify the relationship between PTSD and negative symptoms by examining the proportion of patients meeting various negative symptom criteria in a sample of patients diagnosed with schizophrenia alone or schizophrenia and comorbid PTSD. Results indicated that the presence of PTSD in schizophrenia was associated with increased secondary negative symptoms, with the deficit syndrome (DS) and primary negative symptoms associated with lower rates of current and lifetime diagnoses of PTSD. Furthermore, the deficit/nondeficit classification provided greater differentiation of PTSD symptoms than did negative symptoms defined more broadly using the Scale for the Assessment of Negative Symptoms or primary vs secondary distinctions. These findings suggest that DS patients are at a uniquely low risk for PTSD.</p>
]]></description>
<dc:creator><![CDATA[Strauss, G. P., Duke, L. A., Ross, S. A., Allen, D. N.]]></dc:creator>
<dc:date>Wed, 04 Nov 2009 09:39:10 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp122</dc:identifier>
<dc:title><![CDATA[Posttraumatic Stress Disorder and Negative Symptoms of Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-11-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp128v1?rss=1">
<title><![CDATA[Adopting Evidence-Based Practices--Our Hesitation Waltz]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp128v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Lehman, A. F.]]></dc:creator>
<dc:date>Fri, 30 Oct 2009 14:13:11 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp128</dc:identifier>
<dc:title><![CDATA[Adopting Evidence-Based Practices--Our Hesitation Waltz]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-30</prism:publicationDate>
<prism:section>Editorial</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp118v1?rss=1">
<title><![CDATA[What Are the Components of CBT for Psychosis? A Delphi Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp118v1?rss=1</link>
<description><![CDATA[
<p>There is strong evidence supporting the implementation of cognitive behavior therapy (CBT) for people with psychosis. However, there are a variety of approaches to the delivery and conceptual underpinnings within different research groups, and the degree of consensus or disagreement regarding what are the intrinsic components has not been explored. This study uses the Delphi method to try to establish what a group of experts in CBT for psychosis view as important. Experts were invited to participate in 3 rounds of producing and rating statements that addressed areas such as principles, assessment, models, formulation, change strategies, homework, and therapists&rsquo; assumptions in order to consolidate consensus of opinion. Seventy-seven items were endorsed as important or essential for CBT for psychosis by &gt;80% of the panel. These recommendations should ensure greater fidelity in clinical practice, allow greater evaluation of adherence within clinical trials, facilitate the development of competency frameworks, and be of value in relation to training and dissemination of CBT for psychosis.</p>
]]></description>
<dc:creator><![CDATA[Morrison, A. P., Barratt, S.]]></dc:creator>
<dc:date>Fri, 30 Oct 2009 14:13:10 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp118</dc:identifier>
<dc:title><![CDATA[What Are the Components of CBT for Psychosis? A Delphi Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-30</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp117v1?rss=1">
<title><![CDATA[CHoice of Outcome In Cbt for psychosEs (CHOICE): The Development of a New Service User-Led Outcome Measure of CBT for Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp117v1?rss=1</link>
<description><![CDATA[
<p>Outcome measures for cognitive behavior therapy for psychosis (CBTp) have been derived from pharmacological studies, focusing on symptom change rather than outcomes such as distress or fulfilment. This study presents the development and psychometric properties of a new outcome measure (CHoice of Outcome In Cbt for psychosEs [CHOICE]), which reflects more strongly the aims of CBTp and the priorities of service users. Service users who had received CBTp participated in focus groups to discuss their outcome priorities, using a topic guide generated by a panel of experts in CBTp. A qualitative thematic analysis was undertaken to reach consensus on themes and generate items. Response scales were constructed for 3 dimensions: severity, satisfaction, and importance. The resulting questionnaire was piloted with service users who had not received CBTp, stratified by service type, ethnicity, and first language to ensure that it was user friendly and applicable prior to CBTp. The psychometric properties of the measure were then examined in a sample of 152 service users. Twenty-four items, and 2 of the dimensions (severity and satisfaction), were retained in the final measure. A factor analysis revealed a single psychological recovery factor interspersed throughout with both CBTp and recovery items. Test-retest reliability, construct validity, and sensitivity to change following CBTp were confirmed. The CHOICE measure is unique in being the first psychometrically adequate service user&ndash;led outcome measure of CBTp. It provides the opportunity to examine the evidence base for CBTp with an assessment approach that prioritizes service user definitions of recovery and CBT aims.</p>
]]></description>
<dc:creator><![CDATA[Greenwood, K. E., Sweeney, A., Williams, S., Garety, P., Kuipers, E., Scott, J., Peters, E.]]></dc:creator>
<dc:date>Fri, 30 Oct 2009 14:13:09 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp117</dc:identifier>
<dc:title><![CDATA[CHoice of Outcome In Cbt for psychosEs (CHOICE): The Development of a New Service User-Led Outcome Measure of CBT for Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-30</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp088v2?rss=1">
<title><![CDATA[Global White Matter Abnormalities in Schizophrenia: A Multisite Diffusion Tensor Imaging Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp088v2?rss=1</link>
<description><![CDATA[
<p><I>Background.</I> Emerging evidence implicates white matter (WM) abnormalities in the pathophysiology of schizophrenia. However, there is considerable heterogeneity in the presentation of WM abnormalities in the existing studies. The object of this study was to evaluate WM integrity in a large sample of patients with first-episode (FE) and chronic schizophrenia in comparison to matched control groups. Our goal was to assess whether WM findings occurred early in the illness or whether these abnormalities developed with the illness over time. <I>Methods.</I> Participants included 114 patients with schizophrenia (31 FE and 83 chronic patients) and 138 matched controls. High-resolution structural and diffusion tensor images were obtained on all participants. Measures of fractional anisotropy (FA) were calculated for the 4 cortical lobes and the cerebellum and brain stem. <I>Results.</I> FA was significant lower in patients vs controls in the whole brain and individually in the frontal, parietal, occipital, and temporal lobes. FA was not significantly different in the brain stem or cerebellum. FA differences were significant only in patients with chronic schizophrenia and not in the FE group. <I>Conclusions.</I> We found global differences in the WM microstructure in patients with chronic but not FE schizophrenia. These findings suggest progressive alterations in WM microstructure.</p>
]]></description>
<dc:creator><![CDATA[White, T., Magnotta, V. A., Bockholt, H. J., Williams, S., Wallace, S., Ehrlich, S., Mueller, B. A., Ho, B.-C., Jung, R. E., Clark, V. P., Lauriello, J., Bustillo, J. R., Schulz, S. C., Gollub, R. L., Andreasen, N. C., Calhoun, V. D., Lim, K. O.]]></dc:creator>
<dc:date>Thu, 29 Oct 2009 15:01:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp088</dc:identifier>
<dc:title><![CDATA[Global White Matter Abnormalities in Schizophrenia: A Multisite Diffusion Tensor Imaging Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-29</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp107v1?rss=1">
<title><![CDATA[Social Anhedonia and Schizotypy in a Community Sample: The Maryland Longitudinal Study of Schizotypy]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp107v1?rss=1</link>
<description><![CDATA[
<p>Social anhedonia has been employed in psychometric high-risk studies to identify putative schizotypes. To date, this research has focused almost exclusively on college samples. The current study sought to examine the validity of social anhedonia as an indicator of risk for schizophrenia-spectrum disorders within a community sample. Furthermore, we evaluated the role of other individual difference variables in accounting for variable clinical severity within the social anhedonia group including trait affectivity, social support, and family environment. Following the mailed questionnaire screening of 2434 eighteen-year olds, laboratory assessments were conducted with individuals identified as being high in social anhedonia (<I>n</I> = 86) and a comparison sample (<I>n</I> = 89). Compared with the control group, individuals in the social anhedonia group were found to have higher rates of mood disorders, elevated schizophrenia-spectrum personality disorder characteristics, greater negative symptom characteristics, and lower global functioning. Individuals within the social anhedonia group also reported greater trait negative affectivity, lower positive affectivity, less social support, and more family conflict. Low social support and problematic family environment were found to be related to elevations in spectrum personality disorder characteristics and poorer functioning within the social anhedonia group. These cross-sectional findings from a community sample provide further support for social anhedonia as a possible indicator of schizotypy.</p>
]]></description>
<dc:creator><![CDATA[Blanchard, J. J., Collins, L. M., Aghevli, M., Leung, W. W., Cohen, A. S.]]></dc:creator>
<dc:date>Thu, 22 Oct 2009 06:52:16 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp107</dc:identifier>
<dc:title><![CDATA[Social Anhedonia and Schizotypy in a Community Sample: The Maryland Longitudinal Study of Schizotypy]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-22</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp098v1?rss=1">
<title><![CDATA[Is Arson the Crime Most Strongly Associated With Psychosis?--A National Case-Control Study of Arson Risk in Schizophrenia and Other Psychoses]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp098v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> The association of psychosis with certain serious crimes, such as homicide, has been clearly demonstrated, but it is uncertain to what extent psychotic disorders are associated with arson. <I>Methods:</I> We used a case-control design to investigate the association of being diagnosed with schizophrenia and other psychoses and committing arson. Data were obtained from Swedish national registers for criminal convictions, hospital discharge diagnoses (<I>International Classification of Diseases, Ninth Revision</I> [<I>ICD-9</I>], and <I>International Classification of Diseases, Tenth Revision</I> [<I>ICD-10</I>]), and sociodemographic factors for 1988&ndash;2000. We included all convicted arson offenders of both sexes in Sweden (<I>N</I> = 1689) and compared them with a random sample of general population control subjects (<I>N</I> = 40 560). <I>Results:</I> After adjustment for sociodemographic confounders, arson offenders were more likely to be diagnosed with schizophrenia (in men, adjusted odds ratio [OR] = 22.6, 95% confidence interval [CI] = 14.8&ndash;34.4; in women, adjusted OR = 38.7, 95% CI = 20.4&ndash;73.5) or other psychoses (in men, adjusted OR = 17.4, 95% CI = 11.1&ndash;27.5; in women, adjusted OR = 30.8, 95% CI = 18.8&ndash;50.6). <I>Conclusions:</I> Individuals with schizophrenia and other psychoses have significantly increased risks of an arson conviction. These risk estimates are higher than those reported for other violent crimes and place arson in the same category as homicide as crimes that are most strongly associated with psychotic disorders.</p>
]]></description>
<dc:creator><![CDATA[Anwar, S., Langstrom, N., Grann, M., Fazel, S.]]></dc:creator>
<dc:date>Thu, 22 Oct 2009 06:52:12 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp098</dc:identifier>
<dc:title><![CDATA[Is Arson the Crime Most Strongly Associated With Psychosis?--A National Case-Control Study of Arson Risk in Schizophrenia and Other Psychoses]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-22</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp112v1?rss=1">
<title><![CDATA[Homicide of Strangers by People with a Psychotic Illness]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp112v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> The homicide of strangers by people with psychosis, referred to here as "stranger homicides," are rare and tragic events that generate adverse publicity for mental health services and have resulted in significant changes in mental health policy and law. <I>Aim:</I> To estimate the incidence of stranger homicides, using data from previously published studies, and to compare the characteristics of psychotic offenders who killed strangers with the characteristics of those who killed a close relative. <I>Method:</I> Meta-analysis of the population-based studies of homicide by persons suffering from a psychosis in which the number of subjects who killed strangers was also reported. Characteristics of stranger homicide and family homicide offenders were examined in a multicenter case&ndash;control study of homicide during psychotic illness in four high-income countries. <I>Results:</I> A pooled estimate of 1 stranger homicide per 14.3 million people per year (95% confidence interval, 1 in 18.9 million to 1 in 11.5 million people per year) was calculated by meta-analysis of 7 studies. The characteristics of the 42 stranger homicide offenders from New South Wales [NSW], Quebec and Eastern Ontario, Finland, and the Netherlands were identified. Twenty seven (64%) of these had never previously received treatment with antipsychotic medication. The stranger homicide offenders were more likely to be homeless, have exhibited antisocial conduct, and had fewer negative symptoms than those who killed family members. The victims of stranger homicide were mostly adult males and the homicides rarely occurred in the victim&rsquo;s home or workplace. <I>Conclusions:</I> Stranger homicide in psychosis is extremely rare and is even rarer for a patient who has received treatment with antipsychotic medication. A lack of distinguishing characteristics of stranger homicide offenders and an extremely low base rate of stranger-homicide suggests that risk assessment of patients known to have a psychotic illness will be of little assistance in the prevention of stranger homicides.</p>
]]></description>
<dc:creator><![CDATA[Nielssen, O., Bourget, D., Laajasalo, T., Liem, M., Labelle, A., Hakkanen-Nyholm, H., Koenraadt, F., Large, M. M.]]></dc:creator>
<dc:date>Mon, 12 Oct 2009 01:59:07 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp112</dc:identifier>
<dc:title><![CDATA[Homicide of Strangers by People with a Psychotic Illness]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-12</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp103v2?rss=1">
<title><![CDATA[Reliability and Comparability of Psychosis Patients' Retrospective Reports of Childhood Abuse]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp103v2?rss=1</link>
<description><![CDATA[
<p>An increasing number of studies are demonstrating an association between childhood abuse and psychosis. However, the majority of these rely on retrospective self-reports in adulthood that may be unduly influenced by current psychopathology. We therefore set out to explore the reliability and comparability of first-presentation psychosis patients&rsquo; reports of childhood abuse. Psychosis case subjects were drawn from the Aetiology and Ethnicity of Schizophrenia and Other Psychoses (&AElig;SOP) epidemiological study and completed the Childhood Experience of Care and Abuse Questionnaire to elicit abusive experiences that occurred prior to 16 years of age. High levels of concurrent validity were demonstrated with the Parental Bonding Instrument (antipathy: <I>r<SUB>s</SUB></I> = 0.350&ndash;0.737, <I>P</I> &lt; .001; neglect: <I>r<SUB>s</SUB></I> = 0.688&ndash;0.715, <I>P</I> &lt; .001), and good convergent validity was shown with clinical case notes (sexual abuse:  = 0.526, <I>P</I> &lt; .001; physical abuse:  = 0.394, <I>P</I> &lt; .001). Psychosis patients&rsquo; reports were also reasonably stable over a 7-year period (sexual abuse:  = 0.590, <I>P</I> &lt; .01; physical abuse:  = 0.634, <I>P</I> &lt; .001; antipathy:  = 0.492, <I>P</I> &lt; .01; neglect:  = 0.432, <I>P</I> &lt; .05). Additionally, their reports of childhood abuse were not associated with current severity of psychotic symptoms (sexual abuse: <I>U</I> = 1768.5, <I>P</I> = .998; physical abuse: <I>U</I> = 2167.5, <I>P</I> = .815; antipathy: <I>U</I> = 2216.5, <I>P</I> = .988; neglect: <I>U</I> = 1906.0, <I>P</I> = .835) or depressed mood (sexual abuse: <sup>2</sup> = 0.634, <I>P</I> = .277; physical abuse: <sup>2</sup> = 0.159, <I>P</I> = .419; antipathy: <sup>2</sup> = 0.868, <I>P</I> = .229; neglect: <sup>2</sup> = 0.639, <I>P</I> = .274). These findings provide justification for the use in future studies of retrospective reports of childhood abuse obtained from individuals with psychotic disorders.</p>
]]></description>
<dc:creator><![CDATA[Fisher, H. L., Craig, T. K., Fearon, P., Morgan, K., Dazzan, P., Lappin, J., Hutchinson, G., Doody, G. A., Jones, P. B., McGuffin, P., Murray, R. M., Leff, J., Morgan, C.]]></dc:creator>
<dc:date>Wed, 07 Oct 2009 07:59:06 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp103</dc:identifier>
<dc:title><![CDATA[Reliability and Comparability of Psychosis Patients' Retrospective Reports of Childhood Abuse]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-10-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp101v1?rss=1">
<title><![CDATA[Affective Dysregulation and Reality Distortion: A 10-Year Prospective Study of Their Association and Clinical Relevance]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp101v1?rss=1</link>
<description><![CDATA[
<p>Evidence from clinical patient populations indicates that affective dysregulation is strongly associated with reality distortion, suggesting that a process of misassignment of emotional salience may underlie this connection. To examine this in more detail without clinical confounds, affective regulation-reality distortion relationships, and their clinical relevance, were examined in a German prospective cohort community study. A cohort of 2524 adolescents and young adults aged 14&ndash;24 years at baseline was examined by experienced psychologists. Presence of psychotic experiences and (hypo)manic and depressive symptoms was assessed at 2 time points (3.5 and up to 10 years after baseline) using the Munich-Composite International Diagnostic Interview. Associations were tested between level of affective dysregulation on the one hand and incidence of psychotic experiences, persistence of these experiences, and psychotic Impairment on the other. Most psychotic experiences occurred in a context of affective dysregulation, and bidirectional dose-response was apparent with greater level of both affective dysregulation and psychotic experiences. Persistence of psychotic experiences was progressively more likely with greater level of (hypo)manic symptoms (odds ratio [OR] trend = 1.51, <I>P</I> &lt; .001) and depressive symptoms (OR trend = 1.15, <I>P</I> = .012). Similarly, psychotic experiences of clinical relevance were progressively more likely to occur with greater level of affective dysregulation (depressive symptoms: OR trend = 1.28, <I>P</I> = .002; (hypo)manic symptoms: OR trend = 1.37, <I>P</I> = .036). Correlated genetic liabilities underlying affective and nonaffective psychotic syndromes may be expressed as correlated dimensions in the general population. Also, affective dysregulation may contribute causally to the persistence and clinical relevance of reality distortion, possibly by facilitating a mechanism of aberrant salience attribution.</p>
]]></description>
<dc:creator><![CDATA[van Rossum, I., Dominguez, M.-d.-G., Lieb, R., Wittchen, H.-U., van Os, J.]]></dc:creator>
<dc:date>Wed, 30 Sep 2009 05:03:20 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp101</dc:identifier>
<dc:title><![CDATA[Affective Dysregulation and Reality Distortion: A 10-Year Prospective Study of Their Association and Clinical Relevance]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-30</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp108v1?rss=1">
<title><![CDATA[Referential Failures and Affective Reactivity of Language in Schizophrenia and Unipolar Depression]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp108v1?rss=1</link>
<description><![CDATA[
<p>Reference failures, and their increase in affectively negative conditions (known as affective reactivity of speech), are more frequently observed in schizophrenia patients than in normal controls, but no information is available comparing schizophrenia with depression, ie, a mental disorder closely linked to the concept of affective reactivity. To address this gap in the literature, the present study compared 24 schizophrenia inpatients, 21 unipolar depression inpatients and 21 normal controls. Two 10-minute conversational speech samples (1 on negative and 1 on positive memories) were collected from each patient. The transcripts of the audiotaped interviews were analyzed blindly for frequencies of 6 types of referential failures, employing the Communication Disturbances Index, adapted for use with Italian. The schizophrenia patients made more frequent total reference failures and, specifically, more missing information references than the depression patients. The depression patients made more frequent reference failures than the normal controls, overall, and on most of the specific types of failures. Affective reactivity of speech was observed only for the schizophrenia sample and was greatest for missing information references. This study supports the viability of reference failure analysis as a measure of communication disturbance in a language other than English. The findings indicate that schizophrenia and depression both are associated with high levels of referential failures but that affective reactivity of speech is present only in schizophrenia and not in depression.</p>
]]></description>
<dc:creator><![CDATA[Rubino, I. A., D'Agostino, L., Sarchiola, L., Romeo, D., Siracusano, A., Docherty, N. M.]]></dc:creator>
<dc:date>Wed, 23 Sep 2009 08:10:46 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp108</dc:identifier>
<dc:title><![CDATA[Referential Failures and Affective Reactivity of Language in Schizophrenia and Unipolar Depression]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp105v1?rss=1">
<title><![CDATA[The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp105v1?rss=1</link>
<description><![CDATA[
<p>To provide a rational basis for reconceptualizing catatonia in <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fifth Edition), we briefly review historical sources, the psychopathology of catatonia, and the relevance of catatonic schizophrenia in contemporary practice and research. In contrast to Kahlbaum, Kraepelin and others (Jaspers, Kleist, and Schneider) recognized the prevalence of motor symptoms in diverse psychiatric disorders but concluded that the unique pattern and persistence of certain psychomotor phenomena defined a "catatonic" subtype of schizophrenia, based on intensive long-term studies. The enduring controversy and confusion that ensued underscores the fact that the main problem with catatonia is not just its place in <I>Diagnostic and Statistical Manual of Mental Disorders</I> but rather its lack of conceptual clarity. There still are no accepted principles on what makes a symptom catatonic and no consensus on which signs and symptoms constitute a catatonic syndrome. The resulting heterogeneity is reflected in treatment studies that show that stuporous catatonia in any acute disorder responds to benzodiazepines or electroconvulsive therapy, whereas catatonia in the context of chronic schizophrenia is phenomenologically different and less responsive to either modality. Although psychomotor phenomena are an intrinsic feature of acute and especially chronic schizophrenia, they are insufficiently recognized in practice and research but may have significant implications for treatment outcome and neurobiological studies. While devising a separate category of catatonia as a nonspecific syndrome has heuristic value, it may be equally if not more important to re-examine the psychopathological basis for defining psychomotor symptoms as catatonic and to re-establish psychomotor phenomena as a fundamental symptom dimension or criterion for both psychotic and mood disorders.</p>
]]></description>
<dc:creator><![CDATA[Ungvari, G. S., Caroff, S. N., Gerevich, J.]]></dc:creator>
<dc:date>Wed, 23 Sep 2009 08:10:45 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp105</dc:identifier>
<dc:title><![CDATA[The Catatonia Conundrum: Evidence of Psychomotor Phenomena as a Symptom Dimension in Psychotic Disorders]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp095v1?rss=1">
<title><![CDATA[A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp095v1?rss=1</link>
<description><![CDATA[
<p>Cognitive impairment in schizophrenia is often severe, enduring, and contributes significantly to chronic disability. But clinicians have difficulty in assessing cognition due to a lack of brief instruments. We evaluated whether a brief battery of cognitive tests derived from larger batteries could generate a summary score representing global cognitive function. Using data from 3 previously published trials, we calculated the corrected item-total correlations (CITCs) or the correlation of each test with the battery total score. We computed the proportion of variance that each test shares with the global score excluding that test (<I>R</I><f><SUB><I>t</I></SUB><sup>2</sup></f>=<I>CITC</I><sup>2</sup>) and the variance explained per minute of administration time for each test (<I>R</I><f><SUB><I>t</I></SUB><sup>2</sup></f>/min). The 3 tests with the highest <I>R</I><f><SUB><I>t</I></SUB><sup>2</sup></f>/min were selected for the brief battery. The composite score from the trail making test B, category fluency, and digit symbol correlated .86 with the global score of the larger battery in 2 of the studies and correlated between .73 and .82 with the total battery scores excluding these 3 tests. A Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) using the above 3 tests can be administered in 10&ndash;11 min. The full batteries of the larger studies have administration times ranging from 90 to 210 min. Given prior research suggesting that a single factor of global cognition best explains the pattern of cognitive deficit in schizophrenia, an instrument like B-CATS can provide clinicians with meaningful data regarding their patients&rsquo; cognitive function. It can also serve researchers who want an estimate of global cognitive function without requiring a full neuropsychological battery.</p>
]]></description>
<dc:creator><![CDATA[Hurford, I. M., Marder, S. R., Keefe, R. S. E., Reise, S. P., Bilder, R. M.]]></dc:creator>
<dc:date>Wed, 23 Sep 2009 08:10:42 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp095</dc:identifier>
<dc:title><![CDATA[A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp094v1?rss=1">
<title><![CDATA[Cognitive Impairment in Schizophrenia and Affective Psychoses: Implications for DSM-V Criteria and Beyond]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp094v1?rss=1</link>
<description><![CDATA[
<p>It has recently been suggested that the diagnostic criteria of schizophrenia should include specific reference to cognitive impairments characterizing the disorder. Arguments in support of this assertion contend that such inclusion would not only serve to increase the awareness of cognitive deficits in affected patients, among both clinicians and researchers alike, but also increase the "point of rarity" between schizophrenia and mood disorders. The aim of the current article is to examine this latter assertion in light of the recent opinion piece provided by Keefe and Fenton (Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? <I>Schizophr Bull</I>. 2007;33:912&ndash;920). Through literature review, we explore the issue of whether cognitive deficits do in fact differentiate the major psychoses. The overall results of this inquiry suggest that inclusion of cognitive impairment criteria in <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fifth Edition) (<I>DSM-V</I>) would not provide a major advancement in discriminating schizophrenia from bipolar disorder and affective psychoses. Therefore, while cognitive impairment should be included in <I>DSM-V</I>, it should not dictate diagnostic specificity&mdash;at least not until more comprehensive evidence-based reviews of the current diagnostic system have been undertaken. Based on this evidence, we consider several alternatives for the <I>DSM-V</I> definition of cognitive impairment in schizophrenia, including (1) the inclusion of cognitive impairment as a specifier and (2) the definition of cognitive impairment as a dimension within a hybrid categorical-dimensional system. Given the state of current evidence, these possibilities appear to represent the most parsimonious approaches to the inclusion of cognitive deficits in the diagnostic criteria of schizophrenia and, potentially, of mood disorders.</p>
]]></description>
<dc:creator><![CDATA[Bora, E., Yucel, M., Pantelis, C.]]></dc:creator>
<dc:date>Wed, 23 Sep 2009 08:10:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp094</dc:identifier>
<dc:title><![CDATA[Cognitive Impairment in Schizophrenia and Affective Psychoses: Implications for DSM-V Criteria and Beyond]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp093v1?rss=1">
<title><![CDATA[Cognitive Impairment in Affective Psychoses: A Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp093v1?rss=1</link>
<description><![CDATA[
<p>It has recently been suggested that cognitive impairment should be included in the diagnostic criteria of schizophrenia. One of the main arguments in support of this suggestion has been the hope that cognitive impairment can help distinguish schizophrenia from bipolar disorder (BD). However, recent evidence shows that cognitive deficits occur in BD and persist beyond euthymia. Further, mood disorders with psychotic features might be expected to manifest greater cognitive impairment, which further complicates the potential to differentiate these disorders. The goal of the current meta-analysis was to examine the magnitude and characteristics of cognitive impairments in affective psychoses (AP). A systematic search of the existing literature sourced 27 studies that met the inclusion criteria. These studies compared cognitive performances of 763 patients with AP (550 BD and 213 major depressive disorder) and 1823 healthy controls. Meta-regression and subgroup analyses were used to examine the effects of moderator variables. Meta-analyses of these studies showed that patients with AP were impaired in all 15 cognitive tasks with large effect sizes for most measures. There were no significant differences between the magnitude of impairments between the BD and major depressive disorder groups. The largest effect size was found for symbol coding, stroop task, verbal learning, and category fluency, reflecting impairments in elementary and complex aspects of attentional processing, as well as learning and memory. In general, the pattern of cognitive impairments in AP was similar to reported findings in euthymic patients with BD, but relatively more pronounced.</p>
]]></description>
<dc:creator><![CDATA[Bora, E., Yucel, M., Pantelis, C.]]></dc:creator>
<dc:date>Fri, 18 Sep 2009 07:20:19 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp093</dc:identifier>
<dc:title><![CDATA[Cognitive Impairment in Affective Psychoses: A Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp099v1?rss=1">
<title><![CDATA[Gray Matter in First-Episode Schizophrenia Before and After Antipsychotic Drug Treatment. Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp099v1?rss=1</link>
<description><![CDATA[
<p><I>Background.</I> Cerebral morphological abnormalities in schizophrenia may be modulated by treatment, chronicity, and duration of illness. Comparing brain imaging studies of individuals with first-episode schizophrenia and neuroleptic naive (NN-FES) with that of their neuroleptic-treated counterparts (NT-FES) can help to dissect out the effect of these potential confounders. <I>Methods.</I> We used the anatomical likelihood estimation method to compare voxel-based morphometric studies of NN-FES (<I>n</I> = 162 patients) and NT-FES (<I>n</I> = 336 patients) studies. The analysis included a sample size weighting step based on the Liptak-Stouffer method to reflect the greater power of larger studies. <I>Results.</I> Patient samples were matched for age, gender, and duration of illness. An extensive network of gray matter deficits in frontal, temporal, insular, striatal, posterior cingulate, and cerebellar regions was detected in the NN-FES samples as compared with healthy controls. Major deficits were detected in the frontal, superior temporal, insular, and parahippocampal regions for the NT-FES group compared with the NN-FES group. In addition, the NT-FES group showed minor deficits in the caudate, cingulate, and inferior temporal regions compared with the NN-FES group. There were no regions with gray matter volumetric excess in the NT-FES group. <I>Conclusion.</I> Frontal, striato-limbic, and temporal morphological abnormalities are present in the early stage of schizophrenia and are unrelated to the effects of neuroleptic treatment, chronicity, and duration of illness. There may be dynamic effects of treatment on striato-limbic and temporal, but not frontal, regional gray matter volumes of the brain.</p>
]]></description>
<dc:creator><![CDATA[Leung, M., Cheung, C., Yu, K., Yip, B., Sham, P., Li, Q., Chua, S., McAlonan, G.]]></dc:creator>
<dc:date>Wed, 16 Sep 2009 06:00:39 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp099</dc:identifier>
<dc:title><![CDATA[Gray Matter in First-Episode Schizophrenia Before and After Antipsychotic Drug Treatment. Anatomical Likelihood Estimation Meta-analyses With Sample Size Weighting]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-16</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp097v1?rss=1">
<title><![CDATA[Psychiatric Genocide: Nazi Attempts to Eradicate Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp097v1?rss=1</link>
<description><![CDATA[
<p>Although the Nazi genocide of Jews during World War II is well known, the concurrent Nazi genocide of psychiatric patients is much less widely known. An attempt was made to estimate the number of individuals with schizophrenia who were sterilized and murdered by the Nazis and to assess the effect on the subsequent prevalence and incidence of this disease. It is estimated that between 220 000 and 269 500 individuals with schizophrenia were sterilized or killed. This total represents between 73% and 100% of all individuals with schizophrenia living in Germany between 1939 and 1945. Postwar studies of the prevalence of schizophrenia in Germany reported low rates, as expected. However, postwar rates of the incidence of schizophrenia in Germany were unexpectedly high. The Nazi genocide of psychiatric patients was the greatest criminal act in the history of psychiatry. It was also based on what are now known to be erroneous genetic theories and had no apparent long-term effect on the subsequent incidence of schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Torrey, E. F., Yolken, R. H.]]></dc:creator>
<dc:date>Wed, 16 Sep 2009 06:00:37 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp097</dc:identifier>
<dc:title><![CDATA[Psychiatric Genocide: Nazi Attempts to Eradicate Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-16</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp096v1?rss=1">
<title><![CDATA[The Association Between Childhood Trauma and Memory Functioning in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp096v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Both neurocognitive impairments and a history of childhood abuse are highly prevalent in patients with schizophrenia. Childhood trauma has been associated with memory impairment as well as hippocampal volume reduction in adult survivors. The aim of the following study was to examine the contribution of childhood adversity to verbal memory functioning in people with schizophrenia. <I>Methods:</I> Eighty-five outpatients with a <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fourth Edition) diagnosis of chronic schizophrenia were separated into 2 groups on the basis of self-reports of childhood trauma. Performance on measures of episodic narrative memory, list learning, and working memory was then compared using multivariate analysis of covariance. <I>Results:</I> Thirty-eight (45%) participants reported moderate to severe levels of childhood adversity, while 47 (55%) reported no or low levels of childhood adversity. After controlling for premorbid IQ and current depressive symptoms, the childhood trauma group had significantly poorer working memory and episodic narrative memory. However, list learning was similar between groups. <I>Conclusion:</I> Childhood trauma is an important variable that can contribute to specific ongoing memory impairments in schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Shannon, C., Douse, K., McCusker, C., Feeney, L., Barrett, S., Mulholland, C.]]></dc:creator>
<dc:date>Sun, 13 Sep 2009 21:47:40 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp096</dc:identifier>
<dc:title><![CDATA[The Association Between Childhood Trauma and Memory Functioning in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-13</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn181v2?rss=1">
<title><![CDATA[Seeking Verisimilitude in a Class: A Systematic Review of Evidence That the Criterial Clinical Symptoms of Schizophrenia Are Taxonic]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn181v2?rss=1</link>
<description><![CDATA[
<p>This review examines whether there is evidence that the criterion symptoms of <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fourth Edition) (<I>DSM-IV</I>) schizophrenia are taxonic&mdash;that schizophrenia is not part of a single distribution of normality. Two taxometric methods, coherent cut kinetics (CCK) and latent variable modeling (LVM), are demonstrated to be sensitive to latent classes and, therefore, were regarded as providing relevant statistical evidence. A systematic literature search identified 24 articles describing analyses of 28 participant cohorts in which CCK or LVM methods were used with one or more criterion symptoms of schizophrenia. Virtually all analyses yielded results that, on first impression, favored taxonic over dimensional interpretations of the latent structure of schizophrenia. However, threats to the internal and external validity of these studies&mdash;including biased or inadequate analyses, violation of statistical assumptions, inadequate indicator screening, and the introduction of systematic error through recruitment and sampling&mdash;critically undermine this body of work. Uncertainties about the potential effects of perceptual biases, unimodal assessment, and item parceling are also identified, as are limitations in seeking to validate classes with single or double dissociations of outcomes. We conclude that there is no reason to seriously doubt a single-distribution model of schizophrenia because there is no evidence that provides a serious test of this null hypothesis. A second fundamental question remains outstanding: is schizophrenia truly a group of schizophrenias, with taxonic divisions separating its types? We make design and analysis suggestions for future research addressing these questions.</p>
]]></description>
<dc:creator><![CDATA[Linscott, R. J., Allardyce, J., van Os, J.]]></dc:creator>
<dc:date>Mon, 07 Sep 2009 08:03:29 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn181</dc:identifier>
<dc:title><![CDATA[Seeking Verisimilitude in a Class: A Systematic Review of Evidence That the Criterial Clinical Symptoms of Schizophrenia Are Taxonic]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp087v1?rss=1">
<title><![CDATA[Longitudinal Study of Stressful Life Events and Daily Stressors Among Adolescents at High Risk for Psychotic Disorders]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp087v1?rss=1</link>
<description><![CDATA[
<p>Psychosocial stress preceding the onset or recurrence of psychotic symptoms has been identified in patients with schizophrenia; yet there is limited understanding of the effects of stress in typically developing adolescents or those who show behavioral signs of risk for schizophrenia spectrum disorders. This study examined the developmental course of symptom progression as a function of stressful life events and daily hassles in adolescents with schizotypal personality disorder (SPD), other personality disorders, or no Axis II disorder. In this prospective longitudinal study, life events and daily stressors were assessed in adolescents aged 12 to 18 years. Results revealed that adolescents with SPD and other personality disorders reported significantly greater total, independent, and undesirable life events than individuals with no Axis II disorders. Youth with SPD report daily hassles to cause more distress compared to peers. Correlational analyses and hierarchal linear regression was used to evaluate the relationship of life events and daily stressors with psychiatric symptoms measured concurrently and 1 year later. Across diagnostic groups, the incidence of independent and undesirable life events were associated with current prodromal symptoms, while the frequency of daily stressors predicted a significant increment in positive, but not negative, prodromal symptoms over time. Therefore, adolescents who report greater daily stressors exhibit an increase in prodromal symptoms over a 1 year period. Psychosocial stress has been implicated in the etiology of schizophrenia, and these findings suggest the importance of life events and daily hassles as potential risk factors in the onset of psychotic symptoms during adolescence.</p>
]]></description>
<dc:creator><![CDATA[Tessner, K. D., Mittal, V., Walker, E. F.]]></dc:creator>
<dc:date>Fri, 04 Sep 2009 06:38:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp087</dc:identifier>
<dc:title><![CDATA[Longitudinal Study of Stressful Life Events and Daily Stressors Among Adolescents at High Risk for Psychotic Disorders]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp092v1?rss=1">
<title><![CDATA[Evidence for Impaired Sound Intensity Processing in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp092v1?rss=1</link>
<description><![CDATA[
<p>Patients with schizophrenia are impaired in many aspects of auditory processing, but indirect evidence suggests that intensity perception is intact. However, because the extraction of meaning from dynamic intensity relies on structures that appear to be altered in schizophrenia, we hypothesized that the perception of auditory looming is impaired as well. Twenty inpatients with schizophrenia and 20 control participants, matched for age, gender, and education, gave intensity ratings of rising (looming) and falling intensity sounds with different mean intensities. Intensity change was overestimated in looming as compared with receding sounds in both groups. However, healthy individuals showed a stronger effect at higher mean intensity, in keeping with previous findings, while patients with schizophrenia lacked this modulation. We discuss how this might support the notion of a more general deficit in extracting emotional meaning from different sensory cues, including intensity and pitch.</p>
]]></description>
<dc:creator><![CDATA[Bach, D. R., Buxtorf, K., Strik, W. K., Neuhoff, J. G., Seifritz, E.]]></dc:creator>
<dc:date>Thu, 03 Sep 2009 02:59:30 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp092</dc:identifier>
<dc:title><![CDATA[Evidence for Impaired Sound Intensity Processing in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-09-03</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp086v1?rss=1">
<title><![CDATA[How a Series of Hallucinations Tells a Symbolic Story]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp086v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Greek, M. T.]]></dc:creator>
<dc:date>Fri, 28 Aug 2009 05:34:29 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp086</dc:identifier>
<dc:title><![CDATA[How a Series of Hallucinations Tells a Symbolic Story]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-28</prism:publicationDate>
<prism:section>First Person Account</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp089v1?rss=1">
<title><![CDATA[Nicotine Enhances but Does Not Normalize Visual Sustained Attention and the Associated Brain Network in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp089v1?rss=1</link>
<description><![CDATA[
<p>Sustained attention abnormality in schizophrenia is usually refractory to available treatment. Nicotine can transiently improve sustained attention in schizophrenia patients, although its neural mechanisms are unknown. Understanding the neural basis of this effect may lead to new treatment strategies for this cognitive deficit. Twenty schizophrenia patients and 24 healthy comparison smokers participated in a double-blind, placebo-controlled, crossover, randomized functional magnetic resonance imaging study comparing nicotine vs placebo patch on sustained attention, using the rapid visual information&ndash;processing task. Schizophrenia patients had impaired visual sustained attention accuracy and processing speed (all <I>P</I>&rsquo;s &lt;.001) and showed significantly reduced activation in the frontal-parietal-cingulate-thalamic attention network compared with healthy comparison subjects. Nicotine administration enhanced accuracy and processing speed compared with placebo (all <I>P</I>&rsquo;s &le;.006), with no drug <FONT FACE="arial,helvetica">x</FONT> diagnosis interactions. However, schizophrenia patients&rsquo; task performance remained impaired during the nicotine condition, even when compared with healthy comparison subjects in the placebo condition (all <I>P</I>&rsquo;s &le;.01). Nicotine exerted no significant reversal of the impaired attention network associated with schizophrenia. Activations in brain regions associated with nicotine-induced behavioral improvement were not significantly different between patients and comparison subjects. Thus, nicotine transiently enhanced sustained attention similarly in schizophrenia patients and in healthy comparison smokers. The neural mechanisms for this nicotinic effect in schizophrenia appear similar to those for healthy comparison subjects. However, nicotine, at least in a single sustained dose, does not normalize impaired sustained attention and its associated brain network in schizophrenia. These findings provide guidance for developing new treatment strategies for the sustained attention deficit in schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Hong, L. E., Schroeder, M., Ross, T. J., Buchholz, B., Salmeron, B. J., Wonodi, I., Thaker, G. K., Stein, E. A.]]></dc:creator>
<dc:date>Thu, 27 Aug 2009 06:13:49 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp089</dc:identifier>
<dc:title><![CDATA[Nicotine Enhances but Does Not Normalize Visual Sustained Attention and the Associated Brain Network in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp062v1?rss=1">
<title><![CDATA[Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp062v1?rss=1</link>
<description><![CDATA[
<p>The primary purpose of this study was to compare changes in cognition in early-onset psychosis after 6-months treatment with quetiapine or olanzapine. This is a randomized, single-blind, 6-month study in 50 adolescents with a diagnosis of early-onset psychosis. Patients were randomized to quetiapine (<I>n</I> = 24) or olanzapine (<I>n</I> = 26). A thorough neuropsychological battery was administered at baseline and after 6-month treatment. Out of the total sample included in the study, 32 patients completed at least 6-months treatment with the assigned medication (quetiapine, <I>n</I> = 16; olanzapine, <I>n</I> = 16). No changes were observed in cognitive performance after 6-month treatment with quetiapine or olanzapine. Although some trends toward cognitive improvement were observed for the olanzapine group after 6-month treatment, neither group showed statistically significant gains. Furthermore, there was no evidence of any differential efficacy of olanzapine or quetiapine on cognitive improvement in this sample of adolescents with psychosis.</p>
]]></description>
<dc:creator><![CDATA[Robles, O., Zabala, A., Bombin, I., Parellada, M., Moreno, D., Ruiz-Sancho, A., Arango, C.]]></dc:creator>
<dc:date>Tue, 25 Aug 2009 06:17:16 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp062</dc:identifier>
<dc:title><![CDATA[Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-25</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp084v1?rss=1">
<title><![CDATA[Visual Organization Processes in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp084v1?rss=1</link>
<description><![CDATA[
<p>Patients with schizophrenia are known to be impaired at organizing and exploring the visual environment. However, these impairments vary across studies, and the conditions determining whether patients are impaired or not are unclear. We aim to clarify this question by distinguishing different types of visual organization processes. A total of 23 patients and matched controls had to identify 2 identical figures embedded in a global structure made of connectors linking figures by pairs. The 2 targets belonged to either the same perceptual group (linked by a connector) or 2 different pairs (not linked by a connector). In a neutral condition, no connectors were presented. Top-down processes were explored by manipulating the proportion of targets linked or not by a connector in 3 experimental blocks. Patients needed the same processing time as controls to extract targets linked by a connector from the global structure. They could also focus on connectors when incited to do so. Impairments were observed for targets that were part of different pairs. Extracting such targets is effortful and time consuming, and both groups were slower in this condition than in the neutral condition. However, patients were slowed less than controls. This paradoxical improvement illustrates the fact that patients do not structure visual elements that are part of a global structure and not automatically bound together. Our results suggest this is due to impaired top-down processes.</p>
]]></description>
<dc:creator><![CDATA[van Assche, M., Giersch, A.]]></dc:creator>
<dc:date>Mon, 24 Aug 2009 07:40:51 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp084</dc:identifier>
<dc:title><![CDATA[Visual Organization Processes in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-24</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp083v1?rss=1">
<title><![CDATA[Psychotic-Like Experiences in Major Depression and Anxiety Disorders: A Population-Based Survey in Young Adults]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp083v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Population-based surveys have confirmed that psychotic-like experiences are prevalent in the community. However, it is unclear if these experiences are associated with common mental disorders. The aim of this study was to examine the prevalence of psychotic-like experiences in those with affective and anxiety disorders. <I>Methods</I>: Subjects were drawn from the Mater-University of Queensland Study of Pregnancy. Delusion-like experiences were assessed with the Peters Delusional Inventory (PDI). The Composite International Diagnostic Interview (CIDI) was used to identify individuals with <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fourth Edition) lifetime diagnoses of major depression, anxiety disorder, substance use/dependence, and psychotic disorders. The influence of affective and anxiety disorders on PDI and CIDI psychosis-related items&rsquo; scores were assessed with logistic regression, with adjustments for age, sex, and the presence of the other comorbid psychiatric diagnoses. <I>Results:</I> Having either a lifetime diagnosis of major depressive disorder or an anxiety disorder was associated with significantly higher PDI total scores (highest vs lowest quartile adjusted odds ratios [ORs] and 95% confidence intervals [CIs] = 4.43, 3.09&ndash;6.36; 3.08, 2.26&ndash;4.20, respectively). The odds of endorsing any CIDI hallucination or delusion item was increased in those with a major depressive or anxiety disorder. The presence of current anxiety disorder symptoms was significantly associated with PDI score (OR = 5.81, 95% CI = 3.68&ndash;9.16). <I>Conclusion:</I> While psychotic-like experiences are usually associated with psychotic disorders, individuals with depression and anxiety are also more likely to report these symptoms compared with well individuals. Psychotic-like experiences are associated with a range of common mental disorders.</p>
]]></description>
<dc:creator><![CDATA[Varghese, D., Scott, J., Welham, J., Bor, W., Najman, J., O'Callaghan, M., Williams, G., McGrath, J.]]></dc:creator>
<dc:date>Mon, 17 Aug 2009 07:51:01 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp083</dc:identifier>
<dc:title><![CDATA[Psychotic-Like Experiences in Major Depression and Anxiety Disorders: A Population-Based Survey in Young Adults]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp085v1?rss=1">
<title><![CDATA[First-Time Primary Caregivers' Experience of Caring for Young Adults With First-Episode Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp085v1?rss=1</link>
<description><![CDATA[
<p>Becoming a carer is associated with physical, emotional, and financial hardship, with caregivers often experiencing a maelstrom of emotions as they struggle to understand what has happened to their loved one. While the burden of caring for young people with first-episode psychosis (FEP) has been well documented, much less is known about how carers develop the strength and resilience to continue caring. This qualitative study aimed to understand the experience of 20 first-time primary caregivers of young adults with FEP. Most caregivers were female (85%, <I>n</I> = 17) and parents (85%, <I>n</I> = 17). The average length of involvement as a caregiver at an FEP service was 14.5 months. Six main themes were identified in the data, highlighting the carers&rsquo; experience in supporting young adults with FEP. Caregiving is a burdensome responsibility and is characterized as a roller coaster and unpredictable experience. Caregivers often feel responsible for the young person's illness; however, eventually most come to terms with the changes that have occurred in the young person with FEP. As a consequence of the illness, the relationship between caregiver and care recipient frequently becomes closer and deeper, although it is important that they both maintain hope for the future. These findings provide important insights into the experiences of first-time caregivers of young people with FEP, with direct implications for improving the information and support given to caregivers by FEP services, as well as the development of interventions that effectively address the unique challenges caregivers face following the onset of FEP.</p>
]]></description>
<dc:creator><![CDATA[McCann, T. V., Lubman, D. I., Clark, E.]]></dc:creator>
<dc:date>Thu, 13 Aug 2009 10:16:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp085</dc:identifier>
<dc:title><![CDATA[First-Time Primary Caregivers' Experience of Caring for Young Adults With First-Episode Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-13</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp081v1?rss=1">
<title><![CDATA["Where Do Auditory Hallucinations Come From?"--A Brain Morphometry Study of Schizophrenia Patients With Inner or Outer Space Hallucinations]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp081v1?rss=1</link>
<description><![CDATA[
<p>Auditory verbal hallucinations are a cardinal symptom of schizophrenia. Bleuler and Kraepelin distinguished 2 main classes of hallucinations: hallucinations heard outside the head (outer space, or external, hallucinations) and hallucinations heard inside the head (inner space, or internal, hallucinations). This distinction has been confirmed by recent phenomenological studies that identified 3 independent dimensions in auditory hallucinations: language complexity, self-other misattribution, and spatial location. Brain imaging studies in schizophrenia patients with auditory hallucinations have already investigated language complexity and self-other misattribution, but the neural substrate of hallucination spatial location remains unknown. Magnetic resonance images of 45 right-handed patients with schizophrenia and persistent auditory hallucinations and 20 healthy right-handed subjects were acquired. Two homogeneous subgroups of patients were defined based on the hallucination spatial location: patients with only outer space hallucinations (<I>N</I> = 12) and patients with only inner space hallucinations (<I>N</I> = 15). Between-group differences were then assessed using 2 complementary brain morphometry approaches: voxel-based morphometry and sulcus-based morphometry. Convergent anatomical differences were detected between the patient subgroups in the right temporoparietal junction (rTPJ). In comparison to healthy subjects, opposite deviations in white matter volumes and sulcus displacements were found in patients with inner space hallucination and patients with outer space hallucination. The current results indicate that spatial location of auditory hallucinations is associated with the rTPJ anatomy, a key region of the "where" auditory pathway. The detected tilt in the sulcal junction suggests deviations during early brain maturation, when the superior temporal sulcus and its anterior terminal branch appear and merge.</p>
]]></description>
<dc:creator><![CDATA[Plaze, M., Paillere-Martinot, M.-L., Penttila, J., Januel, D., de Beaurepaire, R., Bellivier, F., Andoh, J., Galinowski, A., Gallarda, T., Artiges, E., Olie, J.-P., Mangin, J.-F., Martinot, J.-L., Cachia, A.]]></dc:creator>
<dc:date>Fri, 07 Aug 2009 12:16:05 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp081</dc:identifier>
<dc:title><![CDATA["Where Do Auditory Hallucinations Come From?"--A Brain Morphometry Study of Schizophrenia Patients With Inner or Outer Space Hallucinations]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp074v1?rss=1">
<title><![CDATA[Prefrontal Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp074v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> The prodromal phase of psychosis is characterized by impaired executive function and altered prefrontal activation. The extent to which the severity of these deficits at presentation predicts subsequent clinical outcomes is unclear. <I>Methods:</I> We employed functional magnetic resonance imaging in a cohort of subjects at clinical risk for psychosis and in healthy controls. Images were acquired at clinical presentation and again after 1 year, using a 1.5-T Signa MRI scanner while subjects were performing a verbal fluency task. SPM5 was used for the analysis of imaging data. Psychopathological assessment of the "at-risk" symptoms was performed by using the Comprehensive Assessment for the At-Risk Mental State (CAARMS) and the Positive and Negative Symptom Scale (PANSS). <I>Results:</I> In the at-risk mental state (ARMS) group, between presentation and follow-up, the CAARMS (perceptual disorder and thought disorder subscales) and the PANSS general scores decreased, while the Global Assessment of Functioning (GAF) score increased. Both the ARMS and control groups performed the verbal fluency task with a high degree of accuracy. The ARMS group showed greater activation in the left inferior frontal gyrus but less activation in the anterior cingulate gyrus than controls. Within the ARMS group, the longitudinal normalization of neurofunctional response in the left inferior frontal gyrus was positively correlated with the improvement in severity of hallucination-like experiences. <I>Conclusions:</I> The normalization of the abnormal prefrontal response during executive functioning is associated with 12-month psychopathological improvement of prodromal symptoms.</p>
]]></description>
<dc:creator><![CDATA[Fusar-Poli, P., Broome, M.R., Matthiasson, P., Woolley, J.B., Mechelli, A., Johns, L.C., Tabraham, P., Bramon, E., Valmaggia, L., Williams, S.C., McGuire, P.]]></dc:creator>
<dc:date>Fri, 07 Aug 2009 12:16:04 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp074</dc:identifier>
<dc:title><![CDATA[Prefrontal Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp066v1?rss=1">
<title><![CDATA[Who Benefits From Supported Employment: A Meta-analytic Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp066v1?rss=1</link>
<description><![CDATA[
<p><I>Aims:</I> This meta-analysis sought to identify which subgroups of clients with severe mental illness (SMI) benefited from evidence-based supported employment. <I>Methods:</I> We used meta-analysis to pool the samples from 4 randomized controlled trials comparing the Individual Placement and Support (IPS) model of supported employment to well-regarded vocational approaches using stepwise models and brokered services. Meta-analysis was used to determine the magnitude of effects for IPS/control group differences within specific client subgroups (defined by 2 work history, 7 sociodemographic, and 8 clinical variables) on 3 competitive employment outcomes (obtaining a job, total weeks worked, and job tenure). <I>Results:</I> The findings strongly favored IPS, with large effect sizes across all outcomes: 0.96 for job acquisition, 0.79 for total weeks worked, and 0.74 for job tenure. Overall, 90 (77%) of the 117 effect sizes calculated for the 39 subgroups exceeded 0.70, and all 117 favored IPS. <I>Conclusions:</I> IPS produces better competitive employment outcomes for persons with SMI than alternative vocational programs regardless of background demographic, clinical, and employment characteristics.</p>
]]></description>
<dc:creator><![CDATA[Campbell, K., Bond, G. R., Drake, R. E.]]></dc:creator>
<dc:date>Thu, 06 Aug 2009 07:22:05 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp066</dc:identifier>
<dc:title><![CDATA[Who Benefits From Supported Employment: A Meta-analytic Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-08-06</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp073v1?rss=1">
<title><![CDATA[Brain Anatomical Abnormalities in High-Risk Individuals, First-Episode, and Chronic Schizophrenia: An Activation Likelihood Estimation Meta-analysis of Illness Progression]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp073v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> The present study reviewed voxel-based morphometry (VBM) studies on high-risk individuals with schizophrenia, patients experiencing their first-episode schizophrenia (FES), and those with chronic schizophrenia. We predicted that gray matter abnormalities would show progressive changes, with most extensive abnormalities in the chronic group relative to FES and least in the high-risk group. <I>Method:</I> Forty-one VBM studies were reviewed. Eight high-risk studies, 14 FES studies, and 19 chronic studies were analyzed using anatomical likelihood estimation meta-analysis. <I>Results:</I> Less gray matter in the high-risk group relative to controls was observed in anterior cingulate regions, left amygdala, and right insula. Lower gray matter volumes in FES compared with controls were also found in the anterior cingulate and right insula but not the amygdala. Lower gray matter volumes in the chronic group were most extensive, incorporating similar regions to those found in FES and high-risk groups but extending to superior temporal gyri, thalamus, posterior cingulate, and parahippocampal gryus. Subtraction analysis revealed less frontotemporal, striatal, and cerebellar gray matter in FES than the high-risk group; the high-risk group had less gray matter in left subcallosal gyrus, left amygdala, and left inferior frontal gyrus compared with FES. Subtraction analysis confirmed lower gray matter volumes through ventral-dorsal anterior cingulate, right insula, left amygdala and thalamus in chronic schizophrenia relative to FES. <I>Conclusions:</I> Frontotemporal brain structural abnormalities are evident in nonpsychotic individuals at high risk of developing schizophrenia. The present meta-analysis indicates that these gray matter abnormalities become more extensive through first-episode and chronic illness. Thus, schizophrenia appears to be a progressive cortico-striato-thalamic loop disorder.</p>
]]></description>
<dc:creator><![CDATA[Chan, R. C. K., Di, X., McAlonan, G. M., Gong, Q.-y.]]></dc:creator>
<dc:date>Fri, 24 Jul 2009 12:50:50 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp073</dc:identifier>
<dc:title><![CDATA[Brain Anatomical Abnormalities in High-Risk Individuals, First-Episode, and Chronic Schizophrenia: An Activation Likelihood Estimation Meta-analysis of Illness Progression]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-07-24</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp067v1?rss=1">
<title><![CDATA[Dysfunction of a Cortical Midline Network During Emotional Appraisals in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp067v1?rss=1</link>
<description><![CDATA[
<p>A cardinal feature of schizophrenia is the poor comprehension, or misinterpretation, of the emotional meaning of social interactions and events, which can sometimes take the form of a persecutory delusion. It has been shown that the comprehension of the emotional meaning of the social world involves a midline paralimbic cortical network. However, the function of this network during emotional appraisals in patients with schizophrenia is not well understood. In this study, hemodynamic responses were measured in 14 patients with schizophrenia and 18 healthy subjects during the evaluation of descriptions of social situations with negative, positive, and neutral affective valence. The healthy and schizophrenia groups displayed opposite patterns of responses to emotional and neutral social situations within the medial prefrontal and posterior cingulate cortices&mdash;healthy participants showed greater activity to the emotional compared to the neutral situations, while patients exhibited greater responses to the neutral compared to the emotional situations. Moreover, the magnitude of the response within bilateral cingulate gyri to the neutral social stimuli predicted delusion severity in the patients with schizophrenia. These findings suggest that impaired functioning of cortical midline structures in schizophrenia may underlie faulty interpretations of social events, contributing to delusion formation.</p>
]]></description>
<dc:creator><![CDATA[Holt, Daphne. J., Lakshmanan, B., Freudenreich, O., Goff, D. C., Rauch, S. L., Kuperberg, G. R.]]></dc:creator>
<dc:date>Wed, 15 Jul 2009 06:05:14 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp067</dc:identifier>
<dc:title><![CDATA[Dysfunction of a Cortical Midline Network During Emotional Appraisals in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-07-15</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp059v1?rss=1">
<title><![CDATA[Catatonia Is not Schizophrenia: Kraepelin's Error and the Need to Recognize Catatonia as an Independent Syndrome in Medical Nomenclature]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp059v1?rss=1</link>
<description><![CDATA[
<p><I>Catatonia</I> is a motor dysregulation syndrome described by Karl Kahlbaum in 1874. He understood catatonia as a disease of its own. Others quickly recognized it among diverse disorders, but Emil Kraepelin made it a linchpin of his concept of dementia praecox. Eugen Bleuler endorsed this singular association. During the 20th century, catatonia has been considered a type of schizophrenia. In the 1970s, American authors identified catatonia in patients with mania and depression, as a toxic response, and in general medical and neurologic illnesses. It was only occasionally found in patients with schizophrenia. When looked for, catatonia is found in 10% or more of acute psychiatric admissions. It is readily diagnosable, verifiable by a lorazepam challenge test, and rapidly treatable. Even in its most lethal forms, it responds to high doses of lorazepam or to electroconvulsive therapy. These treatments are not accepted for patients with schizophrenia. Prompt recognition and treatment saves lives. It is time to place catatonia into its own home in the psychiatric classification.</p>
]]></description>
<dc:creator><![CDATA[Fink, M., Shorter, E., Taylor, M. A.]]></dc:creator>
<dc:date>Wed, 08 Jul 2009 04:09:09 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp059</dc:identifier>
<dc:title><![CDATA[Catatonia Is not Schizophrenia: Kraepelin's Error and the Need to Recognize Catatonia as an Independent Syndrome in Medical Nomenclature]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-07-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn118v2?rss=1">
<title><![CDATA[Impaired Modulation of Attention and Emotion in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn118v2?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Fronto-limbic interactions facilitate the generation of task-relevant responses while inhibiting interference from emotionally distracting information. Schizophrenia is associated with deficits in both executive attention and affective regulation. This study aims to elucidate the neural correlates of emotion-attention regulation and shifting in schizophrenia. <I>Method:</I> We employed functional magnetic resonance imaging to probe the fronto-limbic regions in 16 adults with schizophrenia and 13 matched adults with no history of psychiatric illness. Subjects performed a forced-choice visual oddball task where they detected infrequent target circles embedded in a series of infrequent nontarget aversive and neutral pictures and frequent squares. <I>Results:</I> In control participants, target events activated a dorsal frontoparietal network, whereas these regions were deactivated by aversive stimuli. Conversely, ventral frontolimbic brain regions were activated by aversive stimuli and deactivated by target events. In the patient group, regional hemodynamic timecourses revealed not only reduced activation to target and aversive events in dorsal executive and ventral limbic regions, respectively, but also reduced deactivation to target and aversive stimuli in ventral and dorsal regions, respectively, relative to the control group. Patients further showed reduced spatial extent of activation in the right inferior frontal gyrus during the target and aversive conditions. Activation of the anterior cingulate to aversive images was inversely related to severity of avolition and anhedonia symptoms in the schizophrenia group. <I>Conclusions:</I> These results suggest both frontal and limbic dysfunction in schizophrenia as well as aberrant reciprocal inhibitions between these regions during attention-emotion modulation in this disorder.</p>
]]></description>
<dc:creator><![CDATA[Dichter, G. S., Bellion, C., Casp, M., Belger, A.]]></dc:creator>
<dc:date>Wed, 08 Jul 2009 07:50:56 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn118</dc:identifier>
<dc:title><![CDATA[Impaired Modulation of Attention and Emotion in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-07-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp018v1?rss=1">
<title><![CDATA[Selective Emotional Processing Deficits to Social Vignettes in Schizophrenia: An ERP Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp018v1?rss=1</link>
<description><![CDATA[
<p>Schizophrenia is associated with abnormalities in emotional processing and social cognition. However, it remains unclear whether patients show abnormal neurophysiological responses during fast, online appraisals of the emotional meaning of social information. To examine this question, event-related potentials (ERPs) were collected while 18 schizophrenia patients and 18 demographically matched controls evaluated 2-sentence vignettes describing negative, positive, or neutral social situations. ERPs were time locked to a critical word (CW) in the second sentence that conferred emotional valence. A late positivity effect to emotional (vs neutral) CWs was seen in both groups (in controls, to negative and positive CWs; in patients, to negative CWs only). However, the controls showed a greater late positivity effect to the negative and positive (vs neutral) CWs than the schizophrenia patients at mid-posterior (negative vs neutral) and at right posterior peripheral (positive vs neutral) sites. These between-group differences arose from reduced amplitudes of the late positivity to the negative and positive CWs in the patients relative to the controls; there was no difference between the 2 groups in the amplitude of the late positivity to the neutral CWs. These findings suggest that schizophrenia is associated with a specific neural deficit during the online evaluation of emotionally valent, socially relevant information.</p>
]]></description>
<dc:creator><![CDATA[Kuperberg, G. R., Kreher, D. A., Swain, A., Goff, D. C., Holt, D. J.]]></dc:creator>
<dc:date>Mon, 29 Jun 2009 02:34:01 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp018</dc:identifier>
<dc:title><![CDATA[Selective Emotional Processing Deficits to Social Vignettes in Schizophrenia: An ERP Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-29</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp061v1?rss=1">
<title><![CDATA[The Spectrum of Sanity and Insanity]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp061v1?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Reina, A.]]></dc:creator>
<dc:date>Fri, 26 Jun 2009 04:50:06 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp061</dc:identifier>
<dc:title><![CDATA[The Spectrum of Sanity and Insanity]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-26</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp060v1?rss=1">
<title><![CDATA[Gray Matter Deficits, Mismatch Negativity, and Outcomes in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp060v1?rss=1</link>
<description><![CDATA[
<p>Reduced mismatch negativity (MMN) in response to auditory change is a well-established finding in schizophrenia and has been shown to be correlated with impaired daily functioning, rather than with hallmark signs and symptoms of the disorder. In this study, we investigated (1) whether the relationship between reduced MMN and impaired daily functioning is mediated by cortical volume loss in temporal and frontal brain regions in schizophrenia and (2) whether this relationship varies with the type of auditory deviant generating MMN. MMN in response to duration, frequency, and intensity deviants was recorded from 18 schizophrenia subjects and 18 pairwise age- and gender-matched healthy subjects. Patients&rsquo; levels of global functioning were rated on the Social and Occupational Functioning Assessment Scale. High-resolution structural magnetic resonance scans were acquired to generate average cerebral cortex and temporal lobe models using cortical pattern matching. This technique allows accurate statistical comparison and averaging of cortical measures across subjects, despite wide variations in gyral patterns. MMN amplitude was reduced in schizophrenia patients and correlated with their impaired day-to-day function level. Only in patients, bilateral gray matter reduction in Heschl's gyrus, as well as motor and executive regions of the frontal cortex, correlated with reduced MMN amplitude in response to frequency deviants, while reduced gray matter in right Heschl's gyrus also correlated with reduced MMN to duration deviants. Our findings further support the importance of MMN reduction in schizophrenia by linking frontotemporal cerebral gray matter pathology to an automatically generated event-related potential index of daily functioning.</p>
]]></description>
<dc:creator><![CDATA[Rasser, P.E., Schall, U., Todd, J., Michie, P. T., Ward, P. B., Johnston, P., Helmbold, K., Case, V., Soyland, A., Tooney, P. A., Thompson, P. M.]]></dc:creator>
<dc:date>Fri, 26 Jun 2009 04:50:06 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp060</dc:identifier>
<dc:title><![CDATA[Gray Matter Deficits, Mismatch Negativity, and Outcomes in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-26</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp063v1?rss=1">
<title><![CDATA[The Relationship Among Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and Habituation of Arousal in Nonclinical Individuals]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp063v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> Previous studies reported an association between weak habituation of skin conductance orienting response and psychosis proneness. The aim of this study was to investigate the relationship among neuregulin 1 (NRG1)&ndash;stimulated AKT phosphorylation (a putative marker of psychosis), orienting response habituation, delusional ideas, anxiety, and depression in nonclinical individuals. <I>Methods:</I> One hundred twenty individuals participated in the skin conductance measurements. Weak and strong habituators were compared on measures of NRG1-stimulated AKT phosphorylation in B lymphoblasts, delusional ideas, anxiety, and depression. The predictors of delusional ideas were determined by multiple regression analysis. <I>Results:</I> Weak habituators displayed higher levels of delusional ideas/anxiety and a lower ratio of phosphorylated AKT as compared with strong habituators. There were 3 significant predictors of delusional ideas: decreased habituation, NRG1-induced AKT phosphorylation, and anxiety. Age, gender, education, IQ, and depression did not predict delusional ideas. <I>Conclusions:</I> These results suggest that decreased habituation of arousal, NRG1-induced AKT phosphorylation, and anxiety are related to delusional ideation in the general population.</p>
]]></description>
<dc:creator><![CDATA[Keri, S., Seres, I., Kelemen, O., Benedek, G.]]></dc:creator>
<dc:date>Tue, 23 Jun 2009 00:43:56 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp063</dc:identifier>
<dc:title><![CDATA[The Relationship Among Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and Habituation of Arousal in Nonclinical Individuals]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp058v1?rss=1">
<title><![CDATA[Hippocampi, Thalami, and Accumbens Microstructural Damage in Schizophrenia: A Volumetry, Diffusivity, and Neuropsychological Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp058v1?rss=1</link>
<description><![CDATA[
<p>Volumetric abnormalities in the subcortical structures have been described in schizophrenia. However, it still has to be clarified if subtle microstructural damage is also present. Thus, we aimed to detect subcortical volume and mean diffusivity (MD) alterations in 45 patients with diagnosis of schizophrenia compared with 45 age-, gender-, and educational attainment&ndash;matched healthy comparison (HC) participants, by using a combined volumetry and diffusion tensor imaging (DTI) method. A secondary aim was to identify the neuropsychological correlates of subcortical abnormalities in the schizophrenic group. We found thalami and hippocampi bilaterally and left accumbens to show MD increase in the schizophrenic group. No volumetric decrease was found. Moreover, significant correlations between the MD values in subcortical structures (right thalamus and hippocampus and left accumbens) and working memory performance were found. Thus, subcortical microstructural alterations are present in schizophrenia even in absence of volumetric abnormalities. Furthermore, microstructural damage in subcortical areas is linked to working memory, suggesting the presence of a subtle microstructural subcortical dysfunction in the pathoetiological mechanism underlying high cognitive load performances in schizophrenia. Finally, our findings indicate that MD is a more sensitive marker of brain tissue deficits than signal intensity variations measured in T1-weighted imaging data, consistently with previous reports. Thus, DTI appears to be an invaluable tool to investigate subcortical pathology in schizophrenia, greatly enhancing the ability to detect subtle brain changes in this complex disorder.</p>
]]></description>
<dc:creator><![CDATA[Spoletini, I., Cherubini, A., Banfi, G., Rubino, I. A., Peran, P., Caltagirone, C., Spalletta, G.]]></dc:creator>
<dc:date>Fri, 19 Jun 2009 13:51:51 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp058</dc:identifier>
<dc:title><![CDATA[Hippocampi, Thalami, and Accumbens Microstructural Damage in Schizophrenia: A Volumetry, Diffusivity, and Neuropsychological Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-19</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp057v1?rss=1">
<title><![CDATA[Are Screening Instruments Valid for Psychotic-Like Experiences? A Validation Study of Screening Questions for Psychotic-Like Experiences Using In-Depth Clinical Interview]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp057v1?rss=1</link>
<description><![CDATA[
<p>Individuals who report psychotic-like experiences are at increased risk of future clinical psychotic disorder. They constitute a unique "high-risk" group for studying the developmental trajectory to schizophrenia and related illnesses. Previous research has used screening instruments to identify this high-risk group, but the validity of these instruments has not yet been established. We administered a screening questionnaire with 7 items designed to assess psychotic-like experiences to 334 adolescents aged 11&ndash;13 years. Detailed clinical interviews were subsequently carried out with a sample of these adolescents. We calculated sensitivity and specificity and positive predictive value (PPV) and negative predictive value (NPV) for each screening question for the specific symptom it enquired about and also in relation to any psychotic-like experience. The predictive power varied substantially between items, with the question on auditory hallucinations ("Have you ever heard voices or sounds that no one else can hear?") providing the best predictive power. For interview-verified auditory hallucinations specifically, this question had a PPV of 71.4% and an NPV of 90.4%. When assessed for its predictive power for any psychotic-like experience (including, but not limited to, auditory hallucinations), it provided a PPV of 100% and an NPV of 88.4%. Two further questions&mdash;relating to visual hallucinations and paranoid thoughts&mdash;also demonstrated good predictive power for psychotic-like experiences. Our results suggest that it may be possible to screen the general adolescent population for psychotic-like experiences with a high degree of accuracy using a short self-report questionnaire.</p>
]]></description>
<dc:creator><![CDATA[Kelleher, I., Harley, M., Murtagh, A., Cannon, M.]]></dc:creator>
<dc:date>Fri, 19 Jun 2009 13:51:50 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp057</dc:identifier>
<dc:title><![CDATA[Are Screening Instruments Valid for Psychotic-Like Experiences? A Validation Study of Screening Questions for Psychotic-Like Experiences Using In-Depth Clinical Interview]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-19</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp037v1?rss=1">
<title><![CDATA[Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp037v1?rss=1</link>
<description><![CDATA[
<p><I>Introduction:</I> Head-to-head comparisons of antipsychotics have predominantly included patients with chronic conditions. The aim of the present study was to compare the efficacy and tolerability of ziprasidone and olanzapine in patients with recent-onset schizophrenia. <I>Methods:</I> The study was an 8-week, double-blind, parallel-group, randomized, controlled multicenter trial (NCT00145444). Seventy-six patients with schizophreniform disorder, schizophrenia or schizoaffective disorder (diagnosis &lt; 5 y), and a maximum lifetime antipsychotic treatment &lt;16 weeks participated in the study. Efficacy of ziprasidone (80&ndash;160 mg/d) and olanzapine 10&ndash;20 mg was measured using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI) Scale, the Calgary Depression Scale for Schizophrenia (CDSS), and the Heinrich Quality of Life Scale (HQLS); tolerability assessments included laboratory assessments, body weight, and electroencephalogram. <I>Results:</I> Olanzapine (<I>n</I> = 34) and ziprasidone (<I>n</I> = 39) showed equal efficacy as measured by the PANSS, CDSS, CGI, and HQLS. However, mean weight gain was significantly higher in the olanzapine group (6.8 vs 0.1 kg, <I>P</I> &lt; .001). Ziprasidone was associated with decreasing levels of triglycerides, cholesterol, and transaminases, while these parameters increased in the olanzapine group (all <I>P</I> values &lt; .05). There were no significant differences in fasting glucose and prolactin levels or in cardiac or sexual side effects. Patients on ziprasidone used biperiden for extrapyramidal side effects more frequently (<I>P</I> &lt; .05). <I>Discussion:</I> The results of this study indicate that ziprasidone and olanzapine have comparable therapeutic efficacy but differ in their side effect profile. However, there is a risk of a type II error with this sample size. Clinically significant weight gain and laboratory abnormalities appear early after initiating treatment and are more prominent with olanzapine, while more patients on ziprasidone received anticholinergic drugs to treat extrapyramidal symptoms.</p>
]]></description>
<dc:creator><![CDATA[Grootens, K. P., van Veelen, N. M. J., Peuskens, J., Sabbe, B. G. C., Thys, E., Buitelaar, J. K., Verkes, R. J., Kahn, R. S.]]></dc:creator>
<dc:date>Fri, 19 Jun 2009 13:51:49 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp037</dc:identifier>
<dc:title><![CDATA[Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-19</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn191v2?rss=1">
<title><![CDATA[Trimethoprim as Adjuvant Treatment in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn191v2?rss=1</link>
<description><![CDATA[
<p>Various infectious agents, such as <I>Toxoplasma gondii</I>, have been hypothesized to be potentially relevant etiological factors in the onset of some cases of schizophrenia. We conducted a randomized, double-blind, placebo-controlled treatment trial in an attempt to explore the hypothesis that the symptoms of schizophrenia may be related to infection of the central nervous system with <I>toxoplasma gondii</I>. Systematically selected patients with ongoing and at least moderately severe schizophrenia from Butajira, in rural Ethiopia, were randomly allocated to trimethoprim or placebo, which were added on to participants' regular antipsychotic treatments. Trial treatments were given for 6 months. The Positive and Negative Syndrome Scale (PANSS) was used to assess outcome. Ninety-one patients were included in the study, with 80 cases (87.9%) positive for <I>T. gondii</I> immunoglobulin G antibody. Seventy-nine subjects (87.0%) completed the trial. The mean age of subjects was 35.3 (SD = 8.0) years, with a mean duration of illness of 13.2 (SD = 6.7) years. Both treatment groups showed significant reduction in the overall PANSS score with no significant between-group difference. In this sample of patients with chronic schizophrenia, trimethoprim used as adjuvant treatment is not superior to placebo. However, it is not possible to draw firm conclusion regarding the etiological role of toxoplasmosis on schizophrenia based on this study because the timing and the postulated mechanisms through which toxoplasmosis produces schizophrenia are variable.</p>
]]></description>
<dc:creator><![CDATA[Shibre, T., Alem, A., Abdulahi, A., Araya, M., Beyero, T., Medhin, G., Deyassa, N., Negash, A., Nigatu, A., Kebede, D., Fekadu, A.]]></dc:creator>
<dc:date>Tue, 16 Jun 2009 00:11:51 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn191</dc:identifier>
<dc:title><![CDATA[Trimethoprim as Adjuvant Treatment in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-16</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp056v1?rss=1">
<title><![CDATA[Looking at the Schizophrenia Spectrum Through the Prism of Self-disorders: An Empirical Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp056v1?rss=1</link>
<description><![CDATA[
<p>Nonpsychotic anomalies of subjective experience were emphasized in both classic literature and phenomenological psychiatry as essential clinical features of schizophrenia. However, only in recent years, their topicality with respect to the construct validity of the concept of the schizophrenia spectrum has been explicitly acknowledged, mainly as a consequence of the increasing focus on early detection and prevention of psychosis. The current study tested the hypothesis of a specific aggregation of self-disorders (SDs, various anomalies of self-awareness) in schizophrenia-spectrum conditions, comparing different diagnostic groups; 305 subjects, previously assessed in the Copenhagen Schizophrenia Linkage Study, were grouped into 4 experimental samples, according to their <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Third Edition Revised) main diagnosis: schizophrenia, (<I>n</I> = 29), schizotypal personality disorder (<I>n</I> = 61), other mental illness not belonging to the schizophrenia spectrum (<I>n</I> = 112), and no mental illness (<I>n</I> = 103). The effect of diagnostic grouping on the level of SDs was explored via general linear model and logistic regression. The diagnosis of schizophrenia and schizotypy predicted higher levels of SDs, and SDs scores were significantly different between spectrum and nonspectrum samples; the likelihood of experiencing SDs increased as well with the diagnostic severity. The findings support the assumption that SDs are a discriminant psychopathological feature of the schizophrenia spectrum and suggest their incorporation to strengthen its construct validity, with potential benefit for both early detection and pathogenetic research.</p>
]]></description>
<dc:creator><![CDATA[Raballo, A., Saebye, D., Parnas, J.]]></dc:creator>
<dc:date>Mon, 15 Jun 2009 16:54:44 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp056</dc:identifier>
<dc:title><![CDATA[Looking at the Schizophrenia Spectrum Through the Prism of Self-disorders: An Empirical Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-15</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp044v1?rss=1">
<title><![CDATA[Validating Measures of Real-World Outcome: The Results of the VALERO Expert Survey and RAND Panel]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp044v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> People with schizophrenia demonstrate considerable discrepancy between self-reported functioning and informant reports. It is not clear whether these discrepancies originate from the instruments used or from the perspectives of different informants. The goal of the Validation of Everyday Real-World Outcomes (VALERO) Study is to enhance the measurement of real-world (RW) outcomes in the social, residential, and vocational domains through selection of optimal scales and informants using a multistep process similar to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative. <I>Methods:</I> Forty-eight experts provided their opinion regarding the best scales measuring RW outcomes. Fifty-nine measures were nominated. The investigators selected the 11 scales that were the most highly nominated, had the most published validity data, and best represented the domains of interest. Information was provided to other experts who served as RAND panelists. Panelists rated each measure for its suitability across multiple a priori domains. Discrepant ratings were discussed until consensus was reached. <I>Results:</I> Following the RAND Panel, the 2 scales that scored highest across the various criteria for each of the classes of scales (hybrid, social functioning, and everyday living skills) were selected for use in the first substudy of VALERO. The scales selected were the Quality-of-Life Scale, Specific Levels of Functioning Scale, Social Behavior Schedule, Social Functioning Scale, Independent Living Skills Schedule, and Life Skills Profile. <I>Discussion:</I> The results show that although there are significant limitations with current scales used for the assessment of RW outcome in schizophrenia, a consensus is possible. Further, several existing instruments were rated as useful for measuring social, residential, and vocational outcomes.</p>
]]></description>
<dc:creator><![CDATA[Leifker, F. R., Patterson, T. L., Heaton, R. K., Harvey, P. D.]]></dc:creator>
<dc:date>Fri, 12 Jun 2009 07:37:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp044</dc:identifier>
<dc:title><![CDATA[Validating Measures of Real-World Outcome: The Results of the VALERO Expert Survey and RAND Panel]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-12</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp010v1?rss=1">
<title><![CDATA[Presynaptic Regulation of Dopamine Transmission in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp010v1?rss=1</link>
<description><![CDATA[
<p>A role for dopamine (DA) <I>release</I> in the hallucinations and other positive symptoms associated with schizophrenia has long been inferred from the antipsychotic response to D2 DA receptor antagonists and because the DA releaser amphetamine can be psychotogenic. Recent studies suggest that patients with schizophrenia, including those never exposed to antipsychotic drugs, maintain high presynaptic DA <I>accumulation</I> in the striatum. New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Lyon, G. J., Abi-Dargham, A., Moore, H., Lieberman, J. A., Javitch, J. A., Sulzer, D.]]></dc:creator>
<dc:date>Fri, 12 Jun 2009 07:37:31 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp010</dc:identifier>
<dc:title><![CDATA[Presynaptic Regulation of Dopamine Transmission in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-12</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn165v1?rss=1">
<title><![CDATA[A Randomized Experimental Investigation of Reasoning Training for People With Delusions]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn165v1?rss=1</link>
<description><![CDATA[
<p>The present study aimed to investigate whether a brief reasoning training module changes the "jumping to conclusions" data gathering bias in people with delusions. A secondary aim was to examine whether improvements in reasoning would lead to greater flexibility in thinking about delusions. It was found that people with delusions and a diagnosis of schizophrenia (<I>n</I> = 34) requested less information on a reasoning task compared with a nonclinical control group (<I>n</I> = 34). The clinical group was then randomly allocated to a session of reasoning training or to an attention control condition. Following training, participants showed a significant increase in data gathering, and a small number reported more flexibility and less conviction in their delusions, although this finding was not significant. The presence at baseline of an extreme reasoning bias moderated the effect of training. The study provides further confirmation of the jumping to conclusions bias and shows that data gathering can be improved, though the severest form of the bias is resistant to change. It is recommended that lengthier, delusion-related reasoning packages be developed and evaluated.</p>
]]></description>
<dc:creator><![CDATA[Ross, K., Freeman, D., Dunn, G., Garety, P.]]></dc:creator>
<dc:date>Thu, 11 Jun 2009 06:20:36 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn165</dc:identifier>
<dc:title><![CDATA[A Randomized Experimental Investigation of Reasoning Training for People With Delusions]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-11</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp053v1?rss=1">
<title><![CDATA[Powerful Choices: Peer Support and Individualized Medication Self-Determination]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp053v1?rss=1</link>
<description><![CDATA[
<p>Peer support is unique in the mental health field because peer specialists provide a role model of recovery to both staff and people in recovery. Peer support as an evidence-based practice is reviewed. A personal recovery story and the experience of working as a certified peer specialist are shared to show the power peer supporters have in transforming the mental health system. Research supporting a more selective role for medication is reviewed along with the role of peer supporters in helping individuals to maximize their own unique medication needs with self-advocacy and negotiation skills. The importance of making choices is explained as a key motivating factor to keep both staff and people in recovery from giving up. Two main science-to-service gaps in real-world schizophrenia treatment are discussed: the lack of available peer support and the need for medication self-determination.</p>
]]></description>
<dc:creator><![CDATA[West, C.]]></dc:creator>
<dc:date>Wed, 10 Jun 2009 14:36:34 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp053</dc:identifier>
<dc:title><![CDATA[Powerful Choices: Peer Support and Individualized Medication Self-Determination]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-10</prism:publicationDate>
<prism:section>The Science to Service Gap in Real World Schizophrenia Treatment</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp055v1?rss=1">
<title><![CDATA[Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp055v1?rss=1</link>
<description><![CDATA[
<p>Celiac disease (CD) and schizophrenia have approximately the same prevalence, but epidemiologic data show higher prevalence of CD among schizophrenia patients. The reason for this higher co-occurrence is not known, but the clinical knowledge about the presence of immunologic markers for CD or gluten intolerance in schizophrenia patients may have implications for treatment. Our goal was to evaluate antibody prevalence to gliadin (AGA), transglutaminase (tTG), and endomysium (EMA) in a group of individuals with schizophrenia and a comparison group. AGA, tTG, and EMA antibodies were assayed in 1401 schizophrenia patients who were part of the Clinical Antipsychotic Trials of Intervention Effectiveness study and 900 controls. Psychopathology in schizophrenia patients was assessed using the Positive and Negative Symptoms Scale (PANSS). Logistic regression was used to assess the difference in the frequency of AGA, immunoglobulin A (IgA), and tTG antibodies, adjusting for age, sex, and race. Linear regression was used to predict PANSS scores from AGA and tTG antibodies adjusting for age, gender, and race. Among schizophrenia patients, 23.1% had moderate to high levels of IgA-AGA compared with 3.1% of the comparison group (<sup>2</sup> = 1885, <I>df</I> = 2, <I>P</I> &lt; .001.) Moderate to high levels of tTG antibodies were present in 5.4% of schizophrenia patients vs 0.80% of the comparison group (<sup>2</sup> = 392.0, <I>df</I> = 2, <I>P</I> &lt; .001). Adjustments for sex, age, and race had trivial effects on the differences. Regression analyses failed to predict PANSS scores from AGA and tTG antibodies. Persons with schizophrenia have higher than expected titers of antibodies related to CD and gluten sensitivity.</p>
]]></description>
<dc:creator><![CDATA[Cascella, N. G., Kryszak, D., Bhatti, B., Gregory, P., Kelly, D. L., Mc Evoy, J. P., Fasano, A., Eaton, W. W.]]></dc:creator>
<dc:date>Wed, 03 Jun 2009 13:21:08 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp055</dc:identifier>
<dc:title><![CDATA[Prevalence of Celiac Disease and Gluten Sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-03</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp052v1?rss=1">
<title><![CDATA[Coronavirus Immunoreactivity in Individuals With a Recent Onset of Psychotic Symptoms]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp052v1?rss=1</link>
<description><![CDATA[
<p>Prenatal influenza exposure increases the risk for schizophrenia and brings to question how other respiratory viruses may contribute to neuropsychiatric disease etiopathology. Human coronaviruses cause respiratory infections that range in seriousness from common colds to severe acute respiratory syndrome. Like influenza, coronaviruses can be neurotropic. To test for associations between coronaviruses and serious mental disorders, we utilized a recently developed assay and measured immunoglobulin G (IgG) response against 4 human coronavirus strains (229E, HKU1, NL63, and OC43) in 106 patients with a recent onset of psychotic symptoms and 196 nonpsychiatric controls. We expressed results quantitatively as antibody levels and qualitatively as seroprevalence relative to a defined seropositivity cutoff value. Patient IgG levels were higher than controls for HKU1, NL63, and OC43, with HKU1 and NL63 both showing highly significant patient-to-control differences (HKU1, <I>P</I> &le; .002; NL63, <I>P</I> &le; .00001). All 4 coronaviruses were more seroprevalent in patients vs controls, with greatest intergroup differences observed for HKU1 (93% vs 77%, <I>P</I> &le; .0001). HKU1 and NL63 associations with the patient group were further supported by multivariate analyses that controlled for age, gender, race, socioeconomic status, and smoking status (HKU1, odds ratio [OR] = 1.32, 95% confidence interval [CI] = 1.03&ndash;1.67, <I>P</I> &le; .027; NL63, OR = 2.42, 95% CI = 1.25&ndash;4.66, <I>P</I> &le; .008). Among patients, NL63 was associated with schizophrenia-spectrum (OR = 3.10, 95% CI = 1.27&ndash;7.58, <I>P</I> &le; .013) but not mood disorders. HKU1 and NL63 coronavirus exposures may represent comorbid risk factors in neuropsychiatric disease. Future studies should explore links between the timing of coronavirus infections and subsequent development of schizophrenia and other disorders with psychotic symptoms.</p>
]]></description>
<dc:creator><![CDATA[Severance, E. G., Dickerson, F. B., Viscidi, R. P., Bossis, I., Stallings, C. R., Origoni, A. E., Sullens, A., Yolken, R. H.]]></dc:creator>
<dc:date>Tue, 02 Jun 2009 10:54:29 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp052</dc:identifier>
<dc:title><![CDATA[Coronavirus Immunoreactivity in Individuals With a Recent Onset of Psychotic Symptoms]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-02</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp048v1?rss=1">
<title><![CDATA[Stigma Resistance in Patients With Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp048v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> An individual's capacity to counteract the stigma of mental illness, stigma resistance (SR), is considered as playing a crucial role in fighting stigma. However, little is known about SR and its correlates in patients with schizophrenia or schizoaffective disorder. <I>Aim:</I> Exploring SR in patients with schizophrenia or schizoaffective disorder. <I>Method:</I> One hundred fifty-seven participants completed the "Internalized Stigma of Mental Illness" (ISMI) Scale including its subscale on SR. Measures of perceived devaluation and discrimination, depression, self-esteem, empowerment, quality of life, and demographic and clinical variables were obtained. <I>Results:</I> Two-thirds of all patients showed high SR. SR correlated positively with self-esteem, empowerment, and quality of life and negatively with stigma measures and depression. A social network with a sufficient number of friends, being single or married, in contrast to being separated, as well as receiving outpatient treatment, was associated with higher SR. <I>Conclusions:</I> SR is a new and promising concept. The development of stigma-resisting beliefs might help individuals in their hope of finding a fulfilling life and in their recovery from mental illness.</p>
]]></description>
<dc:creator><![CDATA[Sibitz, I., Unger, A., Woppmann, A., Zidek, T., Amering, M.]]></dc:creator>
<dc:date>Mon, 01 Jun 2009 04:56:14 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp048</dc:identifier>
<dc:title><![CDATA[Stigma Resistance in Patients With Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-06-01</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp039v1?rss=1">
<title><![CDATA[Reinforcement Ambiguity and Novelty Do Not Account for Transitive Inference Deficits in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp039v1?rss=1</link>
<description><![CDATA[
<p>The capacity for transitive inference (TI), a form of relational memory organization, is impaired in schizophrenia patients. In order to disambiguate deficits in TI from the effects of ambiguous reinforcement history and novelty, 28 schizophrenia and 20 nonpsychiatric control subjects were tested on newly developed TI and non-TI tasks that were matched on these 2 variables. Schizophrenia patients performed significantly worse than controls on the TI task but were able to make equivalently difficult nontransitive judgments as well as controls. Neither novelty nor reinforcement ambiguity accounted for the selective deficit of the patients on the TI task. These findings implicate a disturbance in relational memory organization, likely subserved by hippocampal dysfunction, in the pathophysiology of schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Coleman, M. J., Titone, D., Krastoshevsky, O., Krause, V., Huang, Z., Mendell, N. R., Eichenbaum, H., Levy, D. L.]]></dc:creator>
<dc:date>Thu, 21 May 2009 07:56:58 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp039</dc:identifier>
<dc:title><![CDATA[Reinforcement Ambiguity and Novelty Do Not Account for Transitive Inference Deficits in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp022v1?rss=1">
<title><![CDATA[Evidence That Onset of Clinical Psychosis Is an Outcome of Progressively More Persistent Subclinical Psychotic Experiences: An 8-Year Cohort Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp022v1?rss=1</link>
<description><![CDATA[
<p>This study examined the hypothesis that developmental expression of psychometric risk in the form of subclinical psychotic experiences in the general population is usually transitory but in some instances may become abnormally persistent and progress to a clinical psychotic state. A prospective cohort study was conducted in a general population sample of 845 adolescents, aged 14&ndash;17 years, in Munich, Germany (Early Developmental Stages of Psychopathology Study). Expression of psychosis was assessed 4 times (T0&ndash;T3) over a period of 8.4 years. Transition from subclinical psychosis at T0&ndash;T2 to clinical psychosis in terms of impairment at T3 was examined as a function of the level of prior persistence of subclinical psychosis (present never, once, twice, or thrice). The more the subclinical psychosis persisted over the period T0&ndash;T2, the greater the risk of transition to clinical psychosis at T3 in a dose-response fashion (subclinical psychosis expression once over T0&ndash;T2: odds ratio [OR] = 1.5 [95% confidence interval {CI} = 0.6&ndash;3.7], posttest probability [PP] = 5%; twice: OR = 5.0 [95% CI = 1.6&ndash;15.9], PP = 16%; at all 3 measurements: OR = 9.9 [95% CI = 2.5&ndash;39.8], PP = 27%). Of all clinical psychosis at T3, more than a third (38.3%) was preceded by subclinical psychotic experiences at least once and a fifth (19.6%) at least twice. Consequently, a significant proportion of psychotic disorder may be conceptualized as the rare poor outcome of a common developmental phenotype characterized by persistence of psychometrically detectable subclinical psychotic experiences. This may be summarized descriptively as a psychosis proneness-persistence-impairment model of psychotic disorder.</p>
]]></description>
<dc:creator><![CDATA[Dominguez, M.-d.-G., Wichers, M., Lieb, R., Wittchen, H.-U., van Os, J.]]></dc:creator>
<dc:date>Thu, 21 May 2009 07:56:57 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp022</dc:identifier>
<dc:title><![CDATA[Evidence That Onset of Clinical Psychosis Is an Outcome of Progressively More Persistent Subclinical Psychotic Experiences: An 8-Year Cohort Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn190v2?rss=1">
<title><![CDATA[Facial Emotion Processing in Schizophrenia: A Meta-analysis of Functional Neuroimaging Data]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn190v2?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> People with schizophrenia have difficulty with emotion perception. Functional imaging studies indicate regional brain activation abnormalities in patients with schizophrenia when processing facial emotion. However, findings have not been entirely consistent across different studies. <I>Methods:</I> Activation likelihood estimation (ALE) meta-analyses were conducted to examine brain activation during facial emotion processing in patients with schizophrenia, controls, and patients compared with controls. Secondary meta-analyses were performed to assess the contribution of task design and illness chronicity to the results reported. <I>Results:</I> When processing facial expressions of emotions, both patients with schizophrenia and healthy controls activated the bilateral amygdala and right fusiform gyri. However, the extent of activation in these regions was generally much more limited in the schizophrenia samples. When directly compared with controls, the extent of activation in bilateral amygdala, parahippocampal gyrus and fusiform gyrus, right superior frontal gyrus, and lentiform nucleus was significantly less in patients. Patients with schizophrenia, but not controls, activated the left insula. A relative failure to recruit the amygdala in patients occurred regardless of whether the task design was explicit or implicit, while differences in fusiform activation were evident in explicit, not implicit, tasks. Restricting the analysis to patients with chronic illness did not substantially change the results. <I>Conclusions:</I> A marked underrecruitment of the amygdala, accompanied by a substantial limitation in activation throughout a ventral temporal-basal ganglia-prefrontal cortex "social brain" system may be central to the difficulties patients experience when processing facial emotion.</p>
]]></description>
<dc:creator><![CDATA[Li, H., Chan, R. C.K., McAlonan, G. M., Gong, Q.-y.]]></dc:creator>
<dc:date>Wed, 20 May 2009 12:24:30 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn190</dc:identifier>
<dc:title><![CDATA[Facial Emotion Processing in Schizophrenia: A Meta-analysis of Functional Neuroimaging Data]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-20</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp034v1?rss=1">
<title><![CDATA[Neurocognitive Dysfunction in Bipolar and Schizophrenia Spectrum Disorders Depends on History of Psychosis Rather Than Diagnostic Group]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp034v1?rss=1</link>
<description><![CDATA[
<p><I>Objectives:</I> Neurocognitive dysfunction is milder in bipolar disorders than in schizophrenia spectrum disorders, supporting a dimensional approach to severe mental disorders. The aim of this study was to investigate the role of lifetime history of psychosis for neurocognitive functioning across these disorders. We asked whether neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends more on history of psychosis than diagnostic category or subtype. <I>Methods:</I> A sample of individuals with schizophrenia (<I>n</I> = 102), schizoaffective disorder (<I>n</I> = 27), and bipolar disorder (I or II) with history of psychosis (<I>n</I> = 75) and without history of psychosis (<I>n</I> = 61) and healthy controls (<I>n</I> = 280), from a large ongoing study on severe mental disorder, were included. Neurocognitive function was measured with a comprehensive neuropsychological test battery. <I>Results:</I> Compared with controls, all 3 groups with a history of psychosis performed poorer across neurocognitive measures, while the bipolar group without a history of psychosis was only impaired on a measure of processing speed. The groups with a history of psychosis did not differ from each other but performed poorer than the group without a history of psychosis on a number of neurocognitive measures. These neurocognitive group differences were of a magnitude expected to have clinical significance. In the bipolar sample, history of psychosis explained more of the neurocognitive variance than bipolar diagnostic subtype. <I>Conclusions:</I> Our findings suggest that neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders is determined more by history of psychosis than by <I>Diagnostic and Statistical Manual of Mental Disorders</I> (Fourth Edition) diagnostic category or subtype, supporting a more dimensional approach in future diagnostic systems.</p>
]]></description>
<dc:creator><![CDATA[Simonsen, C., Sundet, K., Vaskinn, A., Birkenaes, A. B., Engh, J. A., Faerden, A., Jonsdottir, H., Ringen, P. A., Opjordsmoen, S., Melle, I., Friis, S., Andreassen, O. A.]]></dc:creator>
<dc:date>Thu, 14 May 2009 07:51:15 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp034</dc:identifier>
<dc:title><![CDATA[Neurocognitive Dysfunction in Bipolar and Schizophrenia Spectrum Disorders Depends on History of Psychosis Rather Than Diagnostic Group]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-14</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp035v1?rss=1">
<title><![CDATA[Oculomotor and Pupillometric Indices of Pro- and Antisaccade Performance in Youth-Onset Psychosis and Attention Deficit/Hyperactivity Disorder]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp035v1?rss=1</link>
<description><![CDATA[
<p>The goals of the study were to examine inhibitory deficits on the antisaccade task in 8- to 20-year olds with youth-onset psychosis or attention deficit/hyperactivity disorder (ADHD) and healthy controls and to examine if age-related changes in performance differed across groups. In addition to the conventional measures of performance, pupillary dilations were used to obtain estimates of phasic and tonic level of arousal. Results showed that the psychosis, but not the ADHD, group had elevated antisaccade error rates; however, variability of error rates was high in all groups. These inhibitory failures were accompanied by a lower level of momentary cognitive effort (as indexed by pupillary dilations). The largest differences between the control and clinical groups were found not in the expected indices of inhibition but in the probability of correcting inhibitory errors and in variability of antisaccade response times, which were correlated with each other. These findings did not appear to be attributable to a deficit in maintaining task instructions in mind in either disorder or lack of motivation in ADHD. Instead, results point to impairments in both clinical groups in sustaining attention on a trial-by-trial basis, resulting in deficits in self-monitoring. Thus, results show inhibitory deficits in the context of more general attentional impairments in both disorders.</p>
]]></description>
<dc:creator><![CDATA[Karatekin, C., Bingham, C., White, T.]]></dc:creator>
<dc:date>Fri, 08 May 2009 12:51:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp035</dc:identifier>
<dc:title><![CDATA[Oculomotor and Pupillometric Indices of Pro- and Antisaccade Performance in Youth-Onset Psychosis and Attention Deficit/Hyperactivity Disorder]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp033v1?rss=1">
<title><![CDATA[Fibroblast Growth Factors in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp033v1?rss=1</link>
<description><![CDATA[
<p>A large association study by O'Donovan et al recently suggested that genetic variation in <I>fibroblast growth factor receptor (FGFR) 2</I> increases the risk for developing schizophrenia. Fibroblast growth factors (FGFs) are part of the family of glial growth factors; they control the growth and patterning of specific brain structures and regulate the maintenance and repair of neuronal tissues. In addition, a direct interaction was recently found between FGFRs and adenosine A<SUB>2A</SUB> receptors, leading to corticostriatal plasticity and antagonizing the signaling pathway of dopamine D<SUB>2</SUB> receptors. These findings make <I>FGFs</I> plausible candidate genes for schizophrenia. Here, we review the role of FGFs in schizophrenia and combine evidence from studies on variations in <I>FGF</I> genes, RNA expression, protein levels, and FGF administration, as well as the effects of medication and environmental risk factors for schizophrenia. These data suggest that changes in the FGF system contribute to schizophrenia and possibly to a wider range of psychiatric disorders. The role of FGFs in schizophrenia and related disorders needs to be studied in more detail.</p>
]]></description>
<dc:creator><![CDATA[Terwisscha van Scheltinga, A. F., Bakker, S. C., Kahn, R. S.]]></dc:creator>
<dc:date>Fri, 08 May 2009 12:51:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp033</dc:identifier>
<dc:title><![CDATA[Fibroblast Growth Factors in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp032v1?rss=1">
<title><![CDATA[Ethnic Identity and the Risk of Schizophrenia in Ethnic Minorities: A Case-Control Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp032v1?rss=1</link>
<description><![CDATA[
<p><I>Objectives:</I> The high incidence of schizophrenia in immigrant ethnic groups in Western Europe may be explained by social stress associated with ethnic minority status. Positive identification with one's own ethnic group is a strong predictor of mental health in immigrants. We investigated whether negative ethnic identity is related to schizophrenia risk in non-Western immigrants. <I>Methods:</I> Matched case-control study of first-episode schizophrenia, including 100 non-Western immigrant cases, general hospital controls (<I>n</I> = 100), and siblings (<I>n</I> = 63). Conditional logistic regression analyses were used to investigate associations between schizophrenia and ethnic group identity. <I>Results:</I> Cases had a negative ethnic identity more often than general hospital controls (64% and 35%, respectively, <I>P</I> &lt; .001). After adjustment for marital status, level of education, unemployment, self-esteem, social support, and cannabis use, negative ethnic identity was associated with schizophrenia: odds ratio = 3.29; 95% confidence interval = 1.36&ndash;7.92. Cases significantly more often had an assimilated or a marginalized identity and less often had a separated identity. Comparisons between cases and siblings largely confirmed these findings. <I>Conclusions:</I> Negative identification with the own ethnic group may be a risk factor for schizophrenia in immigrants living in a context of social adversity.</p>
]]></description>
<dc:creator><![CDATA[Veling, W., Hoek, H. W., Wiersma, D., Mackenbach, J. P.]]></dc:creator>
<dc:date>Fri, 08 May 2009 12:51:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp032</dc:identifier>
<dc:title><![CDATA[Ethnic Identity and the Risk of Schizophrenia in Ethnic Minorities: A Case-Control Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp029v1?rss=1">
<title><![CDATA[The Effect of State Anxiety on Paranoid Ideation and Jumping to Conclusions. An Experimental Investigation]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp029v1?rss=1</link>
<description><![CDATA[
<p>Theoretical models of persecutory delusions have emphasized the impact of reasoning biases and negative emotion at the early stages of symptom formation. However, the causal mechanisms remain unclear. This study tests the hypothesis that state anxiety will increase paranoid ideation and that this increase will be moderated by the level of individual vulnerability and mediated by the tendency to jump to conclusions. Healthy participants (<I>n</I> = 90) with varying levels of vulnerability (psychosis symptoms assessed by the Community Assessment of Psychic Experiences) were randomly assigned to either an anxiety or a nonanxiety condition. Anxiety was induced by pictures from the International Affective Picture System and by in sensu exposure to individual anxiety-provoking situations. During each condition, symptoms of paranoia were assessed by a state-adapted version of the Paranoia Checklist. Jumping to conclusions (JTC) was assessed using a modified version of the beads task. Overall, participants in the anxiety condition reported significantly more paranoid thoughts and showed more JTC than participants in the neutral condition. Participants with higher baseline vulnerability were more likely to show an increase in paranoia as reaction to the anxiety manipulation. Moreover, the association of anxiety and paranoia was mediated by the increased tendency to jump to conclusions in the beads task. The results are in line with a threat anticipation conceptualization of paranoia and provide evidence for an interaction of anxiety and reasoning biases in the development of paranoid beliefs. A combination of meta-cognitive training directed at reasoning biases and promoting emotion regulation skills might prove beneficial in preventing symptoms.</p>
]]></description>
<dc:creator><![CDATA[Lincoln, T. M., Lange, J., Burau, J., Exner, C., Moritz, S.]]></dc:creator>
<dc:date>Fri, 08 May 2009 12:51:52 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp029</dc:identifier>
<dc:title><![CDATA[The Effect of State Anxiety on Paranoid Ideation and Jumping to Conclusions. An Experimental Investigation]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp028v1?rss=1">
<title><![CDATA[Concurrent Measurement of "Real-World" Stress and Arousal in Individuals With Psychosis: Assessing the Feasibility and Validity of a Novel Methodology]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp028v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> Psychosis has been repeatedly suggested to be affected by increases in stress and arousal. However, there is a dearth of evidence supporting the temporal link between stress, arousal, and psychosis during "real-world" functioning. This paucity of evidence may stem from limitations of current research methodologies. Our aim is to the test the feasibility and validity of a novel methodology designed to measure concurrent stress and arousal in individuals with psychosis during "real-world" daily functioning. <I>Method:</I> Twenty patients with psychosis completed a 36-hour ambulatory assessment of stress and arousal. We used experience sampling method with palm computers to assess stress (10 times per day, 10 <scp>AM</scp> -&gt; 10 <scp>PM</scp>) along with concurrent ambulatory measurement of cardiac autonomic regulation using a Holter monitor. The clocks of the palm computer and Holter monitor were synchronized, allowing the temporal linking of the stress and arousal data. We used power spectral analysis to determine the parasympathetic contributions to autonomic regulation and sympathovagal balance during 5 minutes before and after each experience sample. <I>Results:</I> Patients completed 79% of the experience samples (75% with a valid concurrent arousal data). Momentary increases in stress had inverse correlation with concurrent parasympathetic activity ( = &ndash;.27, <I>P</I> &lt; .0001) and positive correlation with sympathovagal balance ( = .19, <I>P</I> = .0008). Stress and heart rate were not significantly related ( = &ndash;.05, <I>P</I> = .3875). <I>Conclusion:</I> The findings support the feasibility and validity of our methodology in individuals with psychosis. The methodology offers a novel way to study in high time resolution the concurrent, "real-world" interactions between stress, arousal, and psychosis. The authors discuss the methodology's potential applications and future research directions.</p>
]]></description>
<dc:creator><![CDATA[Kimhy, D., Delespaul, P., Ahn, H., Cai, S., Shikhman, M., Lieberman, J. A., Malaspina, D., Sloan, R. P.]]></dc:creator>
<dc:date>Fri, 08 May 2009 12:51:51 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp028</dc:identifier>
<dc:title><![CDATA[Concurrent Measurement of "Real-World" Stress and Arousal in Individuals With Psychosis: Assessing the Feasibility and Validity of a Novel Methodology]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-05-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp031v1?rss=1">
<title><![CDATA[Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp031v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Our aim was to review recent studies and estimate the rate of cannabis use disorders (CUDs) in schizophrenia, as well as to examine the factors affecting this rate. <I>Methods:</I> We conducted an electronic search of 3 literature databases and a manual search of articles from 1996 to 2008. The key words used were "schizophreni*," "psychos*s," "psychotic," "cannabis abuse," "cannabis dependence," "cannabis use disorder," "substance use disorder," "substance abuse," "substance dependence," and "dual diagnosis." Articles that reported diagnoses according to the <I>Diagnostic and Statistical Manual of Mental Disorders</I> or <I>International Classification of Diseases</I> were included. Regression analysis was used to examine how estimated rates of CUDs are affected by various study characteristics such as the classification system, inpatient vs outpatient status, study location, proportion of males, age of the sample, or duration of illness. <I>Results:</I> Thirty-five studies met our search criteria. The median current rate of CUDs was 16.0% (interquartile range [IQR] = 8.6&ndash;28.6, 10 studies), and the median lifetime rate was 27.1% (IQR = 12.2&ndash;38.5, 28 studies). The median rate of CUDs was markedly higher in first-episode vs long-term patients (current 28.6%/22.0%, lifetime 44.4%/12.2%, respectively) and in studies where more than two-thirds of the participants were males than in the other studies (33.8%/13.2%). CUDs were also more common in younger samples than in the others (current 38.5%/16.0%, lifetime 45.0%/17.9%). <I>Conclusions:</I> Approximately every fourth schizophrenia patient in our sample of studies had a diagnosis of CUDs. CUDs were especially common in younger and first-episode patient samples as well as in samples with a high proportion of males.</p>
]]></description>
<dc:creator><![CDATA[Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., Miettunen, J.]]></dc:creator>
<dc:date>Wed, 22 Apr 2009 04:53:13 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp031</dc:identifier>
<dc:title><![CDATA[Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-22</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp030v1?rss=1">
<title><![CDATA[Intrinsic Motivation Inventory: An Adapted Measure for Schizophrenia Research]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp030v1?rss=1</link>
<description><![CDATA[
<p>This article describes the psychometric validation of a scale designed to measure intrinsic motivation (IM) in schizophrenia. Recent studies have highlighted the relationship between motivation and functional outcome in schizophrenia and identified IM as an important mediating factor between neurocognition and psychosocial outcome. It therefore becomes imperative to have validated measures of IM for empirical use. To that end, we validated a self-report IM scale that gauges the central motivational structures identified by Self-determinism Theory as pertinent to cognitive task engagement, skill acquisition, treatment compliance, and remediation outcome. Participants were schizophrenia outpatients involved in a cognitive remediation study (<I>n</I> = 58), a convenience subsample of clinically stable schizophrenia outpatients (<I>n</I> = 15), and a group of healthy normals (<I>n</I> = 22). The Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR) is a concise instrument, possessing good internal consistency ( = .92) and test-retest reliability (intraclass correlation = .77). Data were analyzed to abridge the original 54 items into a final 21-item questionnaire comprised of 3 domains relevant to motivation for treatments (interest/enjoyment, perceived choice, value/usefulness). The scale was highly associated with germane constructs of motivation for health-related behaviors, including perceived competency for attempting challenging tasks and autonomous treatment engagement. Importantly, the scale was able to distinguish improvers and nonimprovers on a cognitive task and actual learning exercises, delineate high vs low treatment attendance, and demonstrate sensitivity to motivational changes due to intervention variation. The IMI-SR is a viable instrument to measure IM in schizophrenia as part of a cognitive remediation protocol or psychosocial rehabilitation program.</p>
]]></description>
<dc:creator><![CDATA[Choi, J., Mogami, T., Medalia, A.]]></dc:creator>
<dc:date>Tue, 21 Apr 2009 18:45:17 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp030</dc:identifier>
<dc:title><![CDATA[Intrinsic Motivation Inventory: An Adapted Measure for Schizophrenia Research]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp009v1?rss=1">
<title><![CDATA[Pretreatment and Outcome Correlates of Sexual and Physical Trauma in an Epidemiological Cohort of First-Episode Psychosis Patients]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp009v1?rss=1</link>
<description><![CDATA[
<p><I>Objectives:</I> High prevalence of trauma has been reported in psychosis. While role of trauma as a risk factor for developing psychosis is still debated, its negative impact on outcome has been described. Few studies have explored this issue in first-episode psychosis (FEP) patients. We assessed rate of stressful events, as well as premorbid and outcome correlates of past sexual and/or physical abuse (SPA) in an epidemiological FEP patients cohort. <I>Methods:</I> The Early Psychosis Prevention and Intervention Centre admitted 786 FEP patients between 1998 and 2000. Data were collected from patients' files using a standardized questionnaire. A total of 704 files were available, 43 excluded because of a nonpsychotic diagnosis at end point and 3 due to missing data regarding past stressful events; 658 patients were analyzed. <I>Results:</I> A total of 83% patients had been exposed to at least one stressful event and 34% to SPA. SPA patients were more likely to have presented other psychiatric disorders before psychosis onset (posttraumatic stress disorder, substance use disorder), to have made suicide attempts in the past, and to have had poorer premorbid functional levels. Additionally, SPA patients had higher rate of comorbid diagnosis at program entry and were more likely to attempt suicide during treatment. <I>Conclusions:</I> SPA prevalence is high in FEP patients and must be explored by clinicians considering its durable impact on psychological balance and link with long-lasting suicidal risk. More research is warranted to better understand mechanisms involved between trauma and its potential consequences, as well as to develop psychological interventions adapted to this very sensitive and complex issue.</p>
]]></description>
<dc:creator><![CDATA[Conus, P., Cotton, S., Schimmelmann, B. G., McGorry, P. D., Lambert, M.]]></dc:creator>
<dc:date>Tue, 21 Apr 2009 18:45:16 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp009</dc:identifier>
<dc:title><![CDATA[Pretreatment and Outcome Correlates of Sexual and Physical Trauma in an Epidemiological Cohort of First-Episode Psychosis Patients]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp011v1?rss=1">
<title><![CDATA[Neurological Soft Signs in Schizophrenia: A Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp011v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> Neurological soft signs (NSS) are hypothesized as candidate endophenotypes for schizophrenia, but their prevalence and relations with clinical and demographic data are unknown. The authors undertook a quantification (meta-analysis) of the published literature on NSS in patients with schizophrenia and healthy controls. A systematic search was conducted for published articles reporting NSS and related data using standard measures in schizophrenia and healthy comparison groups. <I>Method:</I> A systematic search was conducted for published articles reporting data on the prevalence of NSS in schizophrenia using standard clinical rating scales and healthy comparison groups. Meta-analyses were performed using the Comprehensive Meta-analysis software package. Effect sizes (Cohen <I>d</I>) indexing the difference between schizophrenic patients and the healthy controls were calculated on the basis of reported statistics. Potential moderator variables evaluated included age of patient samples, level of education, sample sex proportions, medication doses, and negative and positive symptoms. <I>Results:</I> A total of 33 articles met inclusion criteria for the meta-analysis. A large and reliable group difference (Cohen <I>d</I>) indicated that, on average, a majority of patients (73%) perform outside the range of healthy subjects on aggregate NSS measures. Cognitive performance and positive and negative symptoms share 2%&ndash;10% of their variance with NSS. <I>Conclusions:</I> NSS occur in a majority of the schizophrenia patient population and are largely distinct from symptomatic and cognitive features of the illness.</p>
]]></description>
<dc:creator><![CDATA[Chan, R. C. K., Xu, T., Heinrichs, R. W., Yu, Y., Wang, Y.]]></dc:creator>
<dc:date>Fri, 17 Apr 2009 19:05:41 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp011</dc:identifier>
<dc:title><![CDATA[Neurological Soft Signs in Schizophrenia: A Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp012v2?rss=1">
<title><![CDATA[Amygdalofrontal Functional Disconnectivity and Aggression in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp012v2?rss=1</link>
<description><![CDATA[
<p>A significant proportion of patients with schizophrenia demonstrate abnormalities in dorsal prefrontal regions including the dorsolateral prefrontal and dorsal anterior cingulate cortices. However, it is less clear to what extent abnormalities are exhibited in ventral prefrontal and limbic regions, despite their involvement in social cognitive dysfunction and aggression, which represent problem domains for patients with schizophrenia. Previously, we found that reduced white matter integrity in right inferior frontal regions was associated with higher levels of aggression. Here, we used resting-state functional magnetic resonance imaging to examine amygdala/ventral prefrontal cortex (vPFC) functional connectivity (FC) and its relation to aggression in schizophrenia. Twenty-one healthy controls and 25 patients with schizophrenia or schizoaffective disorder participated. Aggression was measured using the Buss Perry Aggression Questionnaire. Regions of interest were placed in the amygdala based on previously published work. A voxelwise FC analysis was performed in which the mean time series across voxels for this bilateral amygdala seed was entered as a predictor in a multiple regression model with motion parameters and global, cerebrospinal fluid, and white matter signals as covariates. Patients showed significant reductions in FC between amygdala and vPFC regions. Moreover, in patients, the strength of this connection showed a significant inverse relationship with aggression, such that lower FC was associated with higher levels of self-rated aggression. Similar results were obtained for 2 other measures&mdash;Life History of Aggression and total arrests. These results suggest that amygdala/vPFC FC is compromised in schizophrenia and that this compromise is associated with aggression.</p>
]]></description>
<dc:creator><![CDATA[Hoptman, M. J., D'Angelo, D., Catalano, D., Mauro, C. J., Shehzad, Z. E., Kelly, A. M. C., Castellanos, F. X., Javitt, D. C., Milham, M. P.]]></dc:creator>
<dc:date>Thu, 16 Apr 2009 08:56:14 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp012</dc:identifier>
<dc:title><![CDATA[Amygdalofrontal Functional Disconnectivity and Aggression in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-16</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp026v1?rss=1">
<title><![CDATA[Social Cognition Deficits Among Individuals at Familial High Risk for Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp026v1?rss=1</link>
<description><![CDATA[
<p>Social cognition in young relatives of schizophrenia probands (<I>N</I> = 70) and healthy controls (<I>N</I> = 63) was assessed using the Penn Emotion Recognition Test-40 to examine the presence of social cognitive deficits in individuals at risk for the disorder. Measures of neurocognitive function and prodromal psychopathology were collected to assess the cognitive and clinical correlates of social cognitive impairments in at-risk relatives. Results indicated that when compared with healthy controls, individuals at familial high risk for schizophrenia were significantly more likely to overattribute emotions to neutral faces, with such individuals frequently misinterpreting neutral faces as negative. In addition, at-risk individuals had significantly greater reaction times when completing emotion recognition tasks, regardless of valence. Impairments in neurocognition were largely independent of social cognitive performance, and emotion recognition impairments persisted after adjusting deficits in neurocognitive function. Further, social cognitive impairments in the interpretation of neutral faces were significantly associated with greater positive and general prodromal psychopathology, whereas neurocognitive impairments were only associated with disorganization. These results suggest that impairments in social cognition may be unique endophenotypes for schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Eack, S. M., E. Mermon, D., Montrose, D. M., Miewald, J., Gur, R. E., Gur, R. C., Sweeney, J. A., Keshavan, M. S.]]></dc:creator>
<dc:date>Tue, 14 Apr 2009 12:44:15 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp026</dc:identifier>
<dc:title><![CDATA[Social Cognition Deficits Among Individuals at Familial High Risk for Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-14</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp024v1?rss=1">
<title><![CDATA[Autonomic Dysfunction in Unaffected First-Degree Relatives of Patients Suffering From Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp024v1?rss=1</link>
<description><![CDATA[
<p>Recent studies revealed cardiac autonomic dysfunction in patients with acute schizophrenia, which appears to be mainly related to reduced vagal and increased sympathetic modulation. To understand the significance of cardiac autonomic function in patients with schizophrenia, we extended these studies to relatives of patients. In this study, we assessed cardiac autonomic modulation in healthy first-degree relatives of patients with schizophrenia (<I>n</I> = 36) to investigate a putative genetic influence. Data were compared with control subjects matched for age, gender, and physical activity as well as to patients suffering from schizophrenia. First-degree relatives showed an attenuated, yet identical pattern in autonomic dysfunction as patients with decreased vagal modulation of heart rate, decreased baroreflex sensitivity, but no difference in blood pressure variability could be detected. The patients' relatives also showed a similar pattern in regards to QT variability. In addition, the subgroup comparison of offspring vs. siblings showed a significant difference in heart rate variability suggesting a higher degree of heritability in offspring. In conclusion, the pattern of autonomic dysfunction seen in patients and relatives might indicate underlying disease-inherent genetic vulnerability, especially because autonomic parameters are heritable. In addition, these findings may be of value to identify the high-risk group of patients' relatives in regards to serious cardiovascular events so that early preventive measures can be taken.</p>
]]></description>
<dc:creator><![CDATA[Bar, K.-J., Berger, S., Metzner, M., Boettger, M. K., Schulz, S., Ramachandraiah, C. T., Terhaar, J., Voss, A., Yeragani, V. K., Sauer, H.]]></dc:creator>
<dc:date>Tue, 14 Apr 2009 12:44:15 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp024</dc:identifier>
<dc:title><![CDATA[Autonomic Dysfunction in Unaffected First-Degree Relatives of Patients Suffering From Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-14</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp015v1?rss=1">
<title><![CDATA[Toward a Model of Cognitive Insight in First-Episode Psychosis: Verbal Memory and Hippocampal Structure]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp015v1?rss=1</link>
<description><![CDATA[
<p>Our previous work has linked verbal learning and memory with cognitive insight, but not clinical insight, in individuals with a first-episode psychosis (FEP). The current study reassessed the neurocognitive basis of cognitive and clinical insight and explored their neural basis in 61 FEP patients. Cognitive insight was measured with the Beck Cognitive Insight Scale (BCIS) and clinical insight with the Scale to assess Unawareness of Mental Disorder (SUMD). Global measures for 7 domains of cognition were examined. Hippocampi were manually segmented in to 3 parts: the body, head, and tail. Verbal learning and memory significantly correlated with the BCIS composite index. Composite index scores were significantly associated with total left hippocampal (HC) volume; partial correlations, however, revealed that this relationship was attributable largely to verbal memory performance. The BCIS self-certainty subscale significantly and inversely correlated with bilateral HC volumes, and these associations were independent of verbal learning and memory performance. The BCIS self-reflectiveness subscale significantly correlated with verbal learning and memory but not with HC volume. No significant correlations emerged between the SUMD and verbal memory or HC volume. These results strengthen our previous assertion that in individuals with an FEP cognitive insight may rely on memory whereby current experiences are appraised based on previous ones. The HC may be a viable location among others for the brain system that underlies aspects of cognitive insight in individuals with an FEP.</p>
]]></description>
<dc:creator><![CDATA[Buchy, L., Czechowska, Y., Chochol, C., Malla, A., Joober, R., Pruessner, J., Lepage, M.]]></dc:creator>
<dc:date>Fri, 03 Apr 2009 07:48:35 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp015</dc:identifier>
<dc:title><![CDATA[Toward a Model of Cognitive Insight in First-Episode Psychosis: Verbal Memory and Hippocampal Structure]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-04-03</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn192v1?rss=1">
<title><![CDATA[Facial Emotion Perception in Schizophrenia: A Meta-analytic Review]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn192v1?rss=1</link>
<description><![CDATA[
<p><I>Objectives:</I> A considerable body of literature has reported on emotion perception deficits and the relevance to clinical symptoms and social functioning in schizophrenia. Studies published between 1970&ndash;2007 were examined regarding emotion perception abilities between patient and control groups and potential methodological, demographic, and clinical moderators. <I>Data Sources and Review:</I> Eighty-six studies were identified through a computerized literature search of the MEDLINE, PsychINFO, and PubMed databases. A quality of reporting of meta-analysis standard was followed in the extraction of relevant studies and data. Data on emotion perception, methodology, demographic and clinical characteristics, and antipsychotic medication status were compiled and analyzed using Comprehensive Meta-analysis Version 2.0 (Borenstein M, Hedges L, Higgins J and Rothstein H. Comprehensive Meta-analysis. 2. Englewood, NJ: Biostat; 2005). <I>Results:</I> The meta-analysis revealed a large deficit in emotion perception in schizophrenia, irrespective of task type, and several factors that moderated the observed impairment. Illness-related factors included current hospitalization and&mdash;in part&mdash;clinical symptoms and antipsychotic treatment. Demographic factors included patient age and gender in controls but not race. <I>Conclusion:</I> Emotion perception impairment in schizophrenia represents a robust finding in schizophrenia that appears to be moderated by certain clinical and demographic factors. Future directions for research on emotion perception are discussed.</p>
]]></description>
<dc:creator><![CDATA[Kohler, C. G., Walker, J. B., Martin, E. A., Healey, K. M., Moberg, P. J.]]></dc:creator>
<dc:date>Fri, 27 Mar 2009 07:59:39 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn192</dc:identifier>
<dc:title><![CDATA[Facial Emotion Perception in Schizophrenia: A Meta-analytic Review]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp007v1?rss=1">
<title><![CDATA[Testing Definitions of Symptom Remission in First-Episode Psychosis for Prediction of Functional Outcome at 2 Years]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp007v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> To determine the clinical relevance of different definitions of symptom remission for prediction of functional outcome in first-episode psychosis (FEP). <I>Methods:</I> One hundred forty-one individuals receiving treatment for an FEP at a specialized early intervention service had positive and negative symptoms and functional status rated every month over the first 2 years of treatment using the Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms, and Social and Occupational Functioning Assessment Scale. Subjects were classified according to 4 definitions of remission varying the criteria for severity (negative symptom inclusion/exclusion) and duration (3/6 mo sustained). <I>Results:</I> Positive symptom remission was achieved by 94% and 84% of subjects for 3 and 6 months, respectively, compared with 70% and 56% for positive and negative symptom remission, respectively. Linear regression analyses showed that only definitions of remission containing both positive and negative symptoms independently predicted functional outcome. This was confirmed by receiver operating characteristic analyses where remission based on positive and negative symptoms was marginally better than positive symptoms alone (difference in area under the curve; <I>z</I> = 1.94, <I>P</I> = .052). There was little difference between a time criterion of remission of positive and negative symptoms of 3 (sensitivity = 100%, specificity = 42%) or 6 (sensitivity = 90%, specificity = 57%) months. <I>Discussion:</I> Consistent with the consensus definition of remission in schizophrenia, severity of both positive and negative symptoms in defining remission in FEP is necessary although a 3-month criterion had equal predictive validity to the 6-month criterion.</p>
]]></description>
<dc:creator><![CDATA[Cassidy, C. M., Norman, R., Manchanda, R., Schmitz, N., Malla, A.]]></dc:creator>
<dc:date>Wed, 25 Mar 2009 06:45:16 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp007</dc:identifier>
<dc:title><![CDATA[Testing Definitions of Symptom Remission in First-Episode Psychosis for Prediction of Functional Outcome at 2 Years]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-25</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp003v1?rss=1">
<title><![CDATA[Reductions in the N1 and P2 Auditory Event-Related Potentials in First-Hospitalized and Chronic Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp003v1?rss=1</link>
<description><![CDATA[
<p>The N1 auditory event-related potential (ERP) is reduced in chronic schizophrenia, as is the P2 to attended tones. N1 reduction may be endophenotypic for schizophrenia, being reduced in twins of schizophrenic patients and showing heritability. Results in family members, however, are equivocal, with abnormally small N1 (consistent with an endophenotype) and abnormally large N1 (inconsistent with an endophenotype) reported. P2 has been little studied in schizophrenia or family members. One crucial step in establishing endophenotypes is to rule out causal chronicity factors. We examined schizophrenia patients within 1 year of first hospitalization (most within 2 wk), chronically ill patients, and matched controls to examine N1 and P2 reductions and disease stage. Two active target detection oddball tasks were used, one with 97-dB tones against 70-dB white masking noise, the second with 97-dB tones without noise. Results from 8 samples are reported: first-hospitalized patients and matched controls and chronic patients and matched controls for the 2 tasks. N1 and P2 were measured from the standard stimuli. N1 and P2 were significantly reduced in chronic patients, as expected, and reduced in first-hospitalized patients. Because N1 and P2 are reduced even at the first hospitalization for schizophrenia, they may serve as viable electrophysiological endophenotypes for the disorder. However, deficit early in the disease is necessary but not sufficient to establish these ERPs as endophenotypes. Deficits must next be demonstrated in at least a subset of unaffected family members, a crucial criterion for an endophenotype.</p>
]]></description>
<dc:creator><![CDATA[Salisbury, D. F., Collins, K.C., McCarley, R. W.]]></dc:creator>
<dc:date>Thu, 12 Mar 2009 10:04:24 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp003</dc:identifier>
<dc:title><![CDATA[Reductions in the N1 and P2 Auditory Event-Related Potentials in First-Hospitalized and Chronic Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-12</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp002v1?rss=1">
<title><![CDATA[RGS4 Polymorphisms Associated With Variability of Cognitive Performance in a Family-Based Schizophrenia Sample]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp002v1?rss=1</link>
<description><![CDATA[
<p>Polymorphisms of the gene encoding the regulator of G protein signaling, subtype 4 (<I>RGS4</I>), may be associated with schizophrenia. Among first-episode schizophrenia patients, they are also associated with dorsolateral prefrontal cortex (DLPFC) volume. The DLPFC is a key region that regulates heritable cognitive functions implicated in schizophrenia pathogenesis. To further understand the relationship of <I>RGS4</I> variants to schizophrenia, we examined their associations with cognitive functions among schizophrenia patients and their relatives. We analyzed 31 multiplex, multigenerational Caucasian families with schizophrenia recruited on the basis of 2 affected first-degree relatives. All participants underwent a computerized neurocognitive battery that evaluates accuracy and speed (response time) of performance on abstraction/mental flexibility; attention; verbal, spatial, and face memory; and spatial ability. "Tag" single-nucleotide polymorphisms (SNPs) representing common polymorphisms were genotyped. Measured genotype analyses accounting for family relationships were performed using Sequential Oligogenic Linkage Analysis Routines. SNPs rs10917670 ("SNP1") and rs951439 ("SNP7") were associated with face memory speed (<I>P</I> = .0003) at a significance level that survived Bonferroni correction (<I>P</I> = .039). The same SNPs have earlier been reported to be associated with schizophrenia. There also were uncorrected associations with rs10917670 ("SNP1") and rs951439 ("SNP7") on face memory efficiency (<I>P</I> = .03) and verbal memory efficiency (<I>P</I> = 0.02), rs28757217 on abstraction/mental flexibility speed (<I>P</I> = .02) and verbal memory efficiency (<I>P</I> = .03), SNP18 (rs2661319) on spatial memory accuracy (<I>P</I> = 0.02) and face memory speed (<I>P</I> = .03). <I>RGS4</I> polymorphisms are associated with variations in cognitive functions and contribute a small but statistically significant proportion of variance in a family-based sample.</p>
]]></description>
<dc:creator><![CDATA[Prasad, K. M., Almasy, L., Gur, R. C., Gur, R. E., Pogue-Geile, M., Chowdari, K. V., Talkowski, M. E., Nimgaonkar, V. L.]]></dc:creator>
<dc:date>Thu, 12 Mar 2009 10:04:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp002</dc:identifier>
<dc:title><![CDATA[RGS4 Polymorphisms Associated With Variability of Cognitive Performance in a Family-Based Schizophrenia Sample]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-12</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp005v1?rss=1">
<title><![CDATA[Functional Analysis of Upstream Common Polymorphisms of the Dopamine Transporter Gene]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp005v1?rss=1</link>
<description><![CDATA[
<p>The human dopamine transporter (<I>DAT</I>, <I>SLC6A3</I>) has been extensively investigated because of its potential involvement in neuropsychiatric disorders. The core elements responsible for its transcription have been identified. A regulatory role for certain genomic variants upstream to the core promoter is known. Recently, other single-nucleotide polymorphisms (SNPs) have been identified in this region and are thought to be associated with schizophrenia and bipolar I disorder. Hence, we have investigated the impact of common SNPs in a 2.8-kilobase region flanking the core promoter region (&ndash;2.7 to +63 base pair) in the neuroblastoma cell line SH-SY5Y. Haplotypes generated by site-directed mutagenesis revealed varying impact of individual SNPs on promoter activity using dual luciferase assays. In silico analyses also predicted allele-specific binding of transcription factors for some of these SNPs. Though electrophoretic mobility shift assays indicated several factors that appeared to bind to specific sites within this region, allele-specific binding was not detected for any SNP apart from rs3756450. We have thus identified novel putative regulatory domains flanking the core promoter of <I>DAT</I> that merit further investigation.</p>
]]></description>
<dc:creator><![CDATA[Bamne, M. N., Talkowski, M. E., Chowdari, K. V., Nimgaonkar, V. L.]]></dc:creator>
<dc:date>Mon, 09 Mar 2009 10:33:50 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp005</dc:identifier>
<dc:title><![CDATA[Functional Analysis of Upstream Common Polymorphisms of the Dopamine Transporter Gene]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp001v1?rss=1">
<title><![CDATA[Antecedents and Patterns of Suicide Behavior in First-Admission Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbp001v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> Persons with psychotic illnesses have an increased risk for suicide, especially early in the illness. Sufficient knowledge allowing for early recognition is lacking. <I>Objectives:</I> To describe suicide behaviors before and during the 4 years following first psychiatric hospitalization, examine associations of demographic and psychiatric risk factors, and develop a suicide risk index. <I>Method:</I> Data came from the Suffolk County Mental Health Project, a first-admission cohort (<I>n</I> = 529). Cox regression was used to study associations of risk factors to suicide behaviors; a summary suicide behavior risk index was also tested. <I>Results:</I> Prior to first admission, 28.0% (<I>n</I> = 148) of the cohort had attempted suicide. During the 4-year follow-up, 13.6% (<I>n</I> = 72) of the cohort attempted suicide (29.7% of those with previous attempts and 7.3% making their first attempt) and 3 respondents died of suicide. The significant predictors at index admission of subsequent attempts were prior attempts or ideation, severity of depressive symptoms and thought disorder, lifetime substance abuse, and younger age. Suicide ideation was predicted by the same variables with the addition of insight into illness and with the exception of age at admission. A 3-category risk index was created; 61.1% of those who made a suicide attempt were in the highest risk group (<I>n</I> = 44/72). <I>Conclusion:</I> The current study confirms and extends previous research showing that risk factors early in the course of illness are predictive of subsequent ideation and attempts. The risk index may be a useful adjunct in identifying individuals likely to benefit from preventive interventions.</p>
]]></description>
<dc:creator><![CDATA[Bakst, S., Rabinowitz, J., Bromet, E. J.]]></dc:creator>
<dc:date>Mon, 09 Mar 2009 10:33:48 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbp001</dc:identifier>
<dc:title><![CDATA[Antecedents and Patterns of Suicide Behavior in First-Admission Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn170v1?rss=1">
<title><![CDATA[Neuroplasticity-Based Cognitive Training in Schizophrenia: An Interim Report on the Effects 6 Months Later]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn170v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: New cognitive treatments for schizophrenia are needed that drive persistent gains in cognition and functioning. Using an innovative neuroplasticity-based cognitive training approach, we report our interim findings on the effects on cognition and functional outcome at 6 months after treatment. <I>Methods:</I> Thirty-two clinically stable schizophrenia subjects were randomly assigned to either targeted cognitive training (TCT, <I>N</I> = 22) or a computer games (CGs) control condition (<I>N</I> = 10). Twelve TCT subjects completed 50 hours of auditory based training; 10 TCT subjects completed an additional 50 hours of training targeting visual and cognitive control processes. Subjects were assessed on neurocognition and functional outcome after training and at 6-month follow-up. <I>Results:</I> Both TCT subject groups showed significant durable gains at 6 months on measures of verbal learning/memory and cognitive control. Only TCT subjects who completed 100 hours of training showed durable gains on processing speed and global cognition, with nonsignificant improvement in functional outcome. Improved cognition was significantly associated with improved functional outcome at 6 months for TCT subjects. <I>Conclusions:</I> A total of 50 hours of neuroplasticity-based computerized cognitive training appears sufficient to drive improvements in verbal learning/memory and cognitive control that endure 6 months beyond the intervention, but a higher "dose" and more "broad-spectrum" training may be necessary to drive enduring gains in processing speed and global cognition. Training-induced cognitive improvement is related to enhanced functioning at 6 months. These data suggest that (1) higher and "broader" doses of cognitive training may confer the most benefits for schizophrenia patients; (2) the posttraining period opens a critical window for aggressive adjunctive psychosocial rehabilitation.</p>
]]></description>
<dc:creator><![CDATA[Fisher, M., Holland, C., Subramaniam, K., Vinogradov, S.]]></dc:creator>
<dc:date>Thu, 05 Mar 2009 15:13:44 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn170</dc:identifier>
<dc:title><![CDATA[Neuroplasticity-Based Cognitive Training in Schizophrenia: An Interim Report on the Effects 6 Months Later]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-03-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn178v1?rss=1">
<title><![CDATA[Olfactory Hedonic Judgment in Patients With Deficit Syndrome Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn178v1?rss=1</link>
<description><![CDATA[
<p>Olfactory perception was examined in deficit syndrome (DS) and nondeficit syndrome (ND) schizophrenia patients. Participants included 22 controls (CN) and 41 patients with schizophrenia who were divided into DS (<I>n</I> = 15) and ND (<I>n</I> = 26) subtypes using the Schedule for the Deficit Syndrome (SDS). Olfactory perception for pleasant and unpleasant odors was assessed using the Brief Smell Identification Test. Participants were instructed to identifying each smell as well as provide hedonic judgment ratings of each smell on a 7-point scale (1 = extremely pleasant, 4 = neutral, and 7 = extremely unpleasant). Results indicated that when compared with the ND patients, the DS patients rated pleasant smells as being significantly less pleasant, although no difference between the groups was present for unpleasant smells, and both ND and DS groups significantly differed from CN on rating and identifying pleasant and unpleasant items. Additionally, lower smell identification accuracy was negatively correlated with SDS symptom severity, and valence ratings for pleasant odors were positively correlated with SDS diminished emotional range. Findings suggest that the DS is characterized by a unique pattern of olfactory valence judgment that is characterized by abnormalities in processing positively valenced stimuli.</p>
]]></description>
<dc:creator><![CDATA[Strauss, G. P., Allen, D. N., Ross, S. A., Duke, L. A., Schwartz, J.]]></dc:creator>
<dc:date>Tue, 17 Feb 2009 11:16:02 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn178</dc:identifier>
<dc:title><![CDATA[Olfactory Hedonic Judgment in Patients With Deficit Syndrome Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-02-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn174v1?rss=1">
<title><![CDATA[Neuropsychological Profile in Early-Onset Schizophrenia-Spectrum Disorders: Measured With the MATRICS Battery]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn174v1?rss=1</link>
<description><![CDATA[
<p><I>Objective</I>: Neurocognitive impairments have been documented in adolescents with early-onset schizophrenia (EOS). There is still inconsistency regarding an average profile, which could be due to the fact that each study uses different tests. The purpose of this study was to examine whether the "Measurement and Treatment Research to Improve Cognition in Schizophrenia" (MATRICS) battery is useful in detecting differences between the patient group and the healthy controls, and to describe the neuropsychological pattern in the EOS group. <I>Method</I>: Neuropsychological functioning was examined in 31 adolescents with schizophrenia spectrum disorders and 67 healthy controls, using the MATRICS battery. <I>Results</I>: There were significant differences between the patients and the controls on every domain except for social cognition. Patients showed a generalized neurocognitive deficit of 0.8&ndash;1.8 SDs compared with controls, with verbal learning, working memory, and visual learning being the most affected areas. <I>Conclusions</I>: The MATRICS battery is sensitive in detecting differences between patients and controls in the adolescent population. However, we question the use of Mayer-Salovey-Caruso Emotional Intelligence Test in this age group. Results document a significant generalized deficit in adolescents with EOS.</p>
]]></description>
<dc:creator><![CDATA[Holmen, A., Juuhl-Langseth, M., Thormodsen, R., Melle, I., Rund, B. R.]]></dc:creator>
<dc:date>Tue, 17 Feb 2009 11:16:01 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn174</dc:identifier>
<dc:title><![CDATA[Neuropsychological Profile in Early-Onset Schizophrenia-Spectrum Disorders: Measured With the MATRICS Battery]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-02-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn180v1?rss=1">
<title><![CDATA["Excessive Thinking" as Explanatory Model for Schizophrenia: Impacts on Stigma and "Moral" Status in Mainland China]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn180v1?rss=1</link>
<description><![CDATA[
<p>Although psychiatric stigma in China is particularly pervasive and damaging, rates of high expressed emotion ("EE" or family members' emotional attitudes that predict relapse) are generally lower than rates found in Western countries. In light of this seemingly incongruous juxtaposition and because Chinese comprise approximately one-fifth of the world's mentally ill, we examine how one of the most widely held causal beliefs of schizophrenia&mdash;excessive thinking (xiang tai duo)&mdash;may powerfully shape how those exhibiting psychotic symptoms pass from "normal" status to stigmatized "other." Using a framework by which stigma threatens an actor's capacity to participate in core everyday engagements, we examine how expressions of excessive thinking intersect with psychotic symptoms and how this idiom reduces stigma by preserving essential moral standing. Four focus groups with family members (<I>n</I> = 34 total) of schizophrenia outpatients, who had participated in psychoeducation, were conducted in Beijing. Open coding was conducted by 2 bilingual coders achieving high interrater agreement. Common expressions of excessive thinking&mdash;taking things too hard that is perceived as a causal factor and unwarranted suspicion that is used to benignly interpret paranoid symptoms encapsulated disruptive behaviors that closely overlapped with psychotic symptoms. Because excessive thinking is understood to occur universally, this idiom encourages socially accommodating behavior that signifies acceptance of these individuals as full-status community members. In contrast, due to beliefs implying moral contamination, those labeled mentally ill are threatened with both subtle and outright social exclusion. We discuss implications of this idiom for EE and the detection of schizophrenia "prodrome" in China.</p>
]]></description>
<dc:creator><![CDATA[Yang, L. H., Phillips, M. R., Lo, G., Chou, Y., Zhang, X., Hopper, K.]]></dc:creator>
<dc:date>Wed, 04 Feb 2009 07:02:19 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn180</dc:identifier>
<dc:title><![CDATA["Excessive Thinking" as Explanatory Model for Schizophrenia: Impacts on Stigma and "Moral" Status in Mainland China]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-02-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn193v1?rss=1">
<title><![CDATA[Delusions Are Associated With Poor Cognitive Insight in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn193v1?rss=1</link>
<description><![CDATA[
<p>The purpose of the study was to investigate the relationship between the symptoms delusions and hallucinations measured by the Positive and Negative Syndrome Scale and cognitive insight as assessed with the Beck Cognitive Insight Scale (BCIS) in patients with schizophrenia. The BCIS is based on 2 subscales, self-reflectiveness and self-certainty, measuring objectivity, reflectiveness and openness to feedback, and mental flexibility. Overall cognitive insight was defined as the difference between self-reflectiveness and self-certainty. This cross-sectional study of 143 patients showed that the occurrence of delusions is associated with low self-reflectiveness and high self-certainty, reflecting low cognitive insight. Hallucinations in the absence of delusions were associated with high self-reflectiveness and low self-certainty, possibly reflecting more open-mindedness and higher cognitive insight. The present findings suggest that delusions are associated with low cognitive insight, whereas solitary hallucinations may be associated with high cognitive insight.</p>
]]></description>
<dc:creator><![CDATA[Engh, J. A., Friis, S., Birkenaes, A. B., Jonsdottir, H., Klungsoyr, O., Ringen, P. A., Simonsen, C., Vaskinn, A., Opjordsmoen, S., Andreassen, O. A.]]></dc:creator>
<dc:date>Tue, 27 Jan 2009 13:21:12 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn193</dc:identifier>
<dc:title><![CDATA[Delusions Are Associated With Poor Cognitive Insight in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-01-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn172v1?rss=1">
<title><![CDATA[Influence of Emotional Expression on Memory Recognition Bias in Schizophrenia as Revealed by fMRI]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn172v1?rss=1</link>
<description><![CDATA[
<p>We recently showed that, in healthy individuals, emotional expression influences memory for faces both in terms of accuracy and, critically, in memory response bias (tendency to classify stimuli as previously seen or not, regardless of whether this was the case). Although schizophrenia has been shown to be associated with deficit in episodic memory and emotional processing, the relation between these processes in this population remains unclear. Here, we used our previously validated paradigm to directly investigate the modulation of emotion on memory recognition. Twenty patients with schizophrenia and matched healthy controls completed functional magnetic resonance imaging (fMRI) study of recognition memory of happy, sad, and neutral faces. Brain activity associated with the response bias was obtained by correlating this measure with the contrast <I>subjective old</I> (ie, hits and false alarms) minus <I>subjective new</I> (misses and correct rejections) for sad and happy expressions. Although patients exhibited an overall lower memory performance than controls, they showed the same effects of emotion on memory, both in terms of accuracy and bias. For sad faces, the similar behavioral pattern between groups was mirrored by a largely overlapping neural network, mostly involved in familiarity-based judgments (eg, parahippocampal gyrus). In contrast, controls activated a much larger set of regions for happy faces, including areas thought to underlie recollection-based memory retrieval (eg, superior frontal gyrus and hippocampus) and in novelty detection (eg, amygdala). This study demonstrates that, despite an overall lower memory accuracy, emotional memory is intact in schizophrenia, although emotion-specific differences in brain activation exist, possibly reflecting different strategies.</p>
]]></description>
<dc:creator><![CDATA[Sergerie, K., Armony, J. L., Menear, M., Sutton, H., Lepage, M.]]></dc:creator>
<dc:date>Tue, 27 Jan 2009 13:21:08 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn172</dc:identifier>
<dc:title><![CDATA[Influence of Emotional Expression on Memory Recognition Bias in Schizophrenia as Revealed by fMRI]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2009-01-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn167v1?rss=1">
<title><![CDATA[Periods of Recovery in Deficit Syndrome Schizophrenia: A 20-Year Multi-follow-up Longitudinal Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn167v1?rss=1</link>
<description><![CDATA[
<p>Periods of recovery were examined in patients with and without deficit syndrome schizophrenia. Fifty-six patients with schizophrenia were studied, 39 of whom were divided into deficit and nondeficit syndrome schizophrenia subtypes using a proxy method. We also studied 39 nonpsychotic depressive comparison patients. Patients were evaluated as part of the Chicago Follow-up Study, which prospectively examined patients at regular intervals over a 20-year period. Using standardized instruments, patients were evaluated for the deficit syndrome, global recovery, rehospitalization, social dysfunction, occupational disability, and symptom presentation. Recovery was examined at 6 time points measured at 2-, 4.5-, 7.5-, 10-, 15-, and 20-year postindex hospitalization. Cumulatively, over the 20-year period, 13% of patients classified as meeting criteria for the deficit syndrome showed 1 or more 1-year periods of global recovery, in comparison to 63% of nondeficit schizophrenia patients and 77% of depressed patient controls. Results indicate that the deficit syndrome represents a persistently impaired subsample of schizophrenia patients, with continuous social, occupational, and symptom impairment. In contrast, nondeficit syndrome schizophrenia patients showed at least some periods of remission or recovery, with the likelihood of these periods increasing as they became older. Findings provide further support for the validity of the deficit syndrome concept and suggest that deficit status is characterized by a more persistently impaired course of illness and particularly poor long-term prognosis.</p>
]]></description>
<dc:creator><![CDATA[Strauss, G. P., Harrow, M., Grossman, L. S., Rosen, C.]]></dc:creator>
<dc:date>Thu, 18 Dec 2008 07:13:01 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn167</dc:identifier>
<dc:title><![CDATA[Periods of Recovery in Deficit Syndrome Schizophrenia: A 20-Year Multi-follow-up Longitudinal Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-12-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn161v1?rss=1">
<title><![CDATA[Tract-based Analysis of Magnetization Transfer Ratio and Diffusion Tensor Imaging of the Frontal and Frontotemporal Connections in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn161v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I> In the pathophysiology of schizophrenia, aberrant connectivity between brain regions may be a central feature. Diffusion tensor imaging (DTI) studies have shown altered fractional anisotropy (FA) in white brain matter in schizophrenia. Focal reductions in myelin have been suggested in patients using magnetization transfer ratio (MTR) imaging but to what extent schizophrenia may be related to changes in MTR measured along entire fiber bundles is still unknown. <I>Methods:</I> DTI and MTR images were acquired with a 1.5-T scanner in 40 schizophrenia patients and compared with those of 40 healthy participants. The mean FA and mean MTR were measured along the genu of the corpus callosum and the left and right uncinate fasciculus. <I>Results:</I> A higher mean MTR of 1% was found in the right uncinate fasciculus in patients compared with healthy participants. A significant negative correlation between age and mean FA in the left uncinate fasciculus was found in schizophrenia patients but not in healthy participants. <I>Conclusions:</I> Decreased FA in the left uncinate fasciculus may be more prominent in patients with longer illness duration. The increased mean MTR in the right uncinate fasciculus could reflect a compensatory role for myelin in these fibers or possibly represent aberrant frontotemporal connectivity.</p>
]]></description>
<dc:creator><![CDATA[Mandl, R. C. W., Schnack, H. G., Luigjes, J., van den Heuvel, M. P., Cahn, W., Kahn, R. S., Hulshoff Pol, H. E.]]></dc:creator>
<dc:date>Thu, 27 Nov 2008 21:13:38 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn161</dc:identifier>
<dc:title><![CDATA[Tract-based Analysis of Magnetization Transfer Ratio and Diffusion Tensor Imaging of the Frontal and Frontotemporal Connections in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn141v1?rss=1">
<title><![CDATA[Morphometric Brain Abnormalities in Schizophrenia in a Population-Based Sample: Relationship to Duration of Illness]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn141v1?rss=1</link>
<description><![CDATA[
<p>Biased recruitment and sample selection may cause variability in neuroimaging studies. Epidemiologically principled population-based magnetic resonance imaging (MRI) studies of schizophrenia are very rare. We gathered structural MRI data on 154 subjects from the Northern Finland 1966 Birth Cohort, aged 33&ndash;35 (100 controls, 54 schizophrenia patients). Regional differences in density of gray matter, white matter, and cerebrospinal fluid (CSF) were identified between groups using nonparametric statistical analysis, and the relationship of the regional differences to duration of illness was explored. Gray matter reductions were found bilaterally in the cerebellum, thalamus, basal ganglia, middle frontal gyrus, inferior frontal gyrus, precentral gyrus, insula, superior temporal gyrus, fusiform gyrus, parahippocampal gyrus, cuneus, and lingual gyrus; in the left posterior cingulate, superior frontal gyrus, transverse temporal gyrus, and precuneus; and in the right postcentral gyrus. Gray matter excesses were observed bilaterally in the basal ganglia, anterior cingulate, and medial orbitofrontal cortices. There were white matter deficits in an extensive network including inter- and intrahemispheric tracts bilaterally in the frontal, temporal, parietal, and occipital lobes, subcortical structures, cerebellum, and brain stem. CSF excesses were found bilaterally in the lateral ventricles, third ventricle, interhemispheric, and left Sylvian fissure. We replicated the previous findings of structural brain abnormalities in schizophrenia on a general population level. Gray and white matter deficits were associated with duration of illness suggesting either that developmental brain deficits relate to an earlier age of onset or that brain abnormalities in schizophrenia are progressive in nature.</p>
]]></description>
<dc:creator><![CDATA[Tanskanen, P., Ridler, K., Murray, G. K., Haapea, M., Veijola, J. M., Jaaskelainen, E., Miettunen, J., Jones, P. B., Bullmore, E. T., Isohanni, M. K.]]></dc:creator>
<dc:date>Mon, 17 Nov 2008 05:34:58 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn141</dc:identifier>
<dc:title><![CDATA[Morphometric Brain Abnormalities in Schizophrenia in a Population-Based Sample: Relationship to Duration of Illness]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn160v1?rss=1">
<title><![CDATA[Supportive evidence for reduced expression of GNB1L in schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn160v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: Chromosome 22q11 deletion syndrome (22q11DS) increases the risk of development of schizophrenia more than 10 times compared with that of the general population, indicating that haploinsufficiency of a subset of the more than 20 genes contained in the 22q11DS region could increase the risk of schizophrenia. In the present study, we screened for genes located in the 22q11DS region that are expressed at lower levels in postmortem prefrontal cortex of patients with schizophrenia than in those of controls. <I>Methods</I>: Gene expression was screened by Illumina Human-6 Expression BeadChip arrays and confirmed by real-time reverse transcription-polymerase chain reaction assays and Western blot analysis. <I>Results</I>: Expression of <I>GNB1L</I> was lower in patients with schizophrenia than in control subjects in both Australian (10 schizophrenia cases and 10 controls) and Japanese (43 schizophrenia cases and 11 controls) brain samples. <I>TBX1</I> could not be evaluated due to its low expression levels. Expression levels of the other genes were not significantly lower in patients with schizophrenia than in control subjects. Association analysis of tag single-nucleotide polymorphisms in the <I>GNB1L</I> gene region did not confirm excess homozygosity in 1918 Japanese schizophrenia cases and 1909 Japanese controls. Haloperidol treatment for 50 weeks increased <I>Gnb1l</I> gene expression in prefrontal cortex of mice. <I>Conclusions</I>: Taken together with the impaired prepulse inhibition observed in heterozygous <I>Gnb1l</I> knockout mice reported by the previous study, the present findings support assertions that <I>GNB1L</I> is one of the genes in the 22q11DS region responsible for increasing the risk of schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Ishiguro, H., Koga, M., Horiuchi, Y., Noguchi, E., Morikawa, M., Suzuki, Y., Arai, M., Niizato, K., Iritani, S., Itokawa, M., Inada, T., Iwata, N., Ozaki, N., Ujike, H., Kunugi, H., Sasaki, T., Takahashi, M., Watanabe, Y., Someya, T., Kakita, A., Takahashi, H., Nawa, H., Arinami, T.]]></dc:creator>
<dc:date>Fri, 14 Nov 2008 14:30:47 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn160</dc:identifier>
<dc:title><![CDATA[Supportive evidence for reduced expression of GNB1L in schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-14</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn148v1?rss=1">
<title><![CDATA[Functional MRI of Verbal Self-monitoring in Schizophrenia: Performance and Illness-Specific Effects]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn148v1?rss=1</link>
<description><![CDATA[
<p>Previous small-sample studies have shown altered frontotemporal activity in schizophrenia patients with auditory hallucinations and impaired monitoring of self-generated speech. We examined a large cohort of patients with schizophrenia (<I>n</I> = 63) and a representative group of healthy controls (<I>n</I> = 20) to disentangle performance, illness, and symptom-related effects in functional magnetic resonance imaging&ndash;detected brain abnormalities during monitoring of self- and externally generated speech in schizophrenia. Our results revealed activation of the thalamus (medial geniculate nucleus, MGN) and frontotemporal regions with accurate monitoring across all participants. Less activation of the thalamus (MGN, pulvinar) and superior-middle temporal and inferior frontal gyri occurred in poorly performing patients (1 standard deviation below controls&rsquo; mean; <I>n</I> = 36), relative to the combined group of controls and well-performing patients. In patients, (1) greater deactivation of the ventral striatum and hypothalamus to own voice, combined with nonsignificant activation of the same regions to others&rsquo; voice, associated positively with negative symptoms (blunted affect, emotional withdrawal, poor rapport, passive social avoidance) regardless of performance and (2) exaggerated activation of the right superior-middle temporal gyrus during undistorted, relative to distorted, feedback associated with both positive symptoms (hallucinations, persecution) and poor performance. A further thalamic abnormality characterized schizophrenia patients regardless of performance and symptoms. We conclude that hypoactivation of a neural network comprised of the thalamus and frontotemporal regions underlies impaired speech monitoring in schizophrenia. Positive symptoms and poor monitoring share a common activation abnormality in the right superior temporal gyrus during processing of degraded speech. Altered striatal and hypothalamic modulation to own and others&rsquo; voice characterizes emotionally withdrawn and socially avoidant patients.</p>
]]></description>
<dc:creator><![CDATA[Kumari, V., Fannon, D., ffytche, D. H., Raveendran, V., Antonova, E., Premkumar, P., Cooke, M. A., Anilkumar, A. P.P., Williams, S. C.R., Andrew, C., Johns, L. C., Fu, C. H.Y., McGuire, P. K., Kuipers, E.]]></dc:creator>
<dc:date>Fri, 07 Nov 2008 18:10:27 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn148</dc:identifier>
<dc:title><![CDATA[Functional MRI of Verbal Self-monitoring in Schizophrenia: Performance and Illness-Specific Effects]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn138v1?rss=1">
<title><![CDATA[The Appropriateness of Routine Medication Treatment for Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn138v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Although national guidelines specify appropriate strategies for the treatment of schizophrenia, this disorder presents challenges to clinicians and health-care organizations. To improve care, it is useful to understand how often patients receive appropriate treatment. Most research evaluating treatment was performed when first-generation antipsychotic medications were the modal treatment. Given that most prescriptions are now for second-generation medications, this study describes current clinical problems and the appropriateness of treatment in routine practice. <I>Method:</I> Between 2002 and 2004, a random sample of patients (<I>n</I> = 398) were interviewed at baseline and 1 year at 3 Department of Veterans Affairs mental health clinics. Symptoms and side effects were assessed. Analyses examined whether prescribing were consistent with guidelines in patients with significant psychosis, depression, parkinsonism, akathisia, tardive dyskinesia, or elevated weight. <I>Results:</I> Few patients met criteria for depression, parkinsonism, or akathisia. A total of 44% of patients had significant psychosis, 11% had tardive dyskinesia, and 46% were overweight. Medication was appropriate in 27% of patients with psychosis, 25% of patients with tardive dyskinesia, and 2% of patients with elevated weight. Management of elevated weight improved modestly over time. Treatment was more likely to improve for patients whose psychiatrists had more than 12 patients with schizophrenia in their caseload. <I>Conclusion:</I> Compared with the 1990s, outpatients are more likely to have significant psychosis. The rate of appropriate treatment of psychosis is unchanged. Weight gain has become a prevalent side effect, yet treatment is rarely changed in response to weight. There is a need for interventions that improve management of psychosis and weight.</p>
]]></description>
<dc:creator><![CDATA[Young, A. S., Niv, N., Cohen, A. N., Kessler, C., McNagny, K.]]></dc:creator>
<dc:date>Fri, 07 Nov 2008 18:10:26 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn138</dc:identifier>
<dc:title><![CDATA[The Appropriateness of Routine Medication Treatment for Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn146v1?rss=1">
<title><![CDATA[Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn146v1?rss=1</link>
<description><![CDATA[
<p><I>Background:</I>Several studies have reported the presence of dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia as well as in their first-degree relatives. These movement disorders may therefore form an integral part of the illness and its (genetic) liability. <I>Method:</I> A systematic search was conducted in the Medline, EMBASE, and PsychINFO databases to identify studies reporting on dyskinesia and parkinsonism assessed in antipsychotic-naive patients with schizophrenia (<I>n</I> = 213) and controls (<I>n</I> = 242) and separately in nonill first-degree relatives (<I>n</I> = 395) and controls (<I>n</I> = 379). Effect sizes were pooled using random-effect models to calculate odds ratios (ORs) to compare the risk of these movement disorders among patients and healthy relatives each with matched controls. <I>Results:</I> Antipsychotic-naive schizophrenia was found to be strongly associated with dyskinesia (OR: 3.59, 95% confidence interval [CI]: 1.53&ndash;8.41) and parkinsonism (OR: 5.32, 95% CI: 1.75&ndash;16.23) compared with controls. Dyskinesia and parkinsonism were also significantly more prevalent in healthy first-degree relatives of patients with schizophrenia as compared with healthy controls (OR: 1.38, 95% CI: 1.06&ndash;1.81, and OR: 1.37, 95% CI: 1.05&ndash;1.79, respectively).<I>Conclusion:</I> The results suggest that movement disorders, and by inference abnormalities in the nigrostriatal pathway, are not only associated with schizophrenia itself but may also be related to the (genetic) risk of developing the disease.</p>
]]></description>
<dc:creator><![CDATA[Koning, J. P., Tenback, D. E, van Os, J., Aleman, A., Kahn, R. S., van Harten, P. N.]]></dc:creator>
<dc:date>Wed, 05 Nov 2008 22:41:57 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn146</dc:identifier>
<dc:title><![CDATA[Dyskinesia and Parkinsonism in Antipsychotic-Naive Patients With Schizophrenia, First-Degree Relatives and Healthy Controls: A Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn145v1?rss=1">
<title><![CDATA[Low-Frequency BOLD Fluctuations Demonstrate Altered Thalamocortical Connectivity in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn145v1?rss=1</link>
<description><![CDATA[
<p>The thalamus plays a central and dynamic role in information transmission and processing in the brain. Multiple studies reveal increasing association between schizophrenia and dysfunction of the thalamus, in particular the medial dorsal nucleus (MDN), and its projection targets. The medial dorsal thalamic connections to the prefrontal cortex are of particular interest, and explicit in vivo evidence of this connection in healthy humans is sparse. Additionally, recent neuroimaging evidence has demonstrated disconnection among a variety of cortical regions in schizophrenia, though the MDN thalamic prefrontal cortex network has not been extensively probed in schizophrenia. To this end, we have examined thalamo-anterior cingulate cortex connectivity using detection of low-frequency blood oxygen level dependence fluctuations (LFBF) during a resting-state paradigm. Eleven schizophrenic patients and 12 healthy control participants were enrolled in a study of brain thalamocortical connectivity. Resting-state data were collected, and seed-based connectivity analysis was performed to identify the thalamocortical network. First, we have shown there is MDN thalamocortical connectivity in healthy controls, thus demonstrating that LFBF analysis is a manner to probe the thalamocortical network. Additionally, we have found there is statistically significantly reduced thalamocortical connectivity in schizophrenics compared with matched healthy controls. We did not observe any significant difference in motor networks between groups. We have shown that the thalamocortical network is observable using resting-state connectivity in healthy controls and that this network is altered in schizophrenia. These data support a disruption model of the thalamocortical network and are consistent with a disconnection hypothesis of schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Welsh, R. C., Chen, A. C., Taylor, S. F.]]></dc:creator>
<dc:date>Wed, 05 Nov 2008 22:41:57 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn145</dc:identifier>
<dc:title><![CDATA[Low-Frequency BOLD Fluctuations Demonstrate Altered Thalamocortical Connectivity in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn144v1?rss=1">
<title><![CDATA[Rates of Homicide During the First Episode of Psychosis and After Treatment: A Systematic Review and Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn144v1?rss=1</link>
<description><![CDATA[
<p>The observation that almost half of the homicides committed by people with a psychotic illness occur before initial treatment suggests an increased risk of homicide during the first episode of psychosis. The aim of this study was to estimate the rates of homicide during the first episode of psychosis and after treatment. A systematic search located 10 studies that reported details of all the homicide offenders with a psychotic illness within a known population during a specified period and reported the number of people who had received treatment prior to the offense. Meta-analysis of these studies showed that 38.5% (95% confidence interval [CI] = 31.1%&ndash;46.5%) of homicides occurred during the first episode of psychosis, prior to initial treatment. Homicides during first-episode psychosis occurred at a rate of 1.59 homicides per 1000 (95% CI = 1.06&ndash;2.40), equivalent to 1 in 629 presentations. The annual rate of homicide after treatment for psychosis was 0.11 homicides per 1000 patients (95% CI = 0.07&ndash;0.16), equivalent to 1 homicide in 9090 patients with schizophrenia per year. The rate ratio of homicide in the first episode of psychosis in these studies was 15.5 (95% CI = 11.0&ndash;21.7) times the annual rate of homicide after treatment for psychosis. Hence, the rate of homicide in the first episode of psychosis appears to be higher than previously recognized, whereas the annual rate of homicide by patients with schizophrenia after treatment is lower than previous estimates. Earlier treatment of first-episode psychosis might prevent some homicides.</p>
]]></description>
<dc:creator><![CDATA[Nielssen, O., Large, M.]]></dc:creator>
<dc:date>Wed, 05 Nov 2008 22:41:56 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn144</dc:identifier>
<dc:title><![CDATA[Rates of Homicide During the First Episode of Psychosis and After Treatment: A Systematic Review and Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn137v1?rss=1">
<title><![CDATA[Ethnic Diversity and Pathways to Care for a First Episode of Psychosis in Ontario]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn137v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> To examine ethnic variations in the pathways to care for persons accessing early intervention (EI) services in Ontario. <I>Method:</I> The pathways to care and the duration of untreated psychosis were assessed for first-episode psychosis patients who entered specialized EI services in Ontario. The sample was assigned to the following ethnic classifications: the White (Caucasian), Black (African descent), and Asian (ancestry from the continent) groups, plus all the "other ethnicities" group. <I>Results:</I> There were 200 participants: 78% were male; 61% from the White, 15% Black, 13% Asian, and 11% were from the other ethnicities group. At the first point of contact, more participants used nonmedical contacts (12%), such as clergy and naturopathic healers, than psychologists (8%) or psychiatrists (7%). There were no ethnic differences for duration of untreated psychosis (median 22 weeks) or for initiation of help seeking by family/friends (53%), police (15%), or self (33%). After adjusting for relevant clinical and demographic factors, the Asian and other ethnicities groups were 4 and 3 times (respectively) more likely than the White or Black groups (<I>P</I> = .017) to use emergency room services as the first point of contact in the pathways to care. Participants from the Asian group experienced less involuntary hospitalizations (<I>P</I> = .023) than all the other groups. Yet overall, there were many more similarities than significant differences in the pathways to care. <I>Conclusion:</I> EI services should monitor the pathways to care for young people of diverse ethnic backgrounds to address any disparities in accessing care.</p>
]]></description>
<dc:creator><![CDATA[Archie, S., Akhtar-Danesh, N., Norman, R., Malla, A., Roy, P., Zipursky, R. B.]]></dc:creator>
<dc:date>Wed, 05 Nov 2008 07:00:33 PST</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn137</dc:identifier>
<dc:title><![CDATA[Ethnic Diversity and Pathways to Care for a First Episode of Psychosis in Ontario]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-11-05</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn136v1?rss=1">
<title><![CDATA[Symptom Correlates of Static and Dynamic Facial Affect Processing in Schizophrenia: Evidence of a Double Dissociation?]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn136v1?rss=1</link>
<description><![CDATA[
<p>Schizophrenia patients have been shown to be compromised in their ability to recognize facial emotion. This deficit has been shown to be related to negative symptoms severity. However, to date, most studies have used static rather than dynamic depictions of faces. Nineteen patients with schizophrenia were compared with seventeen controls on 2 tasks; the first involving the discrimination of facial identity, emotion, and butterfly wings; the second testing emotion recognition using both static and dynamic stimuli. In the first task, the patients performed more poorly than controls for emotion discrimination only, confirming a specific deficit in facial emotion recognition. In the second task, patients performed more poorly in both static and dynamic facial emotion processing. An interesting pattern of associations suggestive of a possible double dissociation emerged in relation to correlations with symptom ratings: high negative symptom ratings were associated with poorer recognition of static displays of emotion, whereas high positive symptom ratings were associated with poorer recognition of dynamic displays of emotion. However, while the strength of associations between negative symptom ratings and accuracy during static and dynamic facial emotion processing was significantly different, those between positive symptom ratings and task performance were not. The results confirm a facial emotion-processing deficit in schizophrenia using more ecologically valid dynamic expressions of emotion. The pattern of findings may reflect differential patterns of cortical dysfunction associated with negative and positive symptoms of schizophrenia in the context of differential neural mechanisms for the processing of static and dynamic displays of facial emotion.</p>
]]></description>
<dc:creator><![CDATA[Johnston, P. J., Enticott, P. G., Mayes, A. K., Hoy, K. E., Herring, S. E., Fitzgerald, P. B.]]></dc:creator>
<dc:date>Sun, 26 Oct 2008 01:23:49 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn136</dc:identifier>
<dc:title><![CDATA[Symptom Correlates of Static and Dynamic Facial Affect Processing in Schizophrenia: Evidence of a Double Dissociation?]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-26</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn132v1?rss=1">
<title><![CDATA[Functional Deficits in the Extrastriate Body Area During Observation of Sports-Related Actions in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn132v1?rss=1</link>
<description><![CDATA[
<p>Exercise and sports are increasingly being implemented in the management of schizophrenia. The process of action perception is as important as that of motor execution for learning and acquiring new skills. Recent studies have suggested that body-selective extrastriate body area (EBA) in the posterior temporal-occipital cortex is involved not only in static visual perception of body parts but also in the planning, imagination, and execution of actions. However, functional abnormality of the EBA in schizophrenia has yet to be investigated. Using functional magnetic resonance imaging (fMRI) with a task designed to activate the EBA by sports-related actions, we aimed to elucidate functional abnormality of the EBA during observation of sports-related actions in patients with schizophrenia. Twelve schizophrenia patients and 12 age-sex&ndash;matched control participants participated in the study. Using sports-related motions as visual stimuli, we examined brain activations during observation of context-congruent actions relative to context-incongruent actions by fMRI. Compared with controls, the patients with schizophrenia demonstrated diminished activation in the EBA during observation of sports-related context-congruent actions. Furthermore, the EBA activation in patients was negatively correlated with the severity of negative and general psychopathology symptoms measured by the Positive and Negative Syndrome Scale. Dysfunction of the EBA might reflect a difficulty in representing dynamic aspects of human actions and possibly lead to impairments of simulation, learning, and execution of actions in schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Takahashi, H., Kato, M., Sassa, T., Shibuya, T., Koeda, M., Yahata, N., Matsuura, M., Asai, K., Suhara, T., Okubo, Y.]]></dc:creator>
<dc:date>Thu, 16 Oct 2008 11:30:43 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn132</dc:identifier>
<dc:title><![CDATA[Functional Deficits in the Extrastriate Body Area During Observation of Sports-Related Actions in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-16</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn130v1?rss=1">
<title><![CDATA[Healthy Individuals With Auditory Verbal Hallucinations; Who Are They? Psychiatric Assessments of a Selected Sample of 103 Subjects]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn130v1?rss=1</link>
<description><![CDATA[
<p>Epidemiological studies suggest that auditory verbal hallucinations (AVH) occur in approximately 10%&ndash;15% of the general population, of whom only a small proportion has a clinically relevant psychotic disorder. It is unclear whether these hallucinations occur as an isolated phenomenon or if AVH in nonclinical individuals are part of a more general susceptibility to schizophrenia. For this study, 103 healthy individuals with frequent AVH were compared with 60 controls matched for sex, age, and education. All participants were examined by a psychiatrist using standardized diagnostic interviews and questionnaires. The individuals with AVH did not have clinically defined delusions, disorganization, or negative or catatonic symptoms, nor did they meet criteria for cluster A personality disorder. However, their global level of functioning was lower than in the controls and there was a pronounced increase on all subclusters of the Schizotypal Personality Questionnaire (SPQ) and the Peters Delusion Inventory, indicating a general increased schizotypal and delusional tendency in the hallucinating subjects. History of childhood trauma and family history of axis I disorders were also more prevalent in these individuals. We showed that higher SPQ scores, lower education, and higher family loading for psychiatric disorders, but not presence of AVH, were associated with lower global functioning. Our data suggest that AVH in otherwise healthy individuals are not an isolated phenomenon but part of a general vulnerability for schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Sommer, I. E., Daalman, K., Rietkerk, T., Diederen, K. M., Bakker, S., Wijkstra, J., Boks, M. P.M.]]></dc:creator>
<dc:date>Thu, 09 Oct 2008 20:05:33 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn130</dc:identifier>
<dc:title><![CDATA[Healthy Individuals With Auditory Verbal Hallucinations; Who Are They? Psychiatric Assessments of a Selected Sample of 103 Subjects]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn120v1?rss=1">
<title><![CDATA[Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn120v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: Little is known about the extent of heterogeneity of symptomatology in treated early-onset psychosis. The current study aims to quantify the extent of heterogeneity in trajectories of treated symptom severity in early-episode psychosis and their antecedents. <I>Methods</I>: Data were from 491 persons with early-episode psychosis from a clinical trial of haloperidol and risperidone. Positive and Negative Syndrome Scale (PANSS) administrations were used to measure symptom severity trajectories for (a) rapid treatment response scores over 4 weeks and (b) medium-term course over 24 weeks. Baseline antecedents included sex, <I>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</I>, diagnosis, age of onset, the Premorbid Adjustment Scale, and a cognitive test battery. Symptom severity trajectories were calculated with mixed mode latent class regression modeling from which groups were derived. <I>Results</I>: Five groups based on PANSS scores over time were identified. Over 4 weeks, 3 groups with varied baseline PANSS scores (54&ndash;105) did not surpass 30% PANSS improvement. Another group improved and then was stable (<I>n</I> = 76,15.3%), and another showed marked improvement (<I>n</I> = 94,18.9%). Logistic regression showed that membership in the best response trajectory was associated with not having a diagnosis of schizophrenia, good premorbid functioning, and higher cognitive functioning, whereas membership in the poor response trajectory was associated with earlier age of onset and poorer cognitive functioning. <I>Conclusion</I>: Amelioration generally characterizes treated symptom severity. Age of onset, diagnosis, cognitive functioning, and premorbid functioning have prognostic value in predicting treatment response trajectories.</p>
]]></description>
<dc:creator><![CDATA[Levine, S. Z., Rabinowitz, J.]]></dc:creator>
<dc:date>Thu, 09 Oct 2008 20:05:32 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn120</dc:identifier>
<dc:title><![CDATA[Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn131v1?rss=1">
<title><![CDATA[Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn131v1?rss=1</link>
<description><![CDATA[
<p>Current pharmacotherapy of schizophrenia remains unsatisfactory with little hope for complete functional restoration in patients once the disease has developed. A preventive approach based on intervention in the prodromal stage of the disease aiming to preserve functional integrity by halting the progress of the disease is therefore extremely attractive. Here, we investigated the effects of preventive antipsychotic or antidepressant drug treatment in a well-established neurodevelopmental mouse model of multiple schizophrenia-related abnormalities. Pregnant mice on gestation day 9 were exposed to the viral mimic polyriboinosinic-polyribocytidylic acid (2 mg/kg, intravenously) or corresponding vehicle treatment, and the resulting offspring from both prenatal treatment conditions were subjected to chronic antipsychotic (haloperidol or clozapine), antidepressant (fluoxetine), or placebo treatment during the periadolescent stage of development. The effects of the preventive pharmacotherapy on behavioral and pharmacological functions were then investigated in adulthood using paradigms relevant to schizophrenia, namely prepulse inhibition, latent inhibition, and sensitivity to psychostimulant drugs. We show that periadolescent treatment with the reference antipsychotic and antidepressant drugs can successfully block the emergence of multiple psychosis-related behavioral and pharmacological abnormalities in subjects predisposed to adult brain pathology by exposure to prenatal immune challenge. At the same time, however, our study reveals numerous negative influences of the early pharmacological intervention on normal behavioral development in control subjects. Hence, even though preventive pharmacotherapy may be beneficial in individuals with predisposition to psychosis-related brain dysfunctions, chronic antipsychotic or antidepressant drug treatment in false-positive subjects is associated with substantial risk for long-term behavioral disturbances in adulthood.</p>
]]></description>
<dc:creator><![CDATA[Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., Feldon, J.]]></dc:creator>
<dc:date>Wed, 08 Oct 2008 21:43:11 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn131</dc:identifier>
<dc:title><![CDATA[Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-08</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn119v1?rss=1">
<title><![CDATA[Schizophrenia Patients Show Task Switching Deficits Consistent With N-Methyl-D-Aspartate System Dysfunction But Not Global Executive Deficits: Implications for Pathophysiology of Executive Dysfunction in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn119v1?rss=1</link>
<description><![CDATA[
<p>Schizophrenia is associated with cognitive processing deficits, including deficits in executive processing, that represent a core component of the disorder. In the Task Switching Test, subjects view ambiguous stimuli and must alternate between competing rules to generate correct responses. Subjects show worse performance (prolonged response time and/or increased error rates) on the first response after a switch than on subsequent responses ("switch costs"), as well as performing worse when stimuli are incongruent as opposed to congruent ("congruence costs"). Finally, subjects show worse performance in the dual vs single task condition ("mixing costs"). In monkeys, the <I>N</I>-methyl-<scp>D</scp>-aspartate (NMDA) antagonist ketamine has been shown to increase congruence but not switch costs. Here, subjects viewed colored letters and had to respond alternately based upon letter (X vs O) or color (red vs blue). Switch, congruence and mixing costs were calculated. Patients with schizophrenia (<I>n</I> = 16) and controls (<I>n</I> = 17) showed similar switch costs, consistent with prior literature. Patients nevertheless showed increased congruence and mixing costs. In addition, relative to controls, patients showed worse performance across conditions in the letter vs color tasks, suggesting deficits in form vs color processing. Overall, while confirming executive dysfunction in schizophrenia, this study indicates that not all aspects of executive control are impaired and that the task switching paradigm may be useful for evaluating neurochemical vs neuroanatomic hypotheses of schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Wylie, G. R., Clark, E.A, Butler, P.D., Javitt, D.C.]]></dc:creator>
<dc:date>Fri, 03 Oct 2008 12:22:54 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn119</dc:identifier>
<dc:title><![CDATA[Schizophrenia Patients Show Task Switching Deficits Consistent With N-Methyl-D-Aspartate System Dysfunction But Not Global Executive Deficits: Implications for Pathophysiology of Executive Dysfunction in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-03</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn128v1?rss=1">
<title><![CDATA[The Cognitive Neuropsychology of Auditory Hallucinations: A Parallel Auditory Pathways Framework]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn128v1?rss=1</link>
<description><![CDATA[
<p>Auditory hallucinations are generally defined as false perceptions. Recent developments in auditory neuroscience have rapidly increased our understanding of normal auditory perception revealing (partially) separate pathways for the identification ("what") and localization ("where") of auditory objects. The current review offers a reexamination of the nature of auditory hallucinations in schizophrenia using this object-based framework. First, the structural and functional organization of auditory what and where pathways is briefly described. Then, using recent functional neuroimaging data from healthy subjects and patients with schizophrenia, key phenomenological features of hallucinations are linked to abnormal processing both within and between these pathways. Finally, current cognitive explanations of hallucinations, based on intrusive cognitions and impaired source memory, are briefly outlined and set within this framework to provide an integrated cognitive neuropsychological model of auditory hallucinations.</p>
]]></description>
<dc:creator><![CDATA[Badcock, J. C.]]></dc:creator>
<dc:date>Thu, 02 Oct 2008 23:05:40 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn128</dc:identifier>
<dc:title><![CDATA[The Cognitive Neuropsychology of Auditory Hallucinations: A Parallel Auditory Pathways Framework]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-10-02</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn129v1?rss=1">
<title><![CDATA[Do We Need Multiple Models of Auditory Verbal Hallucinations? Examining the Phenomenological Fit of Cognitive and Neurological Models]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn129v1?rss=1</link>
<description><![CDATA[
<p>The causes of auditory verbal hallucinations (AVHs) are still unclear. The evidence for 2 prominent cognitive models of AVHs, one based on inner speech, the other on intrusions from memory, is briefly reviewed. The fit of these models, as well as neurological models, to the phenomenology of AVHs is then critically examined. It is argued that only a minority of AVHs, such as those with content clearly relating to verbalizations experienced surrounding previous trauma, are consistent with cognitive AVHs-as-memories models. Similarly, it is argued that current neurological models are only phenomenologically consistent with a limited subset of AVHs. In contrast, the phenomenology of the majority of AVHs, which involve voices attempting to regulate the ongoing actions of the voice hearer, are argued to be more consistent with inner speech&ndash;based models. It is concluded that subcategorizations of AVHs may be necessary, with each underpinned by different neurocognitive mechanisms. The need to study what is termed the dynamic developmental progression of AVHs is also highlighted. Future empirical research is suggested in this area.</p>
]]></description>
<dc:creator><![CDATA[Jones, S. R.]]></dc:creator>
<dc:date>Fri, 26 Sep 2008 21:18:03 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn129</dc:identifier>
<dc:title><![CDATA[Do We Need Multiple Models of Auditory Verbal Hallucinations? Examining the Phenomenological Fit of Cognitive and Neurological Models]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-09-26</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn115v2?rss=1">
<title><![CDATA[Getting the Cue: Sensory Contributions to Auditory Emotion Recognition Impairments in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn115v2?rss=1</link>
<description><![CDATA[
<p>Individuals with schizophrenia show reliable deficits in the ability to recognize emotions from vocal expressions. Here, we examined emotion recognition ability in 23 schizophrenia patients relative to 17 healthy controls using a stimulus battery with well-characterized acoustic features. We further evaluated performance deficits relative to ancillary assessments of underlying pitch perception abilities. As predicted, patients showed reduced emotion recognition ability across a range of emotions, which correlated with impaired basic tone matching abilities. Emotion identification deficits were strongly related to pitch-based acoustic cues such as mean and variability of fundamental frequency. Whereas healthy subjects&rsquo; performance varied as a function of the relative presence or absence of these cues, with higher cue levels leading to enhanced performance, schizophrenia patients showed significantly less variation in performance as a function of cue level. In contrast to pitch-based cues, both groups showed equivalent variation in performance as a function of intensity-based cues. Finally, patients were less able than controls to differentiate between expressions with high and low emotion intensity, and this deficit was also correlated with impaired tone matching ability. Both emotion identification and intensity rating deficits were unrelated to valence of intended emotions. Deficits in both auditory emotion identification and more basic perceptual abilities correlated with impaired functional outcome. Overall, these findings support the concept that auditory emotion identification deficits in schizophrenia reflect, at least in part, a relative inability to process critical acoustic characteristics of prosodic stimuli and that such deficits contribute to poor global outcome.</p>
]]></description>
<dc:creator><![CDATA[Leitman, D. I., Laukka, P., Juslin, P. N., Saccente, E., Butler, P., Javitt, D. C.]]></dc:creator>
<dc:date>Tue, 23 Sep 2008 20:38:47 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn115</dc:identifier>
<dc:title><![CDATA[Getting the Cue: Sensory Contributions to Auditory Emotion Recognition Impairments in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-09-23</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn127v1?rss=1">
<title><![CDATA[Neurocognitive Decline in Early-Onset Schizophrenia Compared With ADHD and Normal Controls: Evidence From a 13-Year Follow-up Study]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn127v1?rss=1</link>
<description><![CDATA[
<p>The issue of neurodegeneration in schizophrenia is controversial. Although most studies indicate that neurocognitive deficits are relatively stable over the course of the illness, conclusions are limited by relatively short follow-up periods and absence of age-matched control groups. Furthermore, nearly all studies deal with adult-onset schizophrenia, and few studies have considered the possible effect of age of onset. The current study represents the first attempt to compare groups of adolescents with schizophrenia, attention deficit/hyperactivity disorder (ADHD), and normal controls on a comprehensive neurocognitive test battery in a longitudinal design over 13 years. In the baseline study, adolescents with schizophrenia were examined with a broad battery of neurocognitive tests. The comparison groups consisted of adolescents with ADHD and adolescents without a psychiatric diagnosis, between 12 and 18 years of age. In the follow-up study, the schizophrenia group consisted of 15 of the initial 19 individuals, the ADHD group of 19 of the 20 individuals, and the normal comparison group of all 30 individuals. They were reevaluated with the neurocognitive test battery and clinical measures. Subjects with schizophrenia showed a significant decline or arrest in neurocognitive functioning compared with the other 2 groups, particularly in verbal memory, attention, and processing speed. The impairments may be specific to early-onset schizophrenia due to interaction between ongoing brain maturation during adolescence and disease-related mechanisms and/or secondary to neuroleptic treatment in young age and/or social isolation.</p>
]]></description>
<dc:creator><![CDATA[Oie, M., Sundet, K., Rund, B. R.]]></dc:creator>
<dc:date>Thu, 18 Sep 2008 06:03:46 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn127</dc:identifier>
<dc:title><![CDATA[Neurocognitive Decline in Early-Onset Schizophrenia Compared With ADHD and Normal Controls: Evidence From a 13-Year Follow-up Study]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-09-18</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn107v1?rss=1">
<title><![CDATA[Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn107v1?rss=1</link>
<description><![CDATA[
<p><I>Objective:</I> Both first- (FGAs) and second-generation antipsychotics (SGAs) are routinely used in treating severe and persistent psychiatric disorders. However, until now no articles have analyzed systematically the safety of both classes of psychotropics during pregnancy. <I>Data sources and search strategy:</I> Medical literature information published in any language since 1950 was identified using MEDLINE/PubMed, TOXNET, EMBASE, and The Cochrane Library. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from companies developing drugs. Search terms were pregnancy, psychotropic drugs, (a)typical-first-second-generation antipsychotics, and neuroleptics. A separate search was also conducted to complete the safety profile of each reviewed medication. Searches were last updated on July 2008. <I>Data selection:</I> All articles reporting primary data on the outcome of pregnancies exposed to antipsychotics were acquired, without methodological limitations. <I>Conclusions:</I> Reviewed information was too limited to draw definite conclusions on structural teratogenicity of FGAs and SGAs. Both classes of drugs seem to be associated with an increased risk of neonatal complications. However, most SGAs appear to increase risk of gestational metabolic complications and babies large for gestational age and with mean birth weight significantly heavier as compared with those exposed to FGAs. These risks have been reported rarely with FGAs. Hence, the choice of the less harmful option in pregnancy should be limited to FGAs in drug-naive patients. When pregnancy occurs during antipsychotic treatment, the choice to continue the previous therapy should be preferred.</p>
]]></description>
<dc:creator><![CDATA[Gentile, S.]]></dc:creator>
<dc:date>Thu, 11 Sep 2008 13:32:22 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn107</dc:identifier>
<dc:title><![CDATA[Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-09-11</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn077v3?rss=1">
<title><![CDATA[Schizophrenia and Alterations in Self-experience: A Comparison of 6 Perspectives]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn077v3?rss=1</link>
<description><![CDATA[
<p>Contemporary researchers have tended to examine dysfunction among the lives of persons with schizophrenia as a matter of the impact of biological and social forces. While this has greatly advanced the knowledge base, any account of schizophrenia without a full consideration of the illness's first-person dimensions risks missing that schizophrenia is a disorder that interrupts the lives of people who must continue to struggle to find and create security and meaning. While literature from a range of sources has explored self-experience in schizophrenia, one barrier to the creation of a larger synthesis and application of this work is that it remains unclear whether, and to what degree, these differing views of self-experience are comparable with one another. To address this issue, this article reviews 6 different accounts of self-experience, a fundamental, first-person dimension of schizophrenia. The 6 are early psychiatry, existential psychiatry, psychoanalysis, phenomenology, psychosocial rehabilitation, and dialogical psychology. After comparing and contrasting the 6, we conclude that there is a wide-ranging, if general consensus, which suggests that many suffering from schizophrenia experience themselves as diminished relative to their former selves, ie, after onset they experience themselves as less able to engage the world effectively, which intensifies their anxieties in the face of everyday interactions. However, within this broad consensus, significant disagreements exist around issues such as whether these difficulties meaningfully predate the illness, how recovery is possible, and if so, under what conditions. In closing, we suggest a program of research to address these disagreements.</p>
]]></description>
<dc:creator><![CDATA[Lysaker, P. H., Lysaker, J. T.]]></dc:creator>
<dc:date>Thu, 11 Sep 2008 13:32:23 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn077</dc:identifier>
<dc:title><![CDATA[Schizophrenia and Alterations in Self-experience: A Comparison of 6 Perspectives]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-09-11</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn112v1?rss=1">
<title><![CDATA[First-Rank Symptoms in Schizophrenia: Reexamining Mechanisms of Self-recognition]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn112v1?rss=1</link>
<description><![CDATA[
<p>Disturbances of self are a common feature of schizophrenic psychopathology, with patients reporting that their thoughts and actions are controlled by external forces, as shown in first-rank symptoms (FRS). One widely accepted explanatory model of FRS suggests a deficiency in the internal forward model system. Recent studies in the field of cognitive sciences, however, have generated new insights into how complex sensory and motor systems contribute to the sense of self-recognition, and it is becoming clear that the forward model conceptualization does not have unique access to representations about the self. We briefly evaluate the forward model explanation of FRS, reassess the distinction made between the sense of agency and body ownership, and outline recent developments in 4 domains of sensory-motor control that have supplemented our understanding of the processes underlying the sense of self-recognition. The application of these findings to FRS will open up new research directions into the processes underlying these symptoms.</p>
]]></description>
<dc:creator><![CDATA[Waters, F. A.V., Badcock, J. C.]]></dc:creator>
<dc:date>Wed, 27 Aug 2008 08:21:39 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn112</dc:identifier>
<dc:title><![CDATA[First-Rank Symptoms in Schizophrenia: Reexamining Mechanisms of Self-recognition]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-27</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn110v1?rss=1">
<title><![CDATA[What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn110v1?rss=1</link>
<description><![CDATA[
<p>On September 18, 2007, a collaborative session between the International Society for CNS Clinical Trials and Methodology and the International Society for CNS Drug Development was held in Brussels, Belgium. Both groups, with membership from industry, academia, and governmental and nongovernmental agencies, have been formed to address scientific, clinical, regulatory, and methodological challenges in the development of central nervous system therapeutic agents. The focus of this joint session was the apparent diminution of drug-placebo differences in recent multicenter trials of antipsychotic medications for schizophrenia. To characterize the nature of the problem, some presenters reported data from several recent trials that indicated higher rates of placebo response and lower rates of drug response (even to previously established, comparator drugs), when compared with earlier trials. As a means to identify the possible causes of the problem, discussions covered a range of methodological factors such as participant characteristics, trial designs, site characteristics, clinical setting (inpatient vs outpatient), inclusion/exclusion criteria, and diagnostic specificity. Finally, possible solutions were discussed, such as improving precision of participant selection criteria, improving assessment instruments and/or assessment methodology to increase reliability of outcome measures, innovative methods to encourage greater subject adherence and investigator involvement, improved rater training and accountability metrics at clinical sites to increase quality assurance, and advanced methods of pharmacokinetic/pharmacodynamic modeling to optimize dosing prior to initiating large phase 3 trials. The session closed with a roundtable discussion and recommendations for data sharing to further explore potential causes and viable solutions to be applied in future trials.</p>
]]></description>
<dc:creator><![CDATA[Kemp, A. S., Schooler, N. R., Kalali, A. H., Alphs, L., Anand, R., Awad, G., Davidson, M., Dube, S., Ereshefsky, L., Gharabawi, G., Leon, A. C., Lepine, J.-P., Potkin, S. G., Vermeulen, A.]]></dc:creator>
<dc:date>Fri, 22 Aug 2008 19:17:13 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn110</dc:identifier>
<dc:title><![CDATA[What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-22</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn106v1?rss=1">
<title><![CDATA[Does Adherence to Medications for Type 2 Diabetes Differ Between Individuals With Vs Without Schizophrenia?]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn106v1?rss=1</link>
<description><![CDATA[
<p>Individuals with schizophrenia are at increased risk for poor health outcomes and mortality. This may be due to inadequate self-management of co-occurring conditions, such as type 2 diabetes. We compared adherence to oral hypoglycemic medications for diabetes patients with vs without comorbid schizophrenia. Using Veterans Affairs (VA) health system administrative data, we identified all patients with both schizophrenia and type 2 diabetes and with at least one oral hypoglycemic prescription fill in fiscal year 2002 (N = 11 454) and a comparison group of patients with diabetes who were not diagnosed with schizophrenia (N = 10 560). Nonadherence was operationalized as having a medication possession ratio indicating receipt of less than 80% of needed hypoglycemic medications. Poor adherence was less prevalent among diabetes patients with (43%) than without schizophrenia (52%, <I>P</I> &lt; .001). In multivariable analyses, having schizophrenia was associated with a 25% lower likelihood of poor adherence compared with not having schizophrenia (adjusted odds ratio: 0.75, 95% confidence interval: 0.70&ndash;0.80). Poorer adherence was associated with black race, homelessness, depression, substance use disorder, and medical comorbidity. Having more outpatient visits, a higher proportion of prescriptions delivered by mail, lower prescription copayments, and more complex medication regimens were each associated with increased adherence. Among veterans with diabetes receiving ongoing VA care, overall hypoglycemic medication adherence was low, but individuals with comorbid schizophrenia were more likely to be adherent to these medications. Future studies should investigate whether factors such as comanagement of a chronic psychiatric illness or regular contact with mental health providers bestow benefits for diabetes self-management in persons with schizophrenia.</p>
]]></description>
<dc:creator><![CDATA[Kreyenbuhl, J., Dixon, L. B., McCarthy, J. F., Soliman, S., Ignacio, R. V., Valenstein, M.]]></dc:creator>
<dc:date>Wed, 20 Aug 2008 19:01:16 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn106</dc:identifier>
<dc:title><![CDATA[Does Adherence to Medications for Type 2 Diabetes Differ Between Individuals With Vs Without Schizophrenia?]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-20</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn102v1?rss=1">
<title><![CDATA[A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn102v1?rss=1</link>
<description><![CDATA[
<p>Individuals with schizophrenia have consistently been found to exhibit cognitive deficits, which have been identified as critical mediators of psychosocial functional outcomes. Recent reviews of cognitive remediation (CRT) have concluded that these deficits respond to training. This multi-site community study examined 40 individuals with schizophrenia who underwent cognitive remediation using the Neuropsychological Educational Approach to Remediation<sup>1</sup> (NEAR). Assessments using the same neuropsychological tests and measures of psychosocial outcome were made at four time points: baseline, before start of active intervention, end of active intervention and 4 months after end of active intervention. Dose of antipsychotic medication remained constant throughout the study period. After participating in NEAR, individuals showed significant improvements in verbal and visual memory, sustained attention and executive functioning. This effect persisted 4 months after the treatment ceased. The average effect size was mild to moderate. Social and occupational outcomes also improved from baseline to post-treatment, which persisted 4 months later. Our findings replicate those of previous studies that suggest that NEAR is effective in improving cognition in individuals with schizophrenia in a naturalistic and ecologically valid setting. Further it extends such findings to show a generalisation of effects to social/occupational outcomes and persistence of effects in the short term.</p>
]]></description>
<dc:creator><![CDATA[Hodge, M. A. R., Siciliano, D., Withey, P., Moss, B., Moore, G., Judd, G., Shores, E. A., Harris, A.]]></dc:creator>
<dc:date>Wed, 20 Aug 2008 19:01:15 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn102</dc:identifier>
<dc:title><![CDATA[A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-20</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn104v1?rss=1">
<title><![CDATA[Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn104v1?rss=1</link>
<description><![CDATA[
<p>Atypical antipsychotic treatment has been associated with serious metabolic adverse events, such as glucose dysregulation and development of type 2 diabetes. As part of our studies on possible underlying mechanisms, we investigated the acute effects of various typical and atypical antipsychotics on plasma glucose and insulin in FVB/N mice, a strain that showed a more pronounced hyperglycemic response to clozapine than C57BL/6 and CD-1 mice. Acute administration of high doses of clozapine, olanzapine, quetiapine, perphenazine, or chlorpromazine significantly increased plasma glucose by 100%&ndash;140% above basal levels without significant effects on insulin levels. In contrast, risperidone reduced plasma glucose (&ndash;30%) and markedly enhanced plasma insulin levels. Doses of ziprasidone that gave 50-fold higher free plasma concentrations than therapeutic plasma levels, as well as high doses of aripiprazole and haloperidol, did not significantly alter either glucose or insulin levels. Clozapine- and olanzapine-induced hyperglycemia occurred at free plasma concentrations that were within, or one order of magnitude above, the range of therapeutic plasma levels. Pretreatment with either the ganglionic blocker hexamethonium, or the <SUB>2</SUB> adrenergic receptor antagonist yohimbine, blocked the clozapine- and chlorpromazine-induced increase in glucose levels. Taken together, these results suggest that typical and atypical antipsychotics with known metabolic liability produce acute hyperglycemia in mice and that this effect is likely driven by activation of the sympathetic autonomic nervous system via a central mechanism.</p>
]]></description>
<dc:creator><![CDATA[Savoy, Y. E., Ashton, M. A., Miller, M. W., Nedza, F. M., Spracklin, D. K., Hawthorn, M. H., Rollema, H., Matos, F. F., Hajos-Korcsok, E.]]></dc:creator>
<dc:date>Thu, 14 Aug 2008 08:30:18 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn104</dc:identifier>
<dc:title><![CDATA[Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-14</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn100v1?rss=1">
<title><![CDATA[The Relationship Between IQ, Memory, Executive Function, and Processing Speed in Recent-Onset Psychosis: 1-Year Stability and Clinical Outcome]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn100v1?rss=1</link>
<description><![CDATA[
<p>Studies commonly report poor performance in psychotic patients compared with controls on tasks testing a range of cognitive functions, but, because current IQ is often not matched between these groups, it is difficult to determine whether this represents a generalized deficit or specific abnormalities. Fifty-three first-episode psychosis patients and 53 healthy controls, one-to-one matched for sex, age, and full-scale current IQ, were compared on Wechsler Adult Intelligence Scale (WAIS) subtests representing indices of perceptual organization, verbal comprehension, processing speed, and working memory as well as other tests of executive function and episodic memory. The groups showed an equivalent pattern of performance on all WAIS subtests except digit symbol processing speed, on which the patients were significantly worse. Patients were also worse on measures where performance correlated with digit symbol score, namely working and verbal memory tasks. Standardized residual scores for each subtest were calculated for each patient using the difference between their actual subtest score and a predicted subtest score based on their full-scale IQ and the performance of controls. Scaled scores and residual scores were examined for relationships with clinical measures. Digit symbol&ndash;scaled score was significantly correlated with concurrent negative syndrome score at baseline, and digit symbol residual score significantly predicted residual negative symptoms at 1-year follow-up. In summary, our comparison of patients and controls precisely matched for IQ revealed that processing speed was attenuated in recent-onset schizophrenia, contributed significantly to working and episodic memory deficits, and was a prognostic factor for poor outcome at 1 year.</p>
]]></description>
<dc:creator><![CDATA[Leeson, V. C., Barnes, T. R. E., Harrison, M., Matheson, E., Harrison, I., Mutsatsa, S. H., Ron, M. A., Joyce, E. M.]]></dc:creator>
<dc:date>Mon, 04 Aug 2008 18:54:59 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn100</dc:identifier>
<dc:title><![CDATA[The Relationship Between IQ, Memory, Executive Function, and Processing Speed in Recent-Onset Psychosis: 1-Year Stability and Clinical Outcome]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn098v1?rss=1">
<title><![CDATA[Relating Schizotypy and Personality to the Phenomenology of Creativity]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn098v1?rss=1</link>
<description><![CDATA[
<p><I>Introduction:</I> Although a considerable amount of research has addressed psychopathological and personality correlates of creativity, the relationship between these characteristics and the phenomenology of creativity has been neglected. Relating these characteristics to the phenomenology of creativity may assist in clarifying the precise nature of the relationship between psychopathology and creativity. The current article reports on an empirical study of the relationship between the phenomenology of the creative process and psychopathological and personality characteristics in a sample of artists. <I>Method:</I> A total of 100 artists (43 males, 57 females, mean age = 34.69 years) from a range of disciplines completed the Experience of Creativity Questionnaire and measures of "positive" schizotypy, affective disturbance, mental boundaries, and normal personality. <I>Results:</I> The sample of artists was found to be elevated on "positive" schizotypy, unipolar affective disturbance, thin boundaries, and the personality dimensions of Openness to Experience and Neuroticism, compared with norm data. Schizotypy was found to be the strongest predictor of a range of creative experience scales (Distinct Experience, Anxiety, Absorption, Power/Pleasure), suggesting a strong overlap of schizotypal and creative experience. <I>Discussion:</I> These findings indicate that "positive" schizotypy is associated with central features of "flow"-type experience, including distinct shift in phenomenological experience, deep absorption, focus on present experience, and sense of pleasure. The neurologically based construct of latent inhibition may be a mechanism that facilitates entry into flow-type states for schizotypal individuals. This may occur by reduced latent inhibition providing a "fresh" awareness and therefore a greater absorption in present experience, thus leading to flow-type states.</p>
]]></description>
<dc:creator><![CDATA[Nelson, B., Rawlings, D.]]></dc:creator>
<dc:date>Mon, 04 Aug 2008 18:54:58 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn098</dc:identifier>
<dc:title><![CDATA[Relating Schizotypy and Personality to the Phenomenology of Creativity]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-08-04</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn095v1?rss=1">
<title><![CDATA[Cognitive Performance and Functional Competence as Predictors of Community Independence in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn095v1?rss=1</link>
<description><![CDATA[
<p>Measures of functional competence have been introduced to supplement standard cognitive and neuropsychological evaluations in schizophrenia research and practice. Functional competence comprises skills and abilities that are more relevant to daily life and community adjustment. However, it is unclear whether relevance translates into significantly enhanced prediction of real-world outcomes. The aim of this study was to assess the specific contribution of functional competence in predicting a key aspect of real-world outcome in schizophrenia: community independence. Demographic, clinical, cognitive, and functional competence data were obtained from 127 patients with schizophrenia or schizoaffective disorder and used to predict community independence concurrently and longitudinally after 10 months. Hierarchical regression analyses indicated that demographic, clinical, and cognitive predictors accounted jointly for 35%&ndash;38% of the variance in community independence across assessment points. Functional competence data failed to add significantly to this validity. Considered separately from demographic and clinical predictors, cognitive and functional competence data accounted for significant amounts of outcome variance. However, the addition of functional competence to standard cognitive test data yielded a significant increase in validity only for concurrent and not for longitudinal prediction of community independence. The specific real-world validity of functional competence is modest, yielding information that is largely redundant with standard cognitive performance.</p>
]]></description>
<dc:creator><![CDATA[Heinrichs, R. W., Ammari, N., Miles, A. A., McDermid Vaz, S.]]></dc:creator>
<dc:date>Wed, 30 Jul 2008 07:27:34 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn095</dc:identifier>
<dc:title><![CDATA[Cognitive Performance and Functional Competence as Predictors of Community Independence in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-30</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn091v1?rss=1">
<title><![CDATA[Assessing Social-Cognitive Deficits in Schizophrenia With the Mayer-Salovey-Caruso Emotional Intelligence Test]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn091v1?rss=1</link>
<description><![CDATA[
<p>The emotion management subscale of the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) has recently been recommended by the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia committee as the sole measure of social cognition for trials of cognitive enhancement in schizophrenia, yet the psychometric properties of this subscale and the larger instrument in schizophrenia patients have not been thoroughly examined. This research presents a psychometric investigation of the MSCEIT in a sample of 64 early course outpatients with schizophrenia, schizoaffective, or schizophreniform disorder. Results demonstrated that the MSCEIT possesses adequate internal consistency reliability among its branch and total scales and that patients&rsquo; branch and overall test performance was significantly below normative levels. Estimates of discriminant and concurrent validity indicated that the MSCEIT diverged from measures of neurocognitive functioning and psychopathology, but was only modestly related with objective measures of functional outcome. Convergent validity estimates suggested that, contrary to expectations, the MSCEIT did not correlate with a behavioral measure of social cognition. Finally, exploratory factor analyses suggested the possibility of a shift in the latent structure of emotional intelligence in schizophrenia, compared with studies with healthy individuals. These findings support the use of the MSCEIT as a reliable and potentially valid method of assessing the emotional components of social cognition in schizophrenia, but also point to a need for additional measurement development efforts to assess broader social-cognitive domains that may exhibit stronger relations with functional outcome. Further investigation is warranted to examine the instrument's latent factor structure and convergence with other measures of social cognition.</p>
]]></description>
<dc:creator><![CDATA[Eack, S. M., Greeno, C. G., Pogue-Geile, M. F., Newhill, C. E., Hogarty, G. E., Keshavan, M. S.]]></dc:creator>
<dc:date>Tue, 22 Jul 2008 13:39:51 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn091</dc:identifier>
<dc:title><![CDATA[Assessing Social-Cognitive Deficits in Schizophrenia With the Mayer-Salovey-Caruso Emotional Intelligence Test]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-22</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn094v1?rss=1">
<title><![CDATA[Negative Symptoms in Schizophrenia: Avolition and Occam's Razor]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn094v1?rss=1</link>
<description><![CDATA[
<p>The identification of schizophrenia's negative symptoms dates back to the earliest descriptions of Kraepelin and Bleuler, who each highlighted the central role of avolition in the phenomenology and course of this illness. Since, there have been numerous advances in our understanding of schizophrenia, and the present review tracks the changes that have taken place in our understanding of negative symptoms, their description and measurement. That these symptoms represent a distinct domain of the illness is discussed in the context of their ties to other symptoms and functional outcome. The underlying structure of the negative symptom construct is explored, including several lines of investigation that point towards diminished expression and amotivation as key underlying subdomains. We also discuss findings of intact emotional experience and consummatory pleasure in individuals with schizophrenia, calling into question the presence of anhedonia in this illness. We conclude with a reconceptualization of the negative symptoms, suggesting amotivation (ie, avolition) represents the critical component, particularly in regard to functional outcome. Further exploration and clarification of this core deficit will ultimately enhance our neurobiological understanding of schizophrenia, as well as strategies that may improve outcome.</p>
]]></description>
<dc:creator><![CDATA[Foussias, G., Remington, G.]]></dc:creator>
<dc:date>Mon, 21 Jul 2008 08:31:55 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn094</dc:identifier>
<dc:title><![CDATA[Negative Symptoms in Schizophrenia: Avolition and Occam's Razor]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn075v1?rss=1">
<title><![CDATA[Sex Differences in Wisconsin Schizotypy Scales--A Meta-analysis]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn075v1?rss=1</link>
<description><![CDATA[
<p>Previous single studies have found inconsistent results on sex differences in positive schizotypy, women scoring mainly higher than men, whereas in negative schizotypy studies have often found that men score higher than women. However, information on the overall effect is unknown. In this study, meta-analytic methods were used to estimate sex differences in Wisconsin Schizotypy Scales developed to measure schizotypal traits and psychosis proneness. We also studied the effect of the sample characteristics on possible differences. Studies on healthy populations were extensively collected; the required minimum sample size was 50. According to the results, men scored higher on the scales of negative schizotypy, ie, in the Physical Anhedonia Scale (n = 23 studies, effect size, Cohen <I>d</I> = 0.59, <I>z</I> test <I>P</I> &lt; .001) and Social Anhedonia Scale (n = 14, <I>d</I> = 0.44, <I>P</I> &lt; .001). Differences were virtually nonexistent in the measurements of the positive schizotypy, ie, the Magical Ideation Scale (n = 29, <I>d</I> = &ndash;0.01, <I>P</I> = .74) and Perceptual Aberration Scale (n = 22, <I>d</I> = &ndash;0.08, <I>P</I> = .05). The sex difference was larger in studies with nonstudent and older samples on the Perceptual Aberration Scale (<I>d</I> = &ndash;0.19 vs <I>d</I> = &ndash;0.03, <I>P</I> &lt; .05). This study was the first one to pool studies on sex differences in these scales. The gender differences in social anhedonia both in nonclinical samples and in schizophrenia may relate to a broader aspect of social and interpersonal deficits. The results should be taken into account in studies using these instruments.</p>
]]></description>
<dc:creator><![CDATA[Miettunen, J., Jaaskelainen, E.]]></dc:creator>
<dc:date>Mon, 21 Jul 2008 08:31:53 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn075</dc:identifier>
<dc:title><![CDATA[Sex Differences in Wisconsin Schizotypy Scales--A Meta-analysis]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-21</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn088v1?rss=1">
<title><![CDATA[Sensorimotor Gating of Schizophrenia Patients Depends on Catechol O-Methyltransferase Val158Met Polymorphism]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn088v1?rss=1</link>
<description><![CDATA[
<p>It has been recently shown that Catechol O-methyltransferase (COMT) Val<sup>158</sup>Met polymorphism strongly influences prepulse inhibition (PPI) of the acoustic startle response (ASR) in healthy human volunteers. Given that schizophrenia patients exhibit impairment in PPI and that COMT is a putative susceptibility gene for schizophrenia, we investigated the impact of the COMT Val<sup>158</sup>Met polymorphisms on PPI in schizophrenic inpatients. We analyzed COMT Val<sup>158</sup>Met polymorphisms and assessed startle reactivity, habituation, and PPI of ASR in 68 Caucasian schizophrenia inpatients. Clinical symptoms were measured with the Positive and Negative Syndrome Scale (PANSS). Patients carrying the Val<sup>158</sup>Met Met/Met allele showed elevated PPI levels whereas startle reactivity and habituation did not differ from the other two genotypes. These preliminary results imply that PPI is influenced by COMT Val<sup>158</sup>Met genotype in schizophrenia as well. In concert with other findings, our data suggest that PPI is a polygenic trait.</p>
]]></description>
<dc:creator><![CDATA[Quednow, B. B., Wagner, M., Mossner, R., Maier, W., Kuhn, K.-U.]]></dc:creator>
<dc:date>Thu, 17 Jul 2008 07:58:15 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn088</dc:identifier>
<dc:title><![CDATA[Sensorimotor Gating of Schizophrenia Patients Depends on Catechol O-Methyltransferase Val158Met Polymorphism]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn069v1?rss=1">
<title><![CDATA[Reasoning Anomalies Associated With Delusions in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn069v1?rss=1</link>
<description><![CDATA[
<p>Deluded people differ from nondeluded controls on attributional style questionnaires and probabilistic-reasoning and theory-of-mind (ToM) tasks. No study to date has examined the relations between these 3 reasoning anomalies in the same individuals so as to evaluate their functional independence and potentially inform theories of delusion formation. We did so in 35 schizophrenic patients with a history of delusions, 30 of whom were currently deluded, and 34 healthy controls. Compared with healthy controls, patients showed (<I>a</I>) a jumping-to-conclusions bias and a bias to overadjust when confronted with a change of evidence on probabilistic-reasoning tasks, (<I>b</I>) an excessive externalizing attributional bias, and (<I>c</I>) performance deficits on 3 ToM tasks. Probabilistic-reasoning and ToM measures correlated, while attributional-bias scores were independent of other task measures. A general proneness to delusional ideation correlated with probabilistic-reasoning and ToM measures, while externalizing bias was unrelated to the study measures of delusional ideation. Personalizing bias associated specifically with paranoia across the clinical and nonclinical participants. Findings are consistent with a common underlying mechanism in schizophrenia which contributes to the anomalies on probabilistic-reasoning and ToM tasks associated with delusions. We speculate that this mechanism is impairment of the normal capacity to inhibit "perceived reality" (the evidence of our senses), a capacity that evolved as part of the "social brain" to facilitate intersubjective communication within a shared reality.</p>
]]></description>
<dc:creator><![CDATA[Langdon, R., Ward, P. B., Coltheart, M.]]></dc:creator>
<dc:date>Fri, 11 Jul 2008 19:15:49 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn069</dc:identifier>
<dc:title><![CDATA[Reasoning Anomalies Associated With Delusions in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-11</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn074v1?rss=1">
<title><![CDATA[How Frequent is Chronic Multiyear Delusional Activity and Recovery in Schizophrenia: A 20-Year Multi-follow-up]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn074v1?rss=1</link>
<description><![CDATA[
<p>To determine how frequent chronic multiyear delusional activity is in modern-day schizophrenia, we studied 200 patients over a 20-year period. We also studied the relation of delusions to hallucinations and thought disorder-disorganization, to work disability, and to later periods of global recovery and assessed several protective factors against delusional activity. The sample was assessed 6 times over 20 years and includes 43 patients with schizophrenia. Participants were evaluated at each follow-up for delusions, hallucinations, thought disorder-disorganization, work disability, and global recovery. Possible protective factors were assessed prospectively at index hospitalization. Twenty-six percent of the patients with schizophrenia were delusional at all follow-ups over the 20 years. Overall, 57% had frequently recurring or persistent delusions. A subgroup of over 25% of the schizophrenia patients had no delusional activity at any of the 6 follow-ups over 20 years. Schizophrenia patients with posthospital delusional activity had increased work disability (<I>P</I> &lt; .05). Delusions that persisted after the acute phase in schizophrenia patients predicted a lower likelihood of future global recovery (<I>P</I> &lt; .01). In conclusion, slightly over half of modern-day schizophrenia patients are vulnerable to frequent or "chronic" delusional activity after the acute phase. Schizophreniform patients and other types of psychotic disorders are vulnerable to posthospital delusional activity, but less frequently, less severely, and more episodically. Delusional activity is associated with work disability. Internal factors such as good premorbid developmental achievements and favorable prognostic factors are protective factors that reduce the probability of chronic multiyear, delusional activity in schizophrenia (<I>P</I> &lt; .01).</p>
]]></description>
<dc:creator><![CDATA[Harrow, M., Jobe, T. H.]]></dc:creator>
<dc:date>Wed, 09 Jul 2008 19:24:12 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn074</dc:identifier>
<dc:title><![CDATA[How Frequent is Chronic Multiyear Delusional Activity and Recovery in Schizophrenia: A 20-Year Multi-follow-up]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-07-09</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn072v1?rss=1">
<title><![CDATA[Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn072v1?rss=1</link>
<description><![CDATA[
<p>Symptom development during the prodromal phase of psychosis was explored retrospectively in first-episode psychosis patients with special emphasis on the assumed time-related syndromic sequence of "unspecific symptoms (UN)&ndash;predictive basic symptoms (BS)&ndash;attenuated psychotic symptoms (APS)&ndash;(transient) psychotic symptoms (PS)." Onset of syndromes was defined by first occurrence of any of their respective symptoms. Group means were inspected for time differences between syndromes and influence of sociodemographic and clinical characteristics on the recalled sequence. The sequence of "UN&ndash;BS/APS&ndash;PS" was clearly supported, and both BS and, though slightly less, APS were highly sensitive. However, onset of BS and APS did not show significant time difference in the whole sample (N = 126; 90% schizophrenia), although when each symptom is considered independently, APS tended to occur later than first predictive BS. On descriptive level, about one-third each recalled an earlier, equal and later onset of BS compared with APS. Level of education showed the greatest impact on the recall of the hypothesized sequence. Thereby, those with a higher school&ndash;leaving certificate supported the assumed sequence, whereas those of low educational background retrospectively dated APS before BS. These findings rather point out recognition and recall bias inherent to the retrospective design than true group characteristics. Future long-term prospective studies will have to explore this conclusively. However, as regards the criteria, the results support the notion of BS as at least a complementary approach to the ultrahigh risk criteria, which may also allow for an earlier detection of psychosis.</p>
]]></description>
<dc:creator><![CDATA[Schultze-Lutter, F., Ruhrmann, S., Berning, J., Maier, W., Klosterkotter, J.]]></dc:creator>
<dc:date>Wed, 25 Jun 2008 01:22:19 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn072</dc:identifier>
<dc:title><![CDATA[Basic Symptoms and Ultrahigh Risk Criteria: Symptom Development in the Initial Prodromal State]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-25</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn066v1?rss=1">
<title><![CDATA[Smoking in Schizophrenia: Diagnostic Specificity, Symptom Correlates, and Illness Severity]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn066v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: Cigarette smoking was consistently found to be more prevalent in individuals with schizophrenia than in other psychiatric groups and the general population. These findings have been interpreted as evidence of a specific association between schizophrenia and smoking. However, the supporting data come primarily from cross-sectional studies, which are susceptible to confounding. Our aim was to test specificity of this link longitudinally in an epidemiologic sample. <I>Methods</I>: A cohort of 542 inpatients with psychosis was followed for 10 years after first hospitalization, completing 5 face-to-face interviews. Assessments included ratings of specific symptoms (psychotic, negative, disorganized, and depressive), Global Assessment of Functioning, and a categorical measure of cigarette consumption. All participants were assigned longitudinal consensus diagnoses by study psychiatrists, and 229 were diagnosed with schizophrenia spectrum disorders (SZ). <I>Results</I>: At baseline, 52.4% of participants were current smokers and 69.3% were lifetime smokers. Smoking rates did not differ among the diagnostic groups (schizophrenia spectrum, major depressive, bipolar, or other psychotic disorder) at any assessment point. Smokers were more severely ill than nonsmokers but did not differ in specific symptoms either cross-sectionally or longitudinally. Among smokers, changes in cigarette consumption were linked only with changes in depression (&beta; = .16, <I>P</I> &lt; .001). <I>Conclusions</I>: Rates of smoking were elevated in subjects with schizophrenia but were just as high with other psychotic disorders. Smoking was not associated with psychotic symptoms, but cigarette consumption covaried with depression over time. Given the devastating health consequences of cigarette use, smoking cessation interventions are urgently needed in this population and should specifically address depression.</p>
]]></description>
<dc:creator><![CDATA[Kotov, R., Guey, L. T., Bromet, E. J., Schwartz, J. E.]]></dc:creator>
<dc:date>Tue, 17 Jun 2008 22:51:46 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn066</dc:identifier>
<dc:title><![CDATA[Smoking in Schizophrenia: Diagnostic Specificity, Symptom Correlates, and Illness Severity]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn065v1?rss=1">
<title><![CDATA[Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn065v1?rss=1</link>
<description><![CDATA[
<p><I>Background</I>: Despite disproportionately high rates of hepatitis C (HCV) among patients with severe mental illness, to date, there is scant empirical data available regarding antiviral therapy outcomes within this population. <I>Objective</I>: To compare antiviral therapy completion and response rates between HCV patients with vs those without schizophrenia (SCHZ). <I>Methods</I>: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. All patients confirmed to have SCHZ and to have received antiviral therapy between 1998 and 2006 (n = 30) were compared with a control group of demographically matched (HCV genotype, age, race, gender) patients with no history of SCHZ (n = 30). <I>Results</I>: For HCV patients with genotype 1, antiviral completion, end of treatment response (ETR), and sustained viral response (SVR) rates did not significantly differ between groups. For those with genotypes 2 and 3 combined, antiviral therapy completion rates did not significantly differ between groups; however, the SCHZ group was significantly (<I>P</I> &lt; 0.050) more likely to achieve an ETR and an SVR. For all genotypes combined, the SCHZ patients were no more likely than controls to discontinue therapy early for psychiatric symptoms, medical complications, or other adverse events, and groups did not significantly differ in terms of hospitalization rates during antiviral therapy. <I>Conclusion</I>: Our retrospective chart review suggests that patients with SCHZ complete and respond to antiviral therapy for HCV at rates comparable with those without SCHZ. Based on these data, SCHZ should not be considered a contraindication to antiviral therapy for HCV.</p>
]]></description>
<dc:creator><![CDATA[Huckans, M., Mitchell, A., Ruimy, S., Loftis, J., Hauser, P.]]></dc:creator>
<dc:date>Tue, 17 Jun 2008 22:51:45 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn065</dc:identifier>
<dc:title><![CDATA[Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn064v1?rss=1">
<title><![CDATA[Catechol-O-Methyltransferase Val158Met Polymorphism and Antisaccade Eye Movements in Schizophrenia]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn064v1?rss=1</link>
<description><![CDATA[
<p>The catechol-<I>O</I>-methyltransferase (COMT) enzyme catabolizes dopamine. The val<sup>158</sup>met single nucleotide polymorphism (rs4680) in the COMT gene has received considerable attention as a candidate gene for schizophrenia as well as for frontally mediated cognitive functions. Antisaccade performance is a good measure of frontal lobe integrity. Deficits on the task are considered a trait marker for schizophrenia. The aim of this study was to investigate the association of COMT val<sup>158</sup>met polymorphism with antisaccade eye movements in schizophrenia patients and healthy controls. Schizophrenia patients (N = 105) and healthy controls (N = 95) underwent infrared oculographic assessment of antisaccades. Subjects were genotyped for COMT val<sup>158</sup>met and divided into 3 groups according to genotype (val/val, val/met, and met/met). Patients displayed significantly more reflexive errors, longer and more variable latency, and lower amplitude gain than controls (all <I>P</I> &lt; 0.02). A greater number of val<sup>158</sup> alleles was associated with shorter (<I>P</I> = 0.045) and less variable (<I>P</I> = 0.028) antisaccade latency and, nonsignificantly, with lower reflexive error rate (<I>P</I> = 0.056). None of these variables showed a group-by-genotype interaction (<I>P</I> &gt; 0.1). There were no significant associations of genotype with measures of amplitude gain or spatial error (<I>P</I> &gt; 0.2). The results suggest that COMT val<sup>158</sup> carrier status is associated with better performance on the antisaccade task. Possible explanations of this finding are discussed.</p>
]]></description>
<dc:creator><![CDATA[Haraldsson, H. M., Ettinger, U., Magnusdottir, B. B., Sigmundsson, T., Sigurdsson, E., Ingason, A., Petursson, H.]]></dc:creator>
<dc:date>Tue, 17 Jun 2008 22:51:45 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn064</dc:identifier>
<dc:title><![CDATA[Catechol-O-Methyltransferase Val158Met Polymorphism and Antisaccade Eye Movements in Schizophrenia]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn063v1?rss=1">
<title><![CDATA[Semantic Expectations Can Induce False Perceptions in Hallucination-Prone Individuals]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn063v1?rss=1</link>
<description><![CDATA[
<p>Recently, it has been proposed that exaggerated top-down processing may generate spontaneous perceptual output, and that this may constitute a cognitive predisposition toward hallucinations. In this experiment, we investigated whether hallucination proneness would be associated with increased auditory-verbal perceptual expectations, and at which processing level this occurs. From 351 undergraduate students screened for hallucination proneness, using the Launay-Slade Hallucination Scale (LSHS), 42 subjects were recruited for participation. Two word recognition tasks were administered, in which top-down influences on perception were manipulated through sentence context (semantic task) or auditory imagery (phonological task). Results revealed that LSHS scores were correlated with the number of semantically primed errors. Subjects with higher levels of hallucination proneness were more likely to report hearing a word that fits the sentence context, when it was not actually presented. This effect remained significant after controlling for general performance on the task. In contrast, hallucination proneness was not associated with phonologically primed errors. We conclude that aberrant top-down processing, particularly in the form of strong semantic expectations, may contribute to the experience of auditory-verbal hallucinations.</p>
]]></description>
<dc:creator><![CDATA[Vercammen, A., Aleman, A.]]></dc:creator>
<dc:date>Tue, 17 Jun 2008 22:51:44 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn063</dc:identifier>
<dc:title><![CDATA[Semantic Expectations Can Induce False Perceptions in Hallucination-Prone Individuals]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn061v1?rss=1">
<title><![CDATA[Emotional Experience in Patients With Schizophrenia Revisited: Meta-analysis of Laboratory Studies]]></title>
<link>http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/sbn061v1?rss=1</link>
<description><![CDATA[
<p>Our understanding of the emotion deficits in schizophrenia is limited. Findings from studies employing trait emotion instruments suggest that patients have attenuated levels of positive emotion (ie, anhedonia) and increased levels of negative emotion. Conversely, patients and controls have not statistically differed in their subjective reactions to positive or negative valenced stimuli in most laboratory studies to date. Further obfuscating this issue is the fact that many of these laboratory studies are underpowered and a handful of emotion induction studies have found evidence of anhedonia. We conducted a meta-analysis of 26 published studies employing laboratory emotion induction procedures in patients with schizophrenia and healthy controls. Patients did not differ from controls when strictly rating their subjective hedonic reactions to the stimuli. However, they reported experiencing relatively strong aversion to both positive and neutral stimuli (Hedges <I>D</I> = .72 and .64, respectively). These findings were not the result of demonstrable sample or methodological differences across studies. Patients&rsquo; ability to experience hedonic emotion is preserved, although they also show relatively strong, simultaneously occurring aversive emotion when processing laboratory stimuli considered by others to be pleasant or neutral.</p>
]]></description>
<dc:creator><![CDATA[Cohen, A. S., Minor, K. S.]]></dc:creator>
<dc:date>Tue, 17 Jun 2008 22:51:43 PDT</dc:date>
<dc:identifier>info:doi/10.1093/schbul/sbn061</dc:identifier>
<dc:title><![CDATA[Emotional Experience in Patients With Schizophrenia Revisited: Meta-analysis of Laboratory Studies]]></dc:title>
<dc:publisher>Maryland Psychiatric Research Center</dc:publisher>
<prism:publicationDate>2008-06-17</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

</rdf:RDF>